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Abstract
Hepatitis C is responsible for causing chronic infections in over 170 million people all
over the world who are at a risk of developing into liver cirrhosis and hepatocellular car-
cinoma, locating HCV in a major public health burden. Until recently, the standard-of-
care treatment consisted of Interferon-alpha and ribavirin, in addition to non-structural
protein 3/4 (NS3) protease inhibitors, but due to the undesired side-effects, researchers
developed more efficient therapies. Nowadays, small molecules targeting non-structural
viral proteins: NS3/4 protease, NS5A D1 and NS5B polymerase activities can clear the
infection in 98% of the cases. These direct acting antivirals (DAAs) are widely used,
however, despite advances in recently approved potent DAAs the world-wide applica-
tion of these therapies remains limited due to the expensive cost and potential drug
resistance. NS5A is a nonstructural multifunctional protein. Mainly composed by an
amphipatic helix, which is the major membrane anchor, Domain I, which is involved
in RNA binding and assembly, and Domain II and III which are intrinsically unfolded
domains and are known to interact with host factors. DAA targeting NS5A DI, Da-
clatasvir (DCV), has a picomolar range activity and it is used in combination therapy
to combat HCV infection. Given the enormous medical relevance of NS5A inhibitors,
the aim of this study was to decipher the mode of action of Daclatasvir, together with
more insights to the role of NS5A structural elements. In the present study, experiments
showed that DCV can block the envelopment of viral particles. Furthermore, targeting
the assembly of HCV particles, this fact serve as evidence of the dual mode of action
of DCV. Furthermore, we investigated the role of very conserved Proline residues in the
structure of NS5A, identifying key Proline residues which are critically involved in RNA
replication, and have an impact in HCV infection. This fact, also suggests that the some
of these Prolines might be essential for the DCV binding, as we prove that they have
a direct role in keeping the binding site of DCV. Lastly, we set up a molecular model
which includes the intracellular membrane giving the full picture of how DCV works in
the context of an intracellular membrane and its important interactions. Together our
data, prove the dual mode of action of DCV targeting HCV replication and assembly.
And importantly, we constructed a molecular model that can be use in the future to
study structure-function of developing NS5A inhibitors.
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Chapter 1
Hepatitis C Virus identification
and classification
Hepatitis is an inflammation of the liver, this can be self-limiting or can continue to
develop fibrosis, cirrhosis or liver cancer. According to the World Health Organization
(WHO), hepatitis viruses are the common cause of hepatitis, together with toxic sub-
stances (e.g. alcohol, drugs) and autoimmune diseases which can also cause hepatitis.
There are 5 main hepatitis viruses, A, B, C, D and E. Typically A and E are caused by
contaminated food or water, while B, C, and D usually as a result of parental contact
with infected body fluids as blood or contaminated medical equipment such as needles,
sexual contact or in case of hepatitis B, from mother to baby at birth [2].
In the early 1960s, hepatitis types A and B were recognized and the treatment was
corticosteroid treatment. Shortly after the discovery of hepatitis B, research of drug
treatments began, among these interferon (IFN) appeared as most effective. In the
1970s a non-A non-B hepatitis was discovered too. Originally, it was not considered
to contribute to cirrhosis or cancer. Non-A non-B hepatitis was formerly identified as
putative viral hepatitis occurring after transfusion of blood or intravenous drug use.
The evidence that non-A non-B hepatitis could lead to persistent infection in a high
number of patients lead to discover that indeed it can progress into chronic liver disease,
cirrhosis and hepatocellular carcinoma (HCC) [3]. Hepatitis C virus was discovered to
be the cause of non-A non-B hepatitis in 1989 and now is still one of the main causes of
chronic liver diseases [4].
Hepatitis C has been classified in the genus Hepacivirus within the family Flaviviridae.
The Flaviviridae family including three genera: flavivirus, pestivirus and hepacivirus,
mostly infecting mammals and birds. Many flaviviruses are host-specific and pathogenic,
such as hepatitis C virus [5]. Flaviviruses include hepatitis C, yellow fever virus, dengue
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3fever virus, Japansese encephalitis virus and tick-borne encephalitis virus. The ma-
jority of known members in the genus Flavivirus are arthropod borne, and many are
important human and veterinary pathogens [6]. Members of this family share a number
of basic structural and virological characteristics, enveloped in a lipid bilayer, which
is surrounded by a nucleocapsid, mainly composed by the core (C) protein and inside
it contains the RNA genome [7] However, HCV differs in a number of virological and
epidemiological aspects, as the fact that HCV has a narrow host specificity and tissue
tropism. It can be only transmitted by blood-to-blood contact between humans, instead
of mosquitoes or ticks.
There are 7 HCV genotypes currently classified and each of them are divided into several
subtypes (a,b,c, etc.) according to the geographical distribution. According to literature
genotype 1 is the prevalent worldwide, continued by genotype 3, comprising 83.4 million
cases (46.2% of all HCV cases) and 54.3 million (30.1%) approximately one-third of
which are in East Asia. Genotypes 2, 4, and 6 are responsible for a total 22.8% of
all cases; genotype 5 comprises the remaining less than 1%. While genotypes 1 and 3
dominate in most countries irrespective of economic status, the largest proportions of
genotypes 4 and 5 are in lower-income countries [8].
Figure 1.1: HCV global distribution and genome types
An estimated 130 to 170 million people have HCV infection. HCV prevalence is
highest in Egypt at >10% of the general population and China has the most people
with HCV (29.8 million). Around 25% of patients with acute HCV infection undergo
spontaneous clearance, remaining 75% of patients progress to chronic HCV infection
and are subsequently at risk of progression to hepatic fibrosis, cirrhosis and
hepatocelullar carcinoma (HCC). Taken from [9].
Chapter 2
HCV genome and viral proteins
2.1 HCV genome
The HCV genome encodes 10 viral proteins, divided into two modules: assembly mod-
ule (core to NS2) and replication (NS3-NS5B) module (Figure 2.1). The HCV genome
is single-stranded RNA molecule that has a positive polarity and a length of 9600 nu-
cleotides. The open reading frame (ORF) is flanked by a 5’ and 3’ non-translated regions
(NTR) of 341 and 230 nucleotides length respectively, both containing conserved RNA
structures essential for translation and replication processes. The HCV internal ribo-
some entry site (IRES) is located in the 5’ NTR has the capacity to form a stable
pre-initiation complex by directly binding to the 40S ribosomal subunit without canon-
ical translation initiation factors. The IRES directs the cap-independent translation of
the single ORF [10]. Therefore, HCV exists in its hosts as a pool of genetically distinct
but closely related variants called quasispecies [11].
2.2 5’ and 3’ Non-translated region
The 5’ NTR of HCV contains 341 nucleotides upstream of the ORF translation initiation
codon and it is the most conserved region in the genome. This region contains 4 highly
conserved structural domains (I- IV) containing stem-loops and a pseudoknot [12]. The
domains II, III and IV together with the first 12-30 nucleotides conform the IRES.
The 3’ non translated region contains 225 nucleotides and it is divided in three regions a
variable region 30-40 nucleotides, a long poly(U)- poly(U/UC) tract and a very conserved
3’terminal stretch of about 98 nucleotides (3’X region). The 3’NTR interacts with NS5B,
RNA-dependent, RNA polymerase.
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5Figure 2.1: HCV genome and protein structure
HCV genome and viral proteins. a) One single open reading frame (ORF) within the
viral RNA genome encodes for the HCV polyprotein it is flanked by the 3’ and 5’
non-translated regions (NTR). The genome is arrange into two modules, the
replication module, which contains the nonstructural (NS) proteins which are required
for the RNA replication and the assembly module, which contains the core (C) protein
and the two envelope glycoproteins (E1 and E2), p7 and NS2 which are required for
the assembly of the virus. The scissors indicate the polyprotein cleavage by the cellular
signal peptidase, this cleavage removes the carboxyl-terminal indicated by an asterisk
as the arrows are indicating the viral proteases cleavage. b) Membrane topologies and
major functions of HCV proteins. Each protein is tethered to intracellular membranes,
NS5A protein is anchored by amphipatic α-helices, also note NS5A is shown as a
dimer, but almost all proteins can form homo or heterodimers. Taken from [13].
2.3 HCV viral proteins
The ORF is encoding a single polyprotein, approximately of 3000 amino acid long, which
is co and post-translationally cleaved by cellular and viral proteases into 10 proteins from
the amino-terminal region. As previously mentioned, the structural module, includes
the structural proteins which help building the virus particle: core (C), envelope glyco-
proteins 1 (E1) and (E2), or support assembly but not being part of it: p7, a viroporin,
6ion channel crucial for viral production [14] and the non structural protein NS2. The
rest of the non structural proteins are the result of the polyprotein cleavage: NS3, NS4A,
NS4B, NS5A, NS5B [15], and can sustain viral RNA replication (Figure 2.1). In addition
the so-called ”F” protein which results from a frameshift in the core coding region. The
HCV viral proteins have been extensively studied and in the following sections the main
structure and function aspects are described.
2.4 Core
Core Protein, 21kDa (mature)
During the translation of the HCV polyprotein the polypeptide is targeted to the en-
doplasmic reticulum (ER) membrane for translocation of the Envelope glycoprotein 1
(E1) ectodomain into the ER lumen a process mediated by the internal signal sequence
between core and E1. The polyprotein cleavage yields the immature form of the core
protein which contains the E1 signals sequence at the carboxyl-terminal. Furthermore
this is recognized by the host peptidase giving rise to the mature core protein, most of
core protein is found in the cytosol, where is bound to the ER membranes and located
at the surface of lipid droplets (LD) [16–18].
The core protein is a highly basic RNA-binding protein that forms the viral capsid. It
exists in a precursor of 23kDa and it is release as a mature protein in 21kDa. Its length
is around 177 amino acids and is a dimeric membrane protein consisting of two domains
stabilized by disulfide bonds. The hydrophilic domain is within the first 120 N-terminal
amino acids of the protein, where there are several characteristics of unfolded proteins.
This conformation allows plasticity which is why core protein can interact with different
cellular partners. The C-terminal is hydrophobic, responsible for core association to lipid
droplets (LD) and it predicted to fold into α-helices rich in glycine which can attribute
to an oligomerization motif [18].
2.5 Envelopment proteins
Envelopment protein 1 (E1, 35kDa) and envelopment protein 2 (E2, 65kDa)
These proteins are both transmembrane proteins type I, where the ectodomain is in
the N-terminal 160 and 334 amino acids, it is located in the ER lumen where glycosi-
lation and folding processes take place. While the C-terminal contains the 30 amino
acids long transmembrane domain, this is the membrane anchor for ER retention [19].
7These proteins assemble in non-covalent heterodimers. The transmembrane domain is
composed of two short stretches of hydrophobic amino acids separated by a short polar
segment containing fully charged residues, the second one is acting as a signal peptide
for downstream protein [20]. E1 and E2 might also be involved in fusion between the
viral envelope and the host cell membrane.
2.6 Viroporin protein p7
p7, 63 amino acids
Small, intrinsic membrane protein p7, is composed by two transmembrane domains that
are connected via a cytoplasmic loop [14]. The N- and C-terminal are facing the ER
lumen, with predicted α-helices. The protein can undergo oligomerization and can also
be used as an ion channel. These structural and membrane-permeability properties
suggest that p7 belongs to the viroporin family [21].
2.7 Non-structural proteins
2.7.1 Non-structural protein 2 (NS2, 23kDa)
Non-structural protein 2 is an integral membrane protein, non-glycosylated that does
not seem essential for formation of the replication complex [22]. Its main role is in the
proteolytic cleavage at the NS2-NS3 junction of the HCV polyprotein and it is required
for the zinc-dependent NS2-NS3 proteinase function. However, NS2 is not necessary for
RNA replication but for infectious particles production in cell culture [23].
2.7.2 Non-structural protein 3 (NS3, 70kDa)
NS3 consists of two domains, the serine protease domain, 1-189 amino acids in the N-
terminal, while helicase-NTPase domain, 181-631 amino acids at the C-terminal. The
NS3 associates with the non-structural cofactor 4A of approx. 54 amino acids, which
gives stability to the protein as it activates it to perform the cleavage in 4A/4B, 4B/5A
and 5A/5B [18]. The N-terminal part appears to form a transmembrane structure which
might be important for its ER membrane localisation. The protease domain is being
targeted efficiently by antiviral drugs. The structure of NS3 composes a chymotrypsin-
like fold composed two six-stranded β-barrel subdomains. The catalytic triad is formed
by residues from the same loops of the two β-barrel. The helicase domain on the other
8hand has not been successfully targeted by any drugs. It contains two structurally re-
lated subdomains folded with β−α− β subdomain topology. In addition NS3 interacts
directly with NS5B, NS4B and NS5A via NS4A within the replication complex [24, 25]
(Figure 2.2).
Figure 2.2: NS3-4A protease and NS3 full length structure
NS3-4A protease and full length structure of NS3. Modified from [26]. As it is
described in the text the structure contains a protease domain together with the
cofactor 4A and the full NS3 is shown.
2.7.3 Non-structural protein 4A (NS4A, 16kDa)
As mentioned before, NS4A is a cofactor responsible for several cleavage sites. Because
of this interaction with other non-structural proteins, NS4A contributes to HCV RNA
replication and virus particles assembly. Additionally NS3/4 protease plays a key role
in blocking host antiviral signalling response (see Chapter 5), it is involved in the cleav-
age of CARDIF (caspase recruitment domain adaptor inducing IFN-β) [27] and TRIF
(Toll/interleukin-1 receptor domain containing adaptor inducing IFN-β) [28], this results
in the inhibition of RIG-I (Retinoic-acid inducible gene I) which is the main mediator
of antiviral signalling in the cell [29], more detailed information is given in Chapter 5.
2.7.4 Non-structural protein 4B (NS4B, 27kDa)
NS4B is a hydrophobic transmembrane protein that co-translationally associates with
the ER membrane [10]. Is predicted to be formed by an N-terminal amphipatic α-helix,
which is followed by transmembrane domains [30]. Further NS4B was found to induce the
formation of seemingly ER-derived membranous web that harbours all HCV structural
and non-structural proteins and also allows RNA replication[31]. Thus, NS4B function
provides a scaffold for the assembly of HCV replication complex (RC). In addition NS4B
9has been suggested as a key participant during viral assembly, as it interacts with other
proteins in the replication module [32].
2.7.5 Non-structural protein 5A, (NS5A, 56kDa)
NS5A is a multifunctional phosphoprotein associated to membranes. It is found to be
phosphorylated and hyperphosphorylated. It has been described extensively as it is now
one of the main targets for antiviral drugs. NS5A has been described to be involved
in membranous web formation, RNA replication, viral particle assembly and host cell
interactions. Thus NS5A is described extensively because it is the main protein of study.
2.7.5.1 NS5A organization
NS5A N-terminal contains three domains (D1, D2, and D3) and a very conserved am-
phipatic helix (AH) (Figure 2.3). The AH is located at the N-terminal and it is mainly
involved in targeting NS5A to the cytosolic leaflet of the ER membrane in an in-plane
manner [33]. DI (amino acid 36-214), Domain II (amino acid 250-342), implicated in
RNA replication, and Domain III (356-447) involved in core interactions and viral par-
ticle assembly [34]. The domains are separated by a two low complexity sequences (LCS
I and LCS II). The following paragraphs are dedicated to a more detailed description of
NS5A organization for the further understanding of the results.
Figure 2.3: NS5A organization
HCV non-structural protein 5A organization. AH, amphipathic helix, domain I (DI)
involved in RNA replication, domain II and III (DII and DIII) intrinsically unfolded
involved in interactions with host proteins. Low complexity sequence I and II (LCSI
and LCSII) are separating each domain. LCS regions are predicted to be interdomain
connecting loops. The region believed to comprise domain I (amino acids 1-213)
contains the N-terminal membrane-anchoring helix, as well as a potential metal ion
coordination motif. Modified from [34]
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Figure 2.4: NS5A domains
Ribbon diagram of a model of the full-length NS5A dimer associated with a
phospholipid membrane. Each subunit (lilac and cyan, respectively) consists of the
amino terminal amphipatic α-helix (PDB: 1R7G), the highly structured domain 1 (D1,
PDB: 1ZH1) which is shown in position relative to a
1-palmitoyl-2-oleoyl-3-snglycerol3phospholcholine membrane bilayer. In Domain II, in
stick representation, the binding site for Cyclophilin A (host factor that interacts with
NS5A protein) is shown. DII and DIII are intrinsically unfolded. Modified from[15].
2.7.5.2 Amphipatic helix
The AH is located at the N-terminal in 30 amino acid residues and it serves as a mem-
brane anchor for NS5A. This domain is completely necessary and sufficient to target
NS5A to the ER, which results in an integral membrane association; this association
can occur by a post-translational mechanism [35]. NS5A AH (1-31 aa) was determined
by NMR [33], and it is reported to form an in-plane amphipatic α-helix embedded in
the cytosolic leaflet of the membrane bilayer. Polar residues present in the membrane
surface provide a unique environment to allow protein-protein interactions which are
essential for the assembly of a functional HCV replication complex [26]. Despite the
apparent variability of some amino acids, there are several fully conserved and specific
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charged amino acids with a hydrophatic character in most of HCV genotypes. For exam-
ple, secondary structure predictions have predicted a conserved and consensus α-helix
in the 3-26 amino acid segment. Amino acids from 29-32 including the very conserved
Pro-29, is predicted to form a turned conformation, and segment 36-48 is predicted as
extended [35]. In addition to other amino acid conservation, Prolines are very conserved
residues in the linker connecting the AH with Domain I, as Proline 29, 32 and 35, which
are studied in the present work and are shown in Figure 11.1.
Additionally, due to the natural conformation of AH it has a high propensity to bind
to lipids. However, protein-protein interactions between cytosolic domains within the
HCV replication complex might be weak when compared to membrane association of the
proteins, this will give flexibility to fulfill the polyprotein functions [33]. On the other
hand, the interactions among this proteins might be using the membrane domains within
the bilayer to interact. On this regard, there are still many open questions. Although
there is a NMR structure for AH, there is no information of the linker between the
AH and the Domain I, where most of the resistance mutations appear to be located.
The most prominent mutation affects Tyr 93, which is positioned on the dimer interface
in both X-ray crystallographic structures. Importantly, mutations at this site confer
cross-resistance to several NS5A inhibitors and, in the case of Daclatasvir genotype 1b
subgenomic replicons and approx. 1,800 fold for genotype 1a subgenomic replicons [36].
Furthermore, conserved amino acid sequences on each linker connecting the AH with
Domain I, linker connecting Domain I subdomain a and b, and finally linker connecting
Domain I to Domain II, which are key for NS5A activities, shown in Figure 11.1, which
are subject of the present study due to the importance in maintaining the functionality
of the protein.
Figure 2.5: Amphipatic helix
Amphipatic helix structure created in MOE. The NMR structure is taken from the
PDB entry: 1R7G. From [33]. Colour coded by secondary structure. The linker
connecting AH to Domain I is a Proline rich region, which has not been yet crystalised,
so in this case it has been predicted and shown as: 29-PKLPGLP-35 (prediction
made by collaborator Cristophe Combet, in white end), as also shown in Figure 11.1.
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Figure 2.6: Domain I of NS5A with linker connections
Amphipathic helix (AH), Domain I subdomains a and b. Sequences containing Proline
residues are also shown, in line with the linker structure dividing each part. Courtesy
by Critoph Combet. Linker sequences are also shown in 11.1
2.7.5.3 Domain I
The structure of domain I (DI) has been solved by three independent groups using X-
ray crystallography. These studies describe a four different dimeric forms of DI from
genotypes 1a and 1b with the same monomeric unit, but different dimeric arrangement
[37–39], when compared by primary sequence, DI of NS5A shares a high sequence ho-
mology to the hepaciviruses, suggesting that it has been well conserved and its critical
functions are common to hepaciviruses, whereas the functions of the other two domains
(domain II and III) maybe specific to each virus. In this regard, generally, DI mainly
functions exclusively for genome replication [37]. Finally, it was recently published that
domain I also plays a key role in assembly of infectious viral particles, identification of
key sites might be important for the production of infectious virus. Additionally, this
publication also describes mutations on P35A, V67A and P145A to be important for
the recruitment of NS5A to lipid droplets (LD), which they also impair dimerisation of
the DI and enhance the binding of DI to the HCV 3’UTR RNA, revealing a role of these
NS5A in assembly of viral particles [29].
For a clearer explanation regarding the differences in the structure of DI, Tellinghuisen
et al, described the Domain I subdomains A and B. The subdomain A, is at the N-
terminal loop, next to a three-stranded anti-parallel β-sheet, and an α-helix at the C-
terminus of the third β-strand. All together, form the scaffold for a four-cysteine zinc
atom coordination. This zinc atom has a structural role in the maintenance of NS5A
fold. To connect subdomain A and B there is a Proline-rich region. Subdomain B,
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contains four-strand anti-parallel β-sheet and other two small ones near the C-terminus
surrounded by coil structures [37]. The N-terminal subdomain A has a very basic surface
meanwhile in the subdomain B there is a more acidic character, this is a unusual charge
distribution and has an impact in the dimerisation of the protein. The crystal structure
of domain I region provided strong data for the study of NS5A. The crystal structure
described by Tellinghuisen et al, Figure 2.7 is known as the ”claw-like” structure PDB
entry 1ZH1 [37].
The anchoring helix AH previously described in section 2.7.5.2, is only five residues
from the N-terminal of DI, suggesting it is very close to the membrane [37]. The basic
surface close to the anchor is consistent and it makes it probable that the protein is in
close contact with the negative charged head groups of the membrane, where it could
interact with RNA. As mentioned before NS5A interacts with RNA via domain I via an
RNA-binding groove located at DI [40]. Additionally, the conjunction between AH and
DI is involved in lipid droplet (LD) targeting.
The second crystal structure described by Love et al, describes the association signifi-
cantly different from the ”claw-like” structure Figure 2.7. The crystal structure which
PDB entry is 3FQM and it is known as ”back-to-back”. This describes the long axes
of the monomers are nearly parallel, with numerous interactions along the entire side of
each one of the monomers, which makes a cylinder appearance. The two N-termini are
found on the same end of the dimer, implying that the two AH are colocalizing, which is
a common feature with the Tellinghuisen structure. There is no overlap between the sur-
faces of the monomers, this tells that the monomers have no simple rearrangement, but
rather undergo a transformation that requires a complete separation of the monomers
and translocation of one monomer to the other side of its initial partner and then it is
followed by a slight tilt of each monomer long the axis [38].
The last crystal structure described by Lambert et al, describes a very similar struc-
ture as the one from Love et al, where the monomers are related by a two fold axis
perpendicular to their length. Additionally, it is shown that the binding cleft between
the head-to-head dimer could accommodate NS5A inhibitor (Daclatasvir, DCV) in a
such a fashion that the key resistance mutations (M28, L31, P58, and Y93, as shown in
Figure 2.7), which are shown in close proximity to the inhibitor [39]. NS5A inhibitors
confer resistance, mainly on the sites mentioned and shown in Figure 2.7, however the
resistance continues to be a main problem when developing new antivirals, which is one
of the reasons studying in detail the mechanism of action of DCV, can elucidate a way
of avoiding resistance to new NS5A inhibitors.
More recently, it was proposed that domain I of NS5A plays multiple roles in assembly,
binding nascent genomic RNA and transporting it to lipid droplets where it is transferred
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to Core. Domain I also contributes to a change in lipid droplet morphology, increasing
their size [42].
Figure 2.7: NS5A dimer conformations
NS5A dimer structures from two different PDB entries: The ”claw-like”, belonging to
the 1ZH1 and the ”back-to-back” structure to the 3FQM. In coloured boxes, the
resistance mutations that confer resistance to NS5A inhibitors. Note that the position
of the amphipathic α-helix relative to DI is arbitrary and assumes that resistance
mutations observed in DI and the amphipathic α-helix would be close to each other.
Also note the supposed membrane-proximal positions of the resistance mutations in
both dimer structures. Mutation of Pro58 has been associated with secondary
resistance to DCV but does not confer resistance by itself, this residue is shown to
highlight the alternative orientations of the monomers in the different dimer structures
[41]. Daclatasvir molecule is also shown in stick representation. Modified from[15]
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2.7.5.4 Domain II and domain III
Domain II is required for RNA replication [26] and interactions with host and viral pro-
teins [43]. Domain II plays a key role in HCV genome replication but has no impact on
assembly or release of viral particles [7]. Domain II has a very conserved sequence and
a large segment within DII can be deleted with no significant effect on RNA replication
and virus production in cultured cell lines. Unlike it, domain III is essential for the
assembly of infectious viral particles. These domains are less conserved than domain
I. The DII and DIII of NS5A are both intrinsically unfolded monomers and because of
this the exact position relative to DI is unclear, see Figure 2.4. The structural flexibil-
ity allows different interactions with cellular proteins [44]. However, just Cylophylin A
(CYPA) and Phosphatidylinositol 4-kinase IIIα (PI4KIIIα) [45, 46] have been shown to
be essential for HCV replication and have been also targeted as antiviral drugs. CYPA
probably interacts directly with NS5A to exert its effect, through its peptidyl-prolyl
isomerase activity, on maintaining the proper structure and function of the HCV repli-
case. The major proline substrates are located in DII of NS5A, centered around a DY
dipeptide motif that regulates CYPA dependence and Cyclosporine A (CsA) resistance.
Importantly, Cyclosporine A derivatives that lack immunosuppressive function efficiently
block the CyPA-NS5A interaction and inhibit HCV in cell culture, an animal model,
and human trials [47].
2.7.5.5 NS5A phosphorylation
There are two phosphorylated forms of NS5A, p56 and p58, phosphorylated and hyper-
phosphorylated protein respectively [48]. Basal phosphorylation results in expression of
the protein at 56kDa and when hyperphosphorylated it results in 58kDa and it depends
on sequences from the C-terminal region of the LCSI up to the end of NS5A. The phos-
phorylation sites are mainly in serines [49] located at the C-terminal and to a less extend
threonines and tyrosines. Phosphorylation is a very well conserved feature among other
viruses related to HCV, such as Bovine Viral Diarrhoea Virus (BVDV) and Yellow Fever
Virus (YFV), which suggests it is a critical step for the Flavivirus life cycle. The enzymes
that are involved in the phosphorylation have not been completely identified, regardless
some include: casein kinase I and II (CKI and CKII)[50–52], mitogen-activated protein
kinases (MAPKs) [53], polo-like kinase 1 (PIK1) [54] and glycogen synthase kinase 3
(GSK-3).
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2.7.5.6 NS5A functions
As mentioned already, as a multifunctional protein NS5A has a role during RNA repli-
cation and assembly of the viral particles. NS5A interacts with other non-structural
proteins such as NS5B, this is key for RNA replication. In order to trigger replica-
tion and switch on HCV life cycle, NS5A binds to the 3’UTR of positive and negative
strands of HCV RNA (preferentially on U/G rich single stranded RNA regions), which
is absolutely required [55].
The structure of NS5A previously described gives an overview of what are the func-
tions of NS5A. Additional interactions with other host factors such as protein kinase
R (PKR), p53, TATA-binding protein (TBP), Snf2 related CREBBP activator protein
SRCAP protein, vesicle associated membrane protein (VAPA) have been described [56–
59]. Phosphorylation of the protein also modulates the functions of it, for instance,
VAPA can bridge NS5A p56 with NS5B favouring replication complex formation, mean-
while hypherphosphorilation of NS5A interrupts the interaction allowing viral particle
assembly [60].
Perhaps the multifunctionality of NS5A is also due to the dimerization and further
multimerization of the protein, that can give rise to different conformations.
2.7.5.7 NS5A oligomerization
Domain I of NS5A indeed can form dimers and it is critical for this process. However,
detection of high molecular forms of NS5A is whether representing a nonspecific aggre-
gation complex or these are true higher order NS5A complexes [61]. Importantly, Love
et al, observed an oligomeric state of NS5A and modelled possible NS5A oligomers based
on the crystal structure known [38]. These studies strongly suggest the oligomerisation
state of NS5A. On the other hand, dimeric structures are important for the antiviral ac-
tivities of NS5A inhibitors. Binding experiments have shown that these inhibitors bind
to NS5A directly and that mutations conferring resistance are mapped in the N-terminal
region. Interestingly, when tested NS5A inhibitor DCV also known as BMS-790052, did
not affect NS5A dimerisation, but the blockage of disulphide bridge forming cysteines
in DI can reduced interaction upon treatment [61].
However, experiments measuring ratio of NS5A to NS5A inhibitor DCV present in cells,
suggest that a small amount of inhibitor molecules can impact the function of a large
number of NS5A protein molecules, based on these observations Sun et al developed a
working model for NS5A inhibitors action, in which NS5A proteins interact with each
other and a single bound inhibitor perturbs the function of an NS5A oligomer, thus,
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resulting in the disruption of replication complex formation or NS5A normal function and
this in turn, results in an amplified inhibitory effect. Together with the crystallographic
data of DI and the NMR structure of amphipathic helix, hypothetically assembling in
a polymer network alternating the interfaces, they built up a working model. Under
this structure, DCV is docked across the dimer interface as previously reported [37].
Thereafter, when Sun et al, added a second inhibitor to determine whether it could,
compete with DCV for binding and have no impact or to bind adjacent to NS5A inducing
a conformational change by DCV binding and resulting in enhancement of its potency
[62] see Figure 2.8. The complementary effect of DCV and the second inhibitor called
SYN-395, after its synergistic effect, requires communication within the binding sites,
more detail information on the MOA of the syn compounds is in section 6. However in
this case, the polymer model proposed would suggest that the induced inhibition affects
the NS5A dimer in which DCV is bound and it is also transmitted to the proteins along
the helical axis through P29-P35 loop interactions (which as mentioned before, includes
very conserved Proline residues 29, 32 and 35 and it is located in the linker connecting
the AH to DI) to inhibit multiple NS5A proteins [62]. This study highlights not only the
importance to investigate further the role of Proline residues in the structure of NS5A,
but additionally NS5A oligomer formation. Thus, due to the high conservation of these
Proline residues, we decided to look into their role in HCV infection and DCV binding,
as shown in the Results section III and we also investigated on the oligomerization
process of NS5A protein. For more information given on NS5A inhibitors and other
HCV inhibitors, see section 6.
The results in this publication by Sun et al, suggested a formation of an extended mul-
timeric network of NS5A that may occur through the different dimer interfaces. The
combination of two genotype 1b NS5A-D1 dimers allowed the formation of a superhelical
array which can give support to a model for the oligomerization of NS5A and NS5A-D1
constructs observed in vitro shown by Lambert et al [39]. However, the formation of
these higher order oligomer complexes into a non-planar, superhelical array precludes its
association with a lipid bilayer [38]. Different conformations of DI dimers can suggest
an array of NS5A molecules that form an extended network that could interact with the
membranous web. The NMR data also shows that the protein can aggregate reversibly
in a concentration dependent manner, possibly into ordered oligomeric states [39]. How-
ever, more studies are needed to determine the oligomerization state of NS5A, favouring
monomeric, dimeric or oligomer. In the present study we try to address this problem
and investigate further to determine the oligomerization state of NS5A protein.
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Figure 2.8: NS5A oligomer model
NS5A oligomer model where Daclatasvir (DCV) and Syn-395 are bound to NS5A
dimer and polymer. a, DCV is docked across the NS5A dimer interface stick
representation shown in green, the amphipatic helix shown in red. Some of resistance
mutations to DCV are pointed (L28, L31, Y93), as well as the highly conserved Proline
residues in the AH-DI linker P29, and P35. b, NS5A helical hexamer is composed of
three PDB: 1ZH1, (same colour) and two PDB 3FQM dimer (alternate colours). c,
Graphical representation of conformational changes that can affect inhibition and
further recovery of inhibition by the synergistic effec of SYN-395 compound. Modified
from [62]
2.7.6 Non-structural protein 5B (NS5B, 68kDa)
NS5B, is the RNA-dependent RNA polymerase (RdRp). It is a phosphoprotein anchored
to the membrane via its C-terminal 21 amino acids. As a RdRp has a typical shape:
palm, finger and thumb subdomain structure and the hallmark GDD sequence as it is
shown in Figure 2.9. It forms the catalytic center of HCV replication machinery and is
responsible for synthesis of negative-strand RNA intermediate from the positive-strand
viral genome see next section 3.
The active site is highly conserved and located in the palm subdomain. The catalytic site
domain contains a C-terminal membrane insertion sequence which is essential for RNA
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Figure 2.9: NS5B
NS5B structure, containing palm, fingers and thumb. Taken from [15]. Ribbon
diagram of full-length NS5B (Protein Data Bank (PDB: 1GX6) and the association
with the membrane via the NS5B carboxy-terminal transmembrane tail. The finger,
thumb and palm subdomains are indicated, and the so-called β-loop is shown in
orange. The C-terminal linker sequence (grey) connects the core of the enzyme with
the membrane insertion sequence (magenta). The structure indicates the proposed
membrane topology of NS5B in the so-called closed conformation, on the basis of
available X-ray crystallographic structures, and this is believed to represent the
initiation state of the polymerase. The active site is highlighted by two priming
nucleotides (yellow). In this conformation, the RNA-binding groove is hidden by the
NS5B ectodomain that stacks to the membrane. Modified from [13].
replication in cell culture and for in vitro enzymatic activity. When compared to other
RdRp, NS5B has a closed conformation of the active center, where the C-terminal linker
folds back into the active center involved in RNA synthesis [63–65]. Starting of initiation
is represented by the polymerase closed conformation, after this, the enzyme undergoes
a big conformational change that allows the opening of the structure to generate a
cavity capable of binding the double stranded RNA [13]. NS5B is one of the main
targets for direct acting antivirals (DAAs) together with NS3/4B and NS5A. Many
other polymerases have been target of antiviral therapy and this will be discussed in
section 6.
Chapter 3
HCV replication cycle
Replication of HCV RNA is a multi-step process that is orchestrated by synchronized
action of viral and cellular proteins. Structural arrangements are necessary to origi-
nate the sites where HCV replication takes place. Once HCV has infected an hepato-
cyte (main cellular target), it associates to low-density lipoproteins (LDL), to very-low-
density lipoproteins (VLDL) and to apolipoproteins: E, B, C1, C2 and C3 to form a
complex lipoviroparticle [66, 67], this is process is followed attachment, entry and fusion.
The attachment requires the receptor of E2 glycoprotein, facilitated by heparan sulfate
proteoglycans present on the hepatocyte’s surface. The LDL and VLDL receptors can
bind HCV and promote its entry. The main cellular receptors and entry factors for
HCV are scavenger receptor class B type I (SRBI), [68], CD81 [69] as well as some tight
junction proteins such as claudin-1 (CLDN1) [70] and occludin (OCLN) [71, 72]. Among
other receptors recently identified which are also entry factors to mention: receptor ty-
rosine kinases (RTK), epidermal growth factor receptor (EGFR), ephrin receptor A2
(EphA2) and the Niemann-Pick C1 like cholesterol adsorption receptor (NPC1L1). All
together these receptors are key for attachment and entry which give the essential venue
for HCV to entry the cell and establish infection. At the fusion step, HCV enters the cell
via clathrin-mediated endocytosis and is internalized into target cell via pH-dependent
in the endosome which triggers the viral envelope and endosomal membrane to release
the nucleocapsid to the cytoplasm, where the RNA is released [73–75]. See Figure 3.1.
Once the RNA genome enters the cytoplasm, the HCV polyprotein is translated in
the rough ER with the positive strand as a template. Translation is initiated in a
cap-independent manner using the IRES at the 5’NTR. The HCV single polyprotein
precursor is then processed by cellular (signal peptidases) and viral proteases (NS2,
NS3/4A) to give rise to the 10 viral structural and non-structural proteins as previously
described on section 2.3 [76].
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Like other positive-strand RNA viruses, HCV can remodel intracellular membranes, gen-
erating organelle-like membranous structures, which can be called replication factories
or membranous web. The main functions of the replication factories (vRFs) are: in-
crease local concentration of factors required in RNA replication, spatial coordination in
the replication cycle process (RNA translation, replication and assembly), and protect
the viral proteins and RNA from antiviral defenses [13, 77].
There are two types of membrane rearrangements: invaginated vesicles or double mem-
brane vesicles (DMV) [78]. HCV non-structural proteins are associated with the mem-
branous web which includes DMVs containing nonstructural proteins, ER membranes,
HCV RNA, and lipid droplets. As mentioned before, this membranous web or replica-
tion factories are the sites where RNA replication takes place, viral RNA is amplified
by NS5B, (RdRp), together with most of the NS proteins and some host cell factors
such as cyplophilin A (which can modulate NS5B RNA-binding capacity and interact
with NS5A) [79] and PI4KIIIα (recruited to membranous web by NS5A and required
for HCV replication providing integrity to the membranous viral replication complex)
[46].
As the positive strand is copied into negative strand RNA via replicative form is used
for synthesis of excess amounts of positive strand RNAs viral replicative intermediate.
Starting of RNA synthesis requires highly structured RNA elements in the 3’NTR of
the template, the new synthesized RNA genomes are translated, then RNA replication
takes place, finalizing with the assembly of the virions [80].
The viral RNA is thought to be delivered to the replication sites to the core protein on
LDs by the viral replicase, alternatively, NS5A which can bind RNA may be released
from the replicase complex to move onto the LD surface. The capsids are finally budding
to the ER lumen in a process tightly linked to VLDL synthesis, which is why assembly
then is dependent on (V)LDL synthesis and requires several enzymes and apoE [15, 67,
77]. Infectious HCV particles are pleomorphic, lack discernible surface features and have
broad size range 40-80 nm diameter [81]. More recently, NS5A was identified as a major
determinant in HCV assembly. Domain III, was found to be a key element to ensure
the production of infectious viral particles [26].
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Figure 3.1: HCV replication cycle
HCV replication cycle starts when binding of HCV lipoparticle to the SRB1 and CD81
receptors, further interactions with CLDN1 and OCLN are necessary. Once the virus
enters the cell via receptor-mediated endocytosis (step 1), the positive-sense single
stranded viral RNA is released into the cytoplasm and translated at the rough ER,
giving rise to a single polyprotein cleaved in 10 mature proteins (step 2). Together
viral proteins and host ell factors induce the formation of the membranous web (MW)
located in close proximity to LD (step 3). RNA replication proceeds via negative-sense
copy which is the template for the production of excess amounts of positive-sense
RNAs (step 4). Assembly of HCV particles supposedly taking place close to the ER
and LDs, where core and vRNA accumulate. Viral envelope is acquired by budding
through the ER membrane (step 5). Finally HCV particles, are thought to leave via
constitutive secretory pathway (step 6). The blue boxes represent the viral and host
facotrs which are known or suspected to be essential for the viral life cycle, thus,
potential drug targets. (CYPA: cyclophilin A, PtdIns4KIIIα: phosphatidylinositol
4-kinase IIIα). Taken from [13].
Chapter 4
HCV experimental studies
This chapter is dedicated to describe the HCV experimental tools available for studying
HCV infection. Until 1989, the lack of a cell culture system and the small animal
models to propagate HCV was a major issue for HCV research. In 1997, the only model
to study HCV was the chimpanzees (Pan troglodytes), which could be injected with
HCV, this allowed to study HCV genome and its encoded proteins. However, bioethical
and high costs could not allow a certain number of experiments, other attempts involved
xenotransplantation system of human liver into mice (Mus musculus domesticus). Thus,
there was not much data regarding HCV molecular biology research, finally in 1999 a
major step for HCV investigation was made by the establishment of the subgenomic
system [82], see Figure 4.1. To generate this tool, a full-length clones consensus genome
of the genotype (called Con1); the region encoding p7 and NS2 proteins was replaced by
elements which do not belong to HCV, a selectable marker neomycin (neo) gene for drug
selection G418, the second is the IRES element of encephalomyocarditis virus (EMCV),
which ensures translation of HCV polyprotein NS3-5B. To ensure IRES full activity the
replicon contains 48 nucleotides of core coding sequence at the 3’ end of the HCV IRES.
Thus, this changes made a bicistronic construct that can replicate autonomously within
human hepatoma cell line Huh-7 upon transfection of in vitro transcribed RNA [82].
This tool was then used to generate replicon cell lines with high RNA replication level
that can be selected by treatment. Continuous analysis of these cell clones and replicons
showed increased replication capacity caused by adaptive mutations and increased host
cell permissiveness. Some of these mutations identified have been included to make
a highly adapted replicon, Con1/ET, containing two point mutations NS3 (E1202G,
T1280I) and one in NS4B (K1846T) [82–84].
The neo marker can be also substituted by firefly luciferase (FLuc) bicistronic, or renilla
luciferase (RLuc) monocistronic which can also work as a reporter, additionally other
23
24
Figure 4.1: HCV subgenomic replicons
Structure of the HCV subgenomic replicons created by [82]. Indication of the cleavage
location products and the 5’ and 3’ NTRs. HCV-IRES selected for the construction
and a GDD active site of the NS5B. The selection of subgenomic repicons contain a
5’HCV-IRES, the neo gene, the EMCV-IRES and the HCV non-structural proteins
NS2or NS3 to the 3’ end δ is representing the deletion in the position of the 10-amino
acid in the NS5B polymerase. Normally, GDD stands for an NS5B
polymerase-defective replicon in which the critical GDD motif in the polymerase active
site is replaced by AAG (referred to as GDD). Modified from [82].
reporters have been inserted in the NS5A region such as green fluorescent protein (GFP),
to allow monitor cells by immunofluorescence or western blot [85, 86] as shown in Figure
4.2.
Figure 4.2: Structure of Jc1 based reporter genomes
Reporter genomes containing (blue) structural proteins, (green) non-structural HCV
proteins. Jc1FLuc, containing Firefly Luciferase and EMCV IRES. Jc1GFP containing
green fluorescent protein (GFP) before NS5B. Modified from doctoral thesis of
Margarita Zayas.
In the recent years, other breakthroughs have been made in HCV research, the cloning of
subgenomic replicon of the genotype 2a consensus genome from a Japanese patient with
fulminant hepatitis (JFH1) which has high levels of replication in Huh7 cells without
any cell culture adaptive mutations and also when JFH1 was discovered to be able to
produce infectious virus particles upon transfection of the full length genome in vitro
transcripts into Huh7 cells [87, 88].
Furthermore, the full-length JFH1 genome supports the production of culture-derived
particles (HCVcc), which are infectious in vitro and in vivo [88]. This particles are
around 60-75nm in diameter and spherical and are have high specificity infecting at
a peak buoyant density of approximately 1.10g/ml like serum produced particles. To
improve the system virus chimeras were generated consisting of the JFH1 replicase (NS3-
NS5B) fused to the core to NS2 region of different HCV isolates. Another tool to study
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HCV are HCV pseudo particles (HCVpp) system, this are retroviral nucleopcapsids
surrounded by lipid envelope which contains authentic HCV glycoprotein complexes
this system allowed a robust infection system in Huh7 cells and in primary human
hepatocytes to study the early stages of infection with HCV such as entry and receptor
binding [89, 90].
Nevertheless, the research continues to be improved by trying to develop small animal
models by humanized mice, which can be infected with HCVcc or HCV patient sera.
More reliable experimental set-ups with an authentic and physiological condition present
in the infection with HCV are yet to develop [91, 92]. The following Figure 4.3, contains
the most recent advances in animal models to study HCV infection [93].
Figure 4.3: Table including Animal model for studying HCV infection
Studies using animal models where the complete viral life cycle has been performed (or
parts), viremia levels, liver disease, DAA testing, passive inmunization, vaccine
development and availability are shown for each. Details on the advantages and
disadvanteges are reviwed in citation. Taken from [93].
Chapter 5
HCV and host immune response
As mentioned earlier, HCV can cause persistent infections, this can cause that the host
defenses initially sense HCV by the antiviral innate immune response which is triggered
by pattern recognition receptors (PRRs), these are responsible for a downstream signal-
ing that can activate immunity. Approximately 20-30% infected people can resolve the
infection but 70-80% develop a chronic infection. HCV is among the most successful of
persistent human viruses, it persists in 70% of those infected [94].
The innate immune response against RNA viruses is mainly composed by three classes
of PRRs: retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), toll-like receptors
(TLRs), the nucleotide oligomerization domain-like receptors (NLRs) [95] or double-
stranded RNA sensing proteins such as protein kinase R (PKR), which are in charge
of recognizing pathogen-associated molecular patterns (PAMPs) present during viral in-
fection. The HCV IRES is recognized by RNA-dependent PKR while the HCV 3’poly-
U/UC, 5’ triphosphate of the uncapped HCV RNA and the short double-stranded RNA
region sequences are recognized by the RIG-I. A sequence of downstream signaling pro-
ceeds to activate various genes and cytokines such as interferon I and III and IL-1β,
which in turn activate paracrine or autocirne pathways to establish full antiviral state.
The best described detector of HCV infection is RIG-I, which is a cytosolic RNA sensor
and together with MDA5 (melanoma differentiation-associated protein 5) and LGP2
(laboratory of genetics and physiology 2) can regulate HCV infection. These pathways
converge on the activation of the key transcription factors NF-κ B and the interferon
regulatory factor (IRF) 3 and 7. Activated IRF3 and NF-κB bind to response elements
in the promoters of type I and III IFN genes, which are essential for antiviral defence
[96].
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Innate immune responses rely on interferons (IFNs) to activate and regulate the cellular
components for the antiviral response such as the natural killer (NK) cells. Type I IFN
compromising several IFN-α and one IFN-β and type III IFN-γ1, IFN-γ2 and IFN-
γ3 also called IL29, IL28A and IL28B which are produced by the infected cell and by
macrophages and dendritic cells (DCs). Type II IFN (IFN-γ) is produced by NK and
T cells from antigen specific T cells (CD4+ and CD8+ cytotoxic lymphocytes) [96].
Subsequent activation of IFNs induced transcription of multiple interferon-stimulated
genes (ISGs) through the activation of the JAK/STAT signaling pathway results in the
recruitment of effector immune cells that can trigger the adaptive immune response
[97, 98].
When adaptive immune responses fail to neutralize the infection, chronic infection is
established. Despite the global failure of the immune reaction against HCV, T cell
exhaustion and emergence of viral escape mutations are the main cause of T cell failure,
which causes the establishment of HCV life cycle [99].
Furthermore, HCV supports a reaction against the host cell immune responses. The
viral NS3-4A protease is central in the HCV host immune evasion strategy [100], it
can block RIG-I signaling, because in addition to proteolytically processing of the HCV
polyprotein it targets and cleaves mitochondrial antiviral-signaling protein (MAVS) from
intracellular membranes preventing the subsequent signaling transduction. The cleavage
prevents activation of RIG-I pathway and during acute infection abrogates IFN induction
which supports the progression to a chronic infection [101, 102]. In addition, HCV can
control PKR-mediated translation suppression of host mRNAs during HCV infection
and IFN therapy can inhibit translation of host factors require for HCV replication
(PKR works as an antiviral molecule) but it can also inhibit ISGs and IFN (PKR as
a proviral molecule) [98]. More recently, NS4B was found to degrade TRIF in order
to avoid the activation of TLR3 mediated interferon signaling pathway as part of HCV
host immune system evasion [29].
Further studies on how HCV evades the immune responses of the host can give more
insights into antiviral drug development.
Chapter 6
HCV antiviral therapy
An estimated of 130 million are vulnerable to chronic infections around the world whom
can develop liver cirrhosis (≈ 27%) and hepatocellular carcinoma (≈ 25%) as men-
tioned in section 1. This has made HCV infection a global medical problem which has
drawn the attention and efforts to develop drugs and new antiviral treatments. Un-
fortunately, prophylactic treatment for HCV has not been very successful, having no
vaccine development. Many limitations in HCV vaccine development as genomic vari-
ability and worldwide different genotype distribution see Figure 1.1, which causes poor
cross-genotype immunity [99].
The majority of infections are treated with a combination of pegylated interferon-α
(PEG-IFNα) and ribavirin, as many other viral infections are treated. In some of the
cases this therapy can eliminate HCV infection with this treatment but it depends on
the stage of the disease, genotype and some polymorphisms (for example IL28-B gene).
However, the rest of the cases are unresolved, in the recent years the development of
direct acting antivirals (DAAs) has lead to a big step in HCV antiviral development[13].
Every step of HCV life cycle can be a potential drug target for antiviral therapy, however
the successful inhibitors at the moment are just made for the non-structural proteins
NS3/4A, NS5A and NS5B, which are use in combination, and together they can clear
around 98% of infection, yet resistance mutations and high cost of this inhibitors pro-
motes new development of antiviral treatments. This chapter will describe the DAAs
available, a summary of the DAA inhibitors for the non-structural proteins of HCV are
described in Figure 6.1. We described more in detail NS5A inhibitors due to the purpose
of the present study, in the following subsection 6.1.3.
28
29
Figure 6.1: Table including DAA inhibitors
Summary of FDA-approved antivirals against HCV infection. Table contains targeted
protein, name of the compound, EC50 values in nM for each of HCV genotypes and the
corresponding reference. Taken from [103].
6.1 Inhibitors
6.1.1 Protease NS3-4A inhibitors
NS3 is a multifunctional protein and together with NS4A cofactor constitute the serine-
type protease that HCV uses for cleavage of viral and cellular (MAVS, CARDIF, VISA
and IPS1) proteins while the C-terminal contains the NTPase activity, see section 2.7.2,
both activities have been pursued as drug targets. However, the NS3 protease was
the target for DAAs, by exploiting the fact that after NS3-4A mediated cleavage the
product derived from the N-terminal fragment remains bound to the active site and
thus blocks the enzyme, which gives this DAA a high potency [104–106], see Figure
6.2. These compounds belong to the first class of compounds and they bind to the
active site Serine, being called ’Ser-trap’. These inhibitors antagonize the enzyme by
forming enzyme-inhibitor adduct that dissociates with very slow kinetics. Three classes
of these compounds have been developed: first class linear peptidomimetics are forming a
covalent but reversible link, adducts with enzyme (telaprevir and boceprevir), the second
class are linear peptidomimetics and third class are macrocucylic inhibitors on the basis
of their structure. Unfortunately, these last ones do not target all the HCV genotypes
to the same extent. Furthermore, the barrier to select for resistance against these first-
generation inhibitors is low and cross-resistance has been identified [107]. Consequently,
overcoming these limitations are the goal of the second generation of NS3-4A inhibitors
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like MK-5172 and ACH2684 which are macrocyles that have a pan-genotypic activity
with improved resistance profiles [108, 109]. It is worth mentioning that the NS3/4A
inhibitor simeprevir, as shown in Figure 6.2, in the combination with the NS5B inhibitor
sofosbuvir (NS5B inhibitor, see Figure 6.3, is considered to efficiently inhibit different
stages of HCV life cycle [103].
Figure 6.2: NS3/4 protease structure and docked DAA simeprevir
Tertiary structure of HCV NS3/4A protease. The tertiary structure of NS3/4A
protease in complex with simeprevir (PDB codes: 3KEE and 4B76). HCV NS3 and
NS4A proteins are displayed in orange and pink, respectively [110]. Modified from
[111].
6.1.2 RNA-dependent RNA polymerase NS5B inhibitors
As already described in section 2.7.6, NS5B is a key enzyme for HCV life cycle, it medi-
ates RNA synthesis by using its catalytic core with a typical structure of a polymerase
(right hand: fingers, palm and thumb), see Figure 6.3 and 6.4. There are two groups
of drugs, according to their mode of action which target NS5B protein: nucleoside and
nucleotide inhibitors (NIs) and non-nucleoside inhibitors (NNIs). The first group of NIs,
mimic the natural substrates of the polymerase and act at the active site of the enzyme,
while the NNIs bind to different allosteric states and inhibit conformational changes in
the polymerase. Due to the high degree of conservation NIs are usually more effective
towards resistance than NNIs [112], examples are shown in Figure 6.3
NIs are derivatives of ribonucleosides or ribonucleotides and compete for the natural
active site of the polymerase, they require high intracellular concentrations. Usually
have a low-micromolar range and are typically delivered as prodrugs, where the non-
phosphorylated chemical modifications are cleaved off and the liberated nucleoside is
converted to 5’-triphosphate by cellular enzymes. Once phosphorylation occurs, the
active drug can compete for the natural site and incorporate into the growing RNA.
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Figure 6.3: NS5B structure and docked DAA sofosbuvir and beclabuvir
Tertiary structure of HCV NS5B and structural formulas of approved or experimental
nucleoside inhibitors. NS5B structure in complex with beclabuvir and sofosbuvir
diphosphate (PDB codes: 4NLD and 4WTG) is visualized on top. Modified from [111].
Figure 6.4: NS5B inhibitor, SOF chemical formula
Sofosbuvir chemical formula. The discovery of sofosbuvir undertaking path from
20-C-methylcytidine to 20-F, 20-C-methyluridine 5-phosphoramidate [113]. Modified
from [111].
Another way to inhibition NS5B is to use 3’-deoxy modified nucleosides that are clas-
sical chain terminators, but due to phosphorylation are poorly active in cell culture
[114]. Additionally another drawback from ribonucleoside analogues is their interfer-
ence with human mitochondrial RNA polymerase, which can inhibit mitochondrial gene
expression, which might be the explanation to the serious side effects of several drugs
(Valopicitabine, Balapiravir, and others). On the other hand, NNIs are commonly more
diverse and are grouped into 4-5 classes depending on their allosteric binding, even
though they can be highly active, resistance can be rapidly selected [115].
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Advanced nucleoside analogue, Mericitabine, has been shown to be active in genotype 1
and genotype 4, and the most advanced nucleotide analogue is Sofosbuvir (SOF) struc-
ture shown in Figure 6.4, which has high efficacy against genotypes 1-6 in combination
with PEG-IFNα and ribavirin [113, 116].
Furthermore, there are alternative viral drug targets which can interfere with HCV
life cycle, NS4B and p7 proteins are now under development as antiviral drugs. As an
alternative host cell target, cyclophilins and mir-122 have been extensively studied [103].
6.1.3 Non-structural protein 5A inhibitors
NS5A inhibitors have several effects on HCV life cycle. They might affect formation of
the replication complex at the ER and sequester NS5A in lipid droplets to inhibit virus
formation and release [1] or directly affect the assembly of viral particles [117]. Hence-
forth, the FDA has approved the following drugs: Daclatasvir (BMS-790052), ledipasvir
(GS-5885), ombitasvir (ABT-267), elbasvir (MK-8742), velpatasvir (GS-5816), and on
clinical tests: Pibrentasvir (ABT-530), ravidasvir (PPI-668), GSK2336805, ruzasvir
(MK-8408), EDP-239, samatasvir (IDX719). It is known, that NS5A inhibitors do not
affect stability or dimerisation of NS5A but block HCV RNA synthesis at the stage of
membranous web formation [118]. Recently, it was discovered that DCV, can impair
viral assembly by inhibiting the delivery of HCV genomes to the assembly sites [117].
NS5A inhibitors slowly inhibit HCV RNA synthesis when compared to HCV protease or
polymerase inhibitors [119]. Furthermore, NS5A inhibitors can enhance drug resistance
barrier and restore antiviral activity against NS5A resistance variants [62]. Notably, the
crystallographic structures have been very useful in the development of NS5A inhibitors
and further studies will elucidate the whole picture under the high potency, see Figure
6.5 and 6.6. In the following subsections we describe a more detailed information on
NS5A inhibitor, Daclatasvir (DCV), as main subject of the present study.
6.1.3.1 Daclatasvir
DCV inhibits NS5A at DI and it is a food and drug administration (FDA) approved for
the treatment of HCV infection, see Figures 6.5 and 6.6. DCV has been administered
together with PEG-IFN and RBV as well as IFN free options [120], it can be administered
together in combination with other DAAs including asunaprevir (NS3 protease inhibitor)
(ASV) and sofosbuvir (SOF) (NS5B inhibitor). Normally, DCV plus SOF is given for
12 weeks [121] to have a high treatment efficiency. DCV has high rates of sustained
virological response (SVR) >90%, which has a clinical relevance regarding the clearance
of HCV infection in most patients. Interestingly, studies with DCV in replicon cells
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showed that double or triple inhibitor combination of DAAs can produce resistance
which can be different from when using mono-therapy. Indeed, onset of resistance may
lead to cross-resistance among DAAs or to other NS5A inhibitors, while DCV-variants
remained completely sensitive to other classes of DAAs [122–124].
Importantly, resistance-associated substitutions (RASs) in NS5A have a major impact
clinically. As previously mentioned, RASs at key positions (28, 30, 31, and 93) in
HCV genotype 1a result in broad cross-resistance to early generation NS5A inhibitors,
except L31M RAS on ombitasvir and of the M28V RAS on elbasvir or ledipasvir. Next-
generation NS5A inhibitors pibrentasvir (ABT-530) and ruzasvir (MK-8408) show a
retain activity against all of the key single-position NS5A RASs in HCV genotypes 1a
and 1b and, therefore, may retain activity despite resistance to current NS5A inhibitors
[125].
Alternatively, mathematical models have been proposed to study and predict the possi-
ble mode of action of the inhibitors [126], many other attempts in medicinal chemistry
are undergoing forward to develop new and better antiviral therapies. HCV resistant as-
sociated variants can occur naturally and usually after virological failure,, DCV resistant
variants tend to persist even after discontinuation of the treatment and cross-resistance
can be observed to all NS5A inhibitors. This remarks the importance of understanding
fully the mechanism of action of NS5A inhibitors can elucidate insights into new drug
development or improvement of existent drugs.
6.1.3.2 Discovery and development
At the beginning it was believed NS5A was not druggable mainly because of its lack of
enzymatic activities. But in 2009, a high throughput screening showed pico to nano an-
tiviral efficacy of leading compounds [36, 127]. One of these compounds was Daclatasvir,
which has been widely studied and available against HCV infection. DCV displayed a
therapeutic index (CC50/EC50) of at least 100,000 in vitro fold and works on genotype
1a, 1b, 2a and 3. Symmetry of this compound defined its antiviral activity having an
EC50 of 5 picomolar (pm) and 9 pm (for genotype 1a and 1b, respectively). Then, clin-
ical development increased towards NS5A inhibitors, initially mono-therapy was tried
using DCV single dose, which showed dropping on HCV plasma RNA levels and it
was well-tolerated treatment with few side-effects. Unfortunately, mono-therapy showed
rapid resistance mutation emergence, which is why nowadays is taken in combination
with other DAAs or traditional standard of care (SOC) therapy [36]. In general, HCV
drug development has advanced in several aspects: interferon-free regimens, genotype
specific drugs, therapies based upon one pill per day, drug potency increased, treatment
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duration were shortened, therapies can be administered orally, despite all, HCV drug
discovery challenges remain to identify and treat difficult-to-treat patients [111].
Figure 6.5: NS5A inhibitor, Daclatasvir in NS5A protein
Tertiary structure of HCV NS5A and structural formula of approved DCV docked into
the two units of an NS5A, shown as a dimer, which are coloured by pink and cyan,
respectively. Modified from [111].
Figure 6.6: Daclatasvir chemical formula
NS5A inhibitor Daclatasvir is also illustrated. FDA-approved compound Daclatasvir
[128]. Taken from [111].
6.1.3.3 Resistance mutations
The downside of using DCV as antiviral therapy is that it comes with selective mutation
resistance. Most of the mutations have been found in NS5A between the amphipatic
helix and domain I linker, specifically in amino acids 28-31 and around amino acid
93 of NS5A, which is one of the most described mutations, Y93H. The role of the
amino acids in linker AH-DI is crucial for NS5A protein to fulfill its functions. This
is one of the main reasons in the present study we aimed to understand the mode
of action of DCV in relation of the structure of the linkers present in NS5A protein.
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It has been identified in several genotypes, which points out a conserved inhibitor-
binding site [129]. Substitutions at L31 and Y93 have the greatest ability to confer
resistance to DCV. These substitutions can also confer resistance to first-generation
NS5A inhibitors, double or triple combinations of NS5A inhibitors with other DAAs,
can generate resistance in replicon systems [122], see Figure 2.7. Resistance mutations
at amino acids M28, L31, P58 and Y93, are also found in DI under DCV treatment [13].
Another relevant aspect of DCV resistance is the existence of HCV quasispecies, which
are variants that can replicate at low levels and usually cannot be detected by current
techniques. However, quasispecies can be selected if any NS5A inhibitor, including DCV
is administered and their expression levels can increase. Additionally, escape pattern can
also confer resistance whereby viral replication returns to pre-treatment levels and the
dominant virus harbours amino acid substitutions which can increase the drug resistance
without impairing the fitness of the virus [130].
6.1.3.4 Mechanism of action
Many questions remain unanswered about the molecular mechanism of action of NS5A
inhibitors, fortunately, some elucidating insights have described a major part of what
these inhibitors can be targeting. Due to NS5A critical role in replication and assembly,
NS5A is an attractive antiviral, which is why it has been widely studied. In HCV
replicon cells, inhibition of NS5A resulted in its redistribution form ER to LD, thus,
the targeting molecules have a dramatic effect on the phenotypic localization of NS5A
[131]. On the same study, kinetic compound analysis showed that the redistribution was
concomitant with the onset of inhibition [1]. As previously mentioned, NS5A inhibitors
were found to block HCV replication by preventing the formation of the MW, which
was not linked to an inhibition of PIP4KIIIα [118].
Recently, Boson et al, showed that short exposure of HCV-infected cells to DCV reduced
viral assembly and induced clustering of structural proteins with non-structural proteins
(Core, E2, NS4B and NS5A), where they appear to be inactive. Daclatasvir reduced
the delivery of viral genomes to these core clustered structures. However, when using
the resistant mutant, NS5A-Y93H, DCV showed no induced clustered structures nor
inhibition of HCV assembly, indicating that DCV targets a mutual specific function of
NS5A inhibiting both processes [117]. This dual mode of action described by Boson et
al, was also observed in our experiments, see section Results III, which conclude that
DCV indeed targets NS5A not only during HCV replication but has an additional effect
during assembly of the viral particles.
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Moreover when considering the sub-stoichiometric antiviral activity it was suggested
that not only DCV but all NS5A inhibitors might target one NS5A molecule which com-
municates using conformational changes to neighbouring NS5A molecules of an NS5A
oligomer [39, 62]. This hypothesis was supposed by Sun et al, where they discovered
the synergist compounds (Syn-395 and Syn-535), as already mentioned in section 2.7.5,
and in Figure 2.8. Syn compounds were found inactive alone against both wild-type
and resistant variants but can greatly enhance the potency of DCV against resistant
variants. Specifically, DCV exhibits an EC50 of 0.033 nM against wild type GT-1a, but
has no activity towards a GT-1a Y93N mutant (EC50 339 nM). The synergist Syn-395,
is inactive towards both wild type and Y93N (EC50 214 nM and 215 nM, respectively).
However, in the presence of Syn-395, the potency of DCV against the Y93N variant is
greatly enhanced. For example, no inhibition of Y93N was observed at 40 nM Syn-395,
but in the presence of 40 nM Syn-395 the potency of DCV against Y93N is enhanced
by approximately 2,600-fold, with the EC50 value shifting from 339 nM to 0.13 nM [62].
This study highlights the importance of determining the oligomerization state of NS5A
protein, which will clarify the conformational changes necessary for the mode of action
of DCV and further NS5A inhibitors.
Lastly it was suggested that indeed NS5A is only targeted at a spatially and temporally
restricted point with crucial role in the HCV RNA replication [131]. This might apply
only for a subset of NS5A molecules. However Guedj et al, hypothesized by using
a mathematical multiscale model that NS5A inhibitors not only inhibit HCV RNA
synthesis, but also virion assembly and/or secretion [126]. This hypothesis was the later
confirmed by Boson et al, as already mentioned. However the present study gives a
parallel importance of the dual mode of action of DCV.
Chapter 7
HCV and cellular membrane
interactions
HCV and many other Flaviviruses exploit cellular resources to facilitate viral propa-
gation, one of them is to manipulate cellular membranes. In HCV case, major rear-
rangements of the ER membranes take place during infection. RNA replication occurs
in tight association with the ER derived membranes which are recognized as replica-
tion organelles. As already mentioned, these organelles have defined architecture and
morphology but little is known about the viral or cellular factors involved in their bio-
genesis. The alteration of lipid composition of cellular membranes can serve as scaffold
for replication changes in the biophysical properties of the membrane such as curvature,
permeability and fluidity [132]. The understanding of the membrane interactions with
viral proteins could help in the development of broad-spectrum antiviral drugs.
Experimental studies have been performed trying to elucidate the role of non-structural
proteins of HCV in the membrane remodelling. Glycine zipper motifs within HCV
NS4B transmembrane segments were found to be crucial for the protein’s self-interaction.
Moreover, glycine residues within NS4B transmembrane helices critically contribute to
the biogenesis of functional replication organelles and, thus, efficient viral RNA replica-
tion. These results reveal how glycine zipper motifs in NS4B contribute to structural
and functional integrity of the HCV replication organelles and in viral RNA replication
[133]. Structural importance of NS4B has also being described through the role of a
second amphipathic helix at the N-terminal (AH2), which revealed to have a key role
in the remodelling events that NS4B performs in cellular membranes. The role of AH2
is to cluster negatively charged lipids within the lipid bilayer, thus reducing the strain
within the bilayer and facilitates the its remodelling. Additionally, the same study de-
scribes that this negatively charged lipids are important to promote dissociation of AH2
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oligomers which might be key for lipid recruitment of NS regulating protein interactions
[134]. Other studies remark the importance of amphipathic helix formations in NS4B,
as disrupting its nature results in abolished RNA replication as well as mislocalisation.
This suggests that amphipathic helices might have a key role in membrane-targeting
domain within the NS proteins [135].
Moreover, studies have revealed that not only NS4B has a structural link to membranes,
NS4A, also forms a detergent-stable complex with NS4B-5A polyprotein substrate [136],
which might be the reason of the requirement of 4A to the cleavage of 4B/5A.
Additional studies on NS3 have shown that it can bind spontaneously and penetrate
to an ER complex membrane containing phosphatidylinositol 4,5-bisphosphate (PIP2),
where an amphipathic helix has an anchoring role to keep the protein on the membrane
surface. Residue R161, was found to be crucial to ensure proper orientation. PIP2-
interaction determines the protein orientation at the membrane while both hydrophobic
interplay and PIP2 interaction can stabilize the NS3-membrane complex [137].
Finally, NS5A, as already mentioned, contains a three dimensional structure of the
membrane anchor domain, the alpha helix anchor which includes amino acid 5 to 25,
which was exhibited a hydrophobic tryptophan rich side embedded in detergent micelles,
while the polar charged side was opposed to the solvent side. The amphipatic helix is
embedded in the cytosolic leaflet of the membrane bilayer. Importantly, mutations in this
position might affect RNA replication without interfering with membrane association of
NS5A [33].
Regarding NS5A and its association to membranes, it comes to one key element, the am-
phipatic helix, as mentioned several times, the AH is key for the membrane localisation,
as it is also essential in the binding to cell-derived membranes. The mechanism of bind-
ing for AH on artificial pure lipid bilayers is different from cell-derived membranes. The
difference observed is the rate of association, were in more complex cell-derived mem-
brane bilayer more time is required for NS5A AH to fully interact with partner ligands
as suggested in [138]. Cho et al, suggest that a cellular membrane protein component
contributes to the association, which would explain how NS5A proteins are localised in
ER or Golgi derived membranes, including lipid droplets but not plasma membranes or
subcellular membranes as others have described [65, 139–141]. Finally, genetic disrup-
tion of AH-mediated membrane association of NS5A has been found to abrogate HCV
RNA replication [142], suggesting that such a structural motif is indeed important for
some essential aspect of the HCV life cycle. The relocalisation of NS5A to the nucleus
after disruption of the amphipathic nature of its N-terminal helix and the strict preser-
vation of this motif in all known HCV isolates, which suggests that disruption of the
AH may have signicant consequences for HCV RNA replication [142].
39
7.1 Molecular Dynamics as a tool for membrane studies
x By definition, Molecular dynamics is a method for simulating macromolecular motions
based on an empirical force field that describes the energetics of interactions between
the constituent atoms [143]. This can include atomistic simulations provide us with a
detailed observation of membrane lipid-protein interactions [143–145]. Computer simu-
lations, specifically molecular dynamics are very detailed studies on structural biology,
providing key information from a crystal to a bilayer and monitor its dynamic behaviour
within its native environment. Molecular dynamics is a very powerful tool to understand
and characterize interactions of membrane-protein in order to elucidate mechanisms of
action or conformational changes that might be key for the development of cellular
processes.
In fact, most of membrane protein structures are studied without a lipid bilayer environ-
ment and at best reveal only a small number of bound lipid or detergent molecules, often
incompletely resolved. Importantly, several studies have indicated that lipid molecules
play active roles in modulating membrane protein structure and function [146]. Evi-
dently, there is a need to obtain a better understanding of membrane protein interac-
tions within a bilayer. Ultimately, there has been a growing development in refinement
of computational tools to achieve this purpose. Recently, new methods can predict
bilayer-spanning region of a membrane protein structure, this can already be semi auto-
matic and are available (for example: OPM; http://opm.phar.umich.edu/). However,
for the relevance of the present study we will use the predictions of MD to correlate
experimental data.
Chapter 8
Objectives of the study
The main aim of the present study is to contribute to the studies on NS5A inhibitors
and elucidate the molecular mechanism of action by some specific objectives:
1. Analysis of NS5A domain I structural linkers in vitro and in silico to understand
the importance of conserved Proline residues within linker structure and their
impact in HCV life cycle.
2. Investigate the role of Proline residues in the interaction with NS5A inhibitor,
DCV.
3. Role of NS5A inhibitor DCV in assembly of HCV viral particles.
4. NS5A amphipatic helix role in membrane interaction and DCV interaction.
Together the present data will give experimental approaches in the recently discovered
dual mode of action of NS5A inhibitor, DCV. Its participation during the inhibition of
NS5A protein during HCV replication and assembly of the viral particles. Additional
computational tools were used to understand in silico the mechanism of action involving
specific conserved Proline residues in the linker structures of NS5A and their role in HCV
life cycle. These key Proline residues were analyzed in silico to evaluate DCV binding
site. Finally, we built up a comprehensive model in which NS5A inhibitors can be
located in the context of membrane interaction and can be used to evaluate and test
new antiviral drugs against NS5A protein.
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Materials and Methods
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Chapter 9
Materials
9.1 Antibodies and dyes
The following table (Table 9.1) contains the primary antibodies, secondary antibodies
used during the present study. The only dye used in the study was: 4’, 6’- diamidino-2-
phenylindole (DAPI).
Table 9.1: Antibodies
Antibody Generated in Manufacturer Dilution/Method
Primary
α-NS5A Mouse monoclonal Austral Biologicals 1:200 IF
α-52 Rabbit polyclonal In house 1:2000 WB
α-NS5A-9E10 Mouse monoclonal gift from C.Rice 1:100 IF, 1:10,000 WB
α-Core C-380 Rabbit polyclonal In house 1:200 IF, 1:2000 WB
α-β actin Mouse monoclonal Sigma 1:20,000 WB
α-Flag M2 Mouse monoclonal Sigma 1:20,000 WB
Secondary
α-mouse IgG AlexaFluor488 Goat polyclonal Molecular Probes 1:1000 IF
α-rabbit IgG AlexaFluor546 Goat polyclonal Molecular Probles 1:1000 IF
α-mouse IgG AlexaFLuor647 Goat polyclonal Molecular Probes 1:1000 IF
α-mouse HRP Goat polyclonal Sigma 1:10,000 WB
α-mouse HRP Goat polyclonal Sigma 1:200 TCID50
9.1.1 Bacteria and cell culture
Bacteria
E.coli DH5α: derived from construct F’end A1 hsR17A (rkmk) supE44 thi-recA1 gyrA
(Nalr) relA1δ (lac ZYA-argF) U169deoR (φ80 dlacδ(lacZ) M15.
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Eukaryotic cells
293 MCB cells: are derived from human embryonic kidney cells and later transformed
with large t antigen of Simian Vacolating Virus 40 (SV40) [147], (a gift from Birke
Bartosch).
Huh7 cells: are derived from a human hepatoma cell line, [148]
Huh7 Lunet: this cells are a subclone of Huh7 cells that was generated by curing a
stable replicon cell line; they support high level of RNA replication.
Huh7 Lunet T7: Huh7-Lunet cells expressing T7 RNA polymerase under selection
with 2 g/ml puromycin [84].
Huh7.5: highly infectable Huh7 cell clone. This cell line was generated by curing a
stable replicon cell line and has high level expression of CD81 [83].
9.1.2 Media
Bacteria:
LB:10g/l tryptone, 5g/l yeast extract, 5g/l NaCl: 1.5% agar-agar were added for solid
media; ampicilin or carbenicilin were added at 100g/ml and kanamycin at 30g/ml for
selection media.
Eukaryotic cells:
DMEM complete R©: cell lines were grown in Dulbecco’s modified eagle medium (In-
vitrogen R©) supplemented with 2mM L-glutamine, non-essential amino acids, 100U/ml
penicilin, 100mg/ml streptomycin, 10% fetal calf serum (FCS; seromed, inactivaded at
56◦C for 30 minutes). For selections antibiotics were added in the already mentioned
concentratios.
OptiMEM: modification of DMEM with reduced serum (Invitrogen R©).
9.1.3 Compounds
The following compounds were used for various experiments (Table 9.2). Titration of
the compounds for the present study is described in the Results section III. Strucutre
of Daclatasvir can be found in Figure 6.6
Table 9.2: Compounds
Compounds
Name Class Source
Daclatasvir (DCV) NS5A inhibitors Bristol-Meyers
Sofosbuvir (SOF) NS5B polymerase inhibitors Gilead Sciences
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9.1.4 Plasmid constructs
Vectors for viral constructs:
pFK: low copy plasmid used as template for in vitro RNA transcription of viral con-
structs. Transcription is driven for T7 polymerase.
pTM: high copy plasmid containing T7 promoter that allows the transcription of viral
RNA transcripts in cells stably expressing the T7 polymerase.
Consensus genomes
HCV wild type and chimeric constructs used in this study are bases on the following
sequence genomes:
Con1: genotype 1b, accession number GeneBank AJ238799.
JFH1: genotype 2a, accession number GeneBank AB047639.
All the viral constructs used and generated in the present study are listed here.
Con1 constructs:
pFK-Con1wt : full length Con1 wild type sequence.
pFK-Con1/S2204R: contains a mutation S2204R in NS5A [149].
pFK-Con1ET : contains mutations E1202G, T1280I and K1846T in NS3 and NS4B.
pFK-Con1/NS5A: contains a mutation in S2197P and two silent nucleotide changes
(C6842T and C6926T)[150].
pFK-I389Luc/NS3-3/Con1/wt: bicistronic subgenomic replicon; the FLuc gene is
expressed under the control of the Con1-IRES; the Con1 NS3 to NS5B region is ex-
pressed under the control of the EMCV- IRES. From [151].
pFK-I389Luc/NS3-3/Con1/GND: contains a deletion of previous construct [151].
JFH1 constructs:
pFK-JFH1wt-dg (JFH1wt): full length JFH1 wild type sequence [88].
pTM-NS3-3-JFH1wt (sgJFH1wt): plasmid for T7 promoter-driven expression of
the NS3-3 portion of wild type JFH1 [79].
Chimeric constructs:
pFK-JFH1/J6/C-846-dg (Jc1): full length virus chimera consisting of the 5NTR of
JFH1, the region encoding core to the first putative TMS in NS2 of J6 and the remaining
sequence of JFH1 [152].
pFK-Luc-Jc1 (Jc1FLuc): bicistronic full length reporter virus; it carries the FLuc
gene in the first cistron driven by the JFH1-IRES and the Jc1 polyprotein driven by the
EMCV-IRES in the second cistron. [86].
pFK-RLuc-2A-core-Jc1 (JcR-2A): monocistronic full length reporter virus; RLuc
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is fused in-frame to the N-terminal 16 aa of the core protein with the foot-and-Mouth
Disease Virus (FMDV) 2A peptide between the luciferase and the following complete
Jc1 open reading (from M Poenish).
pFKi389-Luc-NS3-3’-NS5A-HA-Y93H-dg-JFH1: containing a HA tag in the re-
sistance mutation number 93 of NS5A.
Generated plasmid constructs for BRET
Constructs taken from Dr. Berger and new constructs developed using the following
ones (Table 9.3), we use several in combination.
Table 9.3: BRET constructs for each one of NS5A linkers
pcDNA RLucF1 NS5A Linker 1 Thr-Gly-Gly-Ser-Asp-Ile
pcDNA RLucF2 NS5A Linker 1 Thr-Gly-Gly-Ser-Asp-Ile
pcDNA YFPF1 NS5A Linker 1 Thr-Gly-Gly-Ser-Asp-Ile
pcDNA YFPF2 NS5A Linker 1 Thr-Gly-Gly-Ser-Asp-Ile
pcDNA RLucF1 NS5A Linker 2 Thr-Gly-Pro-Ala-Pro-Ala-Pro-Gly-Gly-Ser-Asp-Ile
pcDNA RLucF2 NS5A Linker 2 Thr-Gly-Pro-Ala-Pro-Ala-Pro-Gly-Gly-Ser-Asp-Ile
pcDNA YFPF1 NS5A Linker 2 Thr-Gly-Pro-Ala-Pro-Ala-Pro-Gly-Gly-Ser-Asp-Ile
pcDNA YFPF2 NS5A Linker 2 Thr-Gly-Pro-Ala-Pro-Ala-Pro-Gly-Gly-Ser-Asp-Ile
pcDNA RLucF1 NS5A Linker 3 Thr-[Gly-Gly-Gly-Gly-Ser]3-Asp-Ile
pcDNA RLucF2 NS5A Linker 3 Thr-[Gly-Gly-Gly-Gly-Ser]3-Asp-Ile
pcDNA YFPF1 NS5A Linker 3 Thr-[Gly-Gly-Gly-Gly-Ser]3-Asp-Ile
pcDNA YFPF2 NS5A Linker 3 Thr-[Gly-Gly-Gly-Gly-Ser]3-Asp-Ile
pcDNA RLucF1 NS5A Linker 4 Thr-Gly-Ala-[Glu-Ala-Ala-Ala-Lys]2-Ala-Gly-Gly-Ser-Asp-Ile
pcDNA RLucF2 NS5A Linker 4 Thr-Gly-Ala-[Glu-Ala-Ala-Ala-Lys]2-Ala-Gly-Gly-Ser-Asp-Ile
pcDNA YFPF1 NS5A Linker 4 Thr-Gly-Ala-[Glu-Ala-Ala-Ala-Lys]2-Ala-Gly-Gly-Ser-Asp-Ile
pcDNA YFPF2 NS5A Linker 4 Thr-Gly-Ala-[Glu-Ala-Ala-Ala-Lys]2-Ala-Gly-Gly-Ser-Asp-Ile
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9.1.5 DNA oligonucleotides
Aliquots were made and saved at -20. The following table shows the DNA oligonu-
cleotides used to perform experiments and its respective sequences (Table 9.4).
Table 9.4: Primer sequences
Primer Sequence primer (5’-3’)
S/2A/6978 TCCTCAGTGAGCCAGCTATCAGCA
S/2A/6767 CATAGGTTTGCACCCACACCAAAG
S/2A/7139 GAGCCCTCAATACCATCGGAGTG
S/2A/7194 CCAGGAGCGGGTTTCCACGGGCCT
S/2A/7380 CCATATCAGAAGCCCTCCAGCAA
A/2A/3089 CGTCAGAGCTCACGCTCTGATAAG
A/24/7759 GCCTGGAGATCCGGACCTGGAGTCTG
A/2A/7839 GTCATAATGGGCGTCGAGCACTTG
9.1.6 Chemicals and manufacturers
The following Table shows the chemicals that were used and the manufacturer which
provided them, see Table 9.5. All chemicals are stored under label conditions and in the
chemical room where temperature is regulated.
9.1.7 Buffers and solutions
The following Figure is a list which describes the buffers and solutions used in the present
study (Figure 9.1). Conditions were all established previously in the laboratory, were
most of the buffers and solutions are freshly made and distributed. All buffers and
solutions are stored at the correct temperature and conditions indicated.
47
Chemical Manufacturer
2-Mercaptoethanol Roth, Karlsruhe
35 S methionine/cysteine Perkin Elmer, Rodgau
Agarose Invitrogen, Karlsruhe
Albumin, from bovine serum (BSA) Sigma-Aldrich, Steinheim
Ampicillin Roche, Mannheim
Benzonase Merck, Darmstadt
Calf Intestinal Phosphatase (CIP) New England Biolabs, Frankfurt/Main
Coelenterazine (native-CTZ) PJK, Kleinblittersdorf
Complete protease inhibitor cocktail Roche, Mannheim
CytoTox 96 Non-Radioactive Cytotoxicity Assay Promega, Mannheim
DAPI Molecular Probes, Karlsruhe
Digitonin Sigma-Aldrich, Steinheim
D-Luciferin PJK, Kleinblittersdorf
DMSO Roth, Karlsruhe
DNaseI Promega, Mannheim
dNTPs Roche, Mannheim
ECL Plus Western Blot Detection System Amersham/Perkin-Elmer
Expand Long Template PCR Kit Roche, Mannheim
Expand Reverse Transcriptase System Roche, Mannheim
FCS Invitrogen, Karlsruhe; PAA, Clbe
Geneticin (G418) Invitrogen, Karlsruhe
Glycerol Roth, Karlsruhe
Kanamycin sulfate Serva, Heidelberg
L-Glutamine for cell culture Invitrogen, Karlsruhe
Lipofectamin 2000 Invitrogen, Karlsruhe
Mirus TransIT Transfection Reagent Mirus Bio, LLC, Madison, WI
Nucleobond PC100 Macherey-Nagel, Dren
Nucleospin Extract II Macherey-Nagel, Dren
Nucleospin Plasmid Macherey-Nagel, Dren
Nucleospin RNA II Macherey-Nagel, Dren
OptiMEM Gibco, Invitrogen
PEG-8000 Applichem, Darmstadt
Penicillin Invitrogen, Karlsruhe
PhosphoStop phosphatase inhibitor cocktail Roche, Mannheim
Polyacrylamide : Bisacrylamide Mix (29:1) Applichem, Darmstadt
Protein A/G sepharose beads Biorad, Mnchen
Puromycin Sigma-Aldrich, Steinheim
PVDF Western Blot membrane Perkin Elmer, USA
RNasin Promega, Mannheim
rNTPs Roche, Mannheim
Sodium dodecylsulfate Applichem, Darmstadt
Streptomycin Invitrogen, Karlsruhe
Sucrose USB, Europe
Superscript III Reverse transcriptase Invitrogen, Karlsruhe
T4 DNA-Ligase Fermentas, St. Leon-Rot
T7 polymerase Promega, Mannheim
T7 RNA polymerase Promega, Mannheim
TEMED Applichem, Darmstadt
Triton X- 100 Merck, Darmstadt
Tween-20 Roth, Karlsruhe
Table 9.5
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Buffer/Solution Composition  
Ampicilin 100mg/ml ampicilin in H2Odd, filter sterilized and stored 
at -20°C  
Blasticidin stock 
solution 
5mg/ml in H2O, sterile filtered  
Bradford reagent 100mg coomassie g250 is dissolved in 50ml 100% ethanol 
and added to 100ml 85% phosphoric acid (final volume 1), 
filtered and stored at 4°C 
Colenterazine 5mg colenterazine in 11.6ml methanol, store at -80°C 
Cytomix 120mM Kcl, 0.15mM CaCl2, 10mM potassium phosphate 
buffer (pH7.6), 25mM HEPES (pH7.6), 2mM EGTA, 
5mM MgCl2, adjust the pH to 7.6 using KOH, freshly add 
2mM ATP (pH 7.6 adjusted with KOH), 5mM glutathione 
and 1.25% DMSO 
DMEM complete Dulbecco’s modifies minimal essential medium (GIBCO, 
Invitrogen) containing 2mM L-glutamine (GIBCO, 
Invitrogen, 1x nonessential aminoacids (GIBCO, 
Invitrogen), 100U/ml streptomycin (GIBCO, Invitrogen) 
and 10% (v/v) fetal calf serum (heat inactivated at 56°C 
for 20 min).  
DNA loading dye 
orange (10x) 
45ml 50% glycerol, 1ml TAE(50x), 0.5ml EDTA (0.1M, 
pH 8.0),0.13g Orange G, H2Odd to 50ml 
Firefly Luciferase 
assay 
buffer25mM glycine-glycine (pH7.8), 15mM potassium 
phosphate buffer (pH7.8), 15mM MgSO4, 4mM EGTA, 
freshly add 1mM DTT and 2mM ATP just before use 
IF blocking buffer 3-5% (w/v) BSA in PBS 
LB-Agar 10g Bacto-Trypton, 5g yeast extract, 2.5g NaCl, 20g Agar 
in 1l H2Odd, autoclaved 
Luciferase lysis 
buffer 
1% (w/v) triton x-100, 10% glycerol, 25mM glycine-
glycine (pH7.8), 15mM MgSO4, 4mM EGTA, keep at 
4°C, freshly add 1mM DTT just before use 
Luciferin solution 1mM luciferine in 25mM glycyl-glycyl, store at -80°C 
Luria Broth (LB) 
medium 
10g Bacto-Trypton, 5g yeast extract, 2.5g NaCl, 20g Agar 
in 1l H2Odd, autoclaved 
NEB buffer 1 10mM Bis Tris Propane Hcl, 10mM MgCl2, 50mM 
NACl, 1mM DTT (pH7.9 at 25°C)  
NEB buffer 2 10mM Tris-HCl, 10mM MgCl2, 50mM NaCl, 1mM DTT 
(pH 7.9 at 25 °C) 
NEB buffer 3 50mM Tris-HCl, 10mM MgCl2, 100mM NaCl, 1mM 
DTT (pH 7.9 at 25 °C) 
Paraformaledhyde 
4% 
4g paraformaldehyde dissolved stirring at 60°C in 100 ml 
PBS 
PBS (10X) 400 g NaCl, 10 gKCl, 12 g KH2O4, 89g Na2HPO4 x 
2H2O, add 5l H2O 
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Buffer/Solution Composition  
Protein sample buffer 
(6x) 
375mM Tris-HCl (pH 6.8), 60% Glycerol, 6% (w/v) SDS, 
0.1% (w/v), Bromphenol Blue, 9% (v/v) b-
Mercaptoethanol 
Puromycin stock 
solution 
1mg/mg in H2O, sterile filtered 
Renilla Luciferase 
assay 
25mM glycine-glycine (pH 7.8), 15mM potassium 
phosphate, buffer (pH 7.8), 15mM MgSO4 , 4mM EGTA 
Resolving gel buffer 1.5 M Tris-HCl, pH 8.8, 0.4% (w/v) SDS 
Semi-dry blotting 
buffer 
48mM Tris, 39mM Glycine, 0.00375 (w/v) SDS, 20% 
(v/v) Methanol in dH2O 
Sodium acetate (pH 
4.5) 3M 
3M Sodium Acetate, pH adjusted to 4.5 with Glacial 
Acetic acid 
Sodium acetate (pH 
6.8) 2M 
2M Sodium Acetate, pH adjusted to 4.5 with Glacial 
Acetic acid 
Stacking gel buffer 1M Tris-HCl (pH 6.8), 0.8% (w/v) SDS 
TAE (50x) 2M Tris, 2M Acetic Acid, and 50mM EDTA, pH 8.3 
TCID 50 detection 
substrate - solution II 
75ml 0.5M NaAcetate, 30ml 0.5M acetic acid, 945ml 
dH2O (store at 4°C) 
TCID 50 detection 
substrate solution I 
0.4g 3-amino-9-ethyl carbazolein in 125ml N,N 
dimethylformamide (store at 4 °C in the dark; use within 3 
months) 
TGS 150mM Tris, 1,92M Glycine, 1% (w/v) SDS 
Transcription buffer 
RRL (5x) 
400mM Hepes (pH 7.5), 60mM MgCl 2, 10mM 
spermidine, 200mM DTT 
Trypsin solution 0.05% trypsin; 0.02% EDTA 
Western Blot 
blocking buffer 
0.5% (w/v) of Tween-20, 5% Protease free Milk Powder 
in PBS 
Western Blot washing 
buffer (PBS-T) 
0.5% (w/v) Tween-20 in PBS 
 
Figure 9.1: Buffers, solutions and composition
Chapter 10
Methods
All centrifugation steps in Eppendorf tubes R© were performed in table top centrifuges,
Biofuge pico (Heraeus instruments R©) or 5417R (Eppendorf R©) for RT or 4◦C, respec-
tively. Fifty ml polypropylene conical tubes (Falcon R©) were centrifuged in a Sorvall
Centrifuge RC5C Plus d with a F15-S FiberLite rotor R©. Cell suspensions were cen-
trifuged in a Multifuge 3 S-R, rotor 75006441 (M&S Laborgerte R©). All centrifugation
steps were performed at RT, if not stated otherwise. Experiments with infectious HCV
were done in a BSL3 laboratory.
10.1 Preparation of plasmid DNA from E. coli cultures
Small scale preparation of plasmid DNA (miniprep) Minipreps of plasmid DNA
were performed with 2 ml o/n E. coli culture which were centrifuged in 2 ml Eppendorf
tubes step wise for 30 s at 11,000 g. Plasmid DNA purification was obtained by using the
NucleoSpin R©Plasmid Kit according to the manufacturer’s protocol. The kit provides
all buffers for an alkaline based cell lysis and uses a silica membrane based spin column
to further purify the plasmid DNA. The DNA was eluted in either 50µl H2O or 5mM
Tris-HCl (pH 7.5).
Middle scale preparation of plasmid DNA (midiprep) For larger plasmid prepa-
rations of low copy vectors 100 ml o/n E. coli cultures were pelleted in 50 ml tubes. For
plasmid preparation the NucleoSpin R© Plasmid Kit was used with all buffer amounts
multiplied by 16. The DNA plasmid elution was divided onto four columns in 75µl H2O
or 5mM Tris-HCl (pH 7.5) per column.
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10.2 Digestion of DNA with restriction enzymes
Separation of linear DNA fragments by their length was done using agarose gel elec-
trophoresis. The percentage of the gel depended on the size of the DNA fragment.
Typically a 1% (w/v) gel was used to separate DNA fragments with a size between 700
and 8,000 bp. For higher fragments a 0.8% and for smaller fragments a 1.2% gel was used,
respectively. The agarose was dissolved and boiled in 1X TAE buffer. Ethidium bromide
was added to a final concentration of 1µg/ml. DNA samples with 10% DNA loading
buffer as well as a molecular weight marker (λ-DNA digested with Eco130I/Sty1I) were
loaded on the agarose gel which was run horizontally in 1X TAE buffer at 100-200 V
for 15 to 45 min. DNA was visualized by UV light and the DNA band of interest was
cut out of the gel. Agarose extraction and DNA purification from the band was done
by using the NucleoSpin R© Extract II Kit according to the manufacturer’s protocol.
Usually DNA was eluted in 30µl H2O or 5mM Tris-HCl (pH 7.5).
10.3 Ligation of DNA fragments
For ligation reactions the linearised and dephosphorylated plasmid as well as one or two
DNA fragments of interest (either a plasmid-derived DNA fragment or a PCR product)
were mixed in a ratio of 1:1 with 5U T4 DNA ligase and 1/10 ligase buffer in a total
reaction volume of 10µl. After incubation for 2h at RT or o/n at 16◦C the complete
reaction was used to transform competent bacteria.
10.4 Generation and transformation of competent bacteria
Competent bacteria DH5α were generated by using the CaCl2 method. Bacteria of an
overnight culture were diluted 1:50 with LB-medium and incubated at 37◦C until the
bacterial growth reached its logarithmic phase (OD 600 of 0.8 to 1). The culture was
centrifuged at 4◦C for 10 min at 6000 rpm and the pellet was resuspended in ice-cold
0.1M CaCl2 and kept for 30 min on ice. After centrifugation at 4
◦C for 5 min at 6000
rpm the pellet was resuspended in a ratio of 1:10 in 0.1M CaCl2 with 15% glycerol,
aliquoted, frozen in liquid nitrogen and stored at -70◦C. For transformation, 100µl of
competent bacteria and 10µl ligation reaction (or approx. 0.1µg plasmid DNA) were
mixed and incubated for 20 min on ice. After a heat shock at 42◦C for 2 min the reaction
was incubated for 5 min on ice, supplemented with 800µl of LB medium and incubated
for 30 min at 37◦C in a shaker. Finally, bacteria were pelleted (2 min, 6000 rpm) and the
supernatant was discarded except for approx. 50µl. The pellet was resuspended in the
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remaining medium and plated on LB agar plates containing the appropriate antibiotic
(ampicillin, 100µg/ml; kanamycin, 30µg/ml). Colonies were grown o/n at 37◦C.
10.5 Sequence analysis of DNA
For sequencing, an ABI 310 sequencer (Applied Biosystems R©) was used according to
the manufacturer’s instruction with slight modifications. Approx. 300ng of plasmid
DNA were mixed with 2µl big dye (containing buffer, polymerase, deoxy- and dideoxy-
nucleotides), 1µl primer (5 pmol/µl), 1µl 5X sequencing buffer and water to a final
volume of 10µl. The following program was used for the cycle sequencing reaction:
1. 95 ◦C for 10 sec
2. 55 ◦C for 30 sec
3. 60 ◦C for 4 min (30 cycles step 1. 3.)
4. 10 ◦C until stop
PCR sample was denatured by addition of 2% SDS in a total volume of 100µl and incu-
bation at 98◦C for 5 min. After cooling down to RT, DNA fragments were precipitated
with 1/10 vol 3M sodium acetate and 2.5 vol ethanol by centrifugation for 20 min at
13000 rpm. Finally, the pellet was washed once with freshly prepared 70% ethanol (3
min, 13,000 rpm), air-dried briefly, dissolved in 20µl Hi-Di-formamide and sequenced
with the ABI PRISM 31.
10.5.1 PCR and site directed mutagenesis
PCR was performed to selectively amplify a defined DNA sequence from a DNA template
using Taq (thermostable DNA polymerase named after the thermophilic bacterium Ther-
mus aquaticus) as polymerase according to the manufacturer’s protocol. Two oligonu-
cleotide primers that are complementary to approx. 25 bp upstream and downstream
(sense, S and antisense, A) of the region of interest had to be designed. Depending on
the following cloning strategy, restriction enzyme recognition sites were added to the
primer sequences. A PCR contained the following reagents:
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Table 10.1: PCR ingredients
Reagent Volume
10x PCV buffer 5µl
dNTPs mix (10mM each) 1µl
sense primer (100pmol/µl 0.5µl
antisense primer (100pmol/l 0.5µl
DNA template <500ng
Taq (5U/µl) 0.25µl
water add 50µl
PCR was performed with the standard program:
1. 95 ◦C for 1 min
2. 55 ◦C for 30 sec (denaturation)
3. 50 ◦C for 1 min (annealing)
4. 68 ◦C for 1 min (elongation, 8 cycles)
5. 68 ◦C for 5 min
6. 4 ◦C until stop
For the site-directed mutagenesis PCR was performed. Two overlapping mutagenesis
primers (sense and antisense) were designed to anneal to the mutation target and have
at least 18 nucleotide overlap. The flanking primers (forward and reverse) are designed
to carry restriction sites for cloning. The products generated from the two first round
PCR involving each flanking primer along with matching fusion primer are purified and
used as template in the subsequent PCR reaction, where the priming is done with the
flanking primers. The products generated are treated with restriction endonucleases
and cloned into target plasmid. For mutagenesis PCR generally a non-proofreading Taq
polymerase was used.
10.6 In vitro transcription and RNA purification
Ten µg of DNA was linearized to prepare run off transcripts of the correct length.
Constructs carrying the genomic ribozyme of hepatitis δ (δg) downstream of the 5’
end of the RNA were additionally digested with MluI, which cuts directly after the
ribozyme sequence, in a reaction volume of 100µl. All full-length Con1 constructs had
to be linearized with AseI and subsequently with ScaI. For purification, plasmid DNA
was mixed with 20µl 3M sodium acetate (pH 6.0) in a total volume of 200µl extracted
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twice with 200µl TE saturated phenol and once with 200µl chloroform. At each step,
the sample was first mixed with a vortex and then centrifuged (5 min, 13,000 rpm) for
proper separation of the organic and aqueous phases and the upper aqueous phase was
transferred to a new Eppendorf tube. To precipitate the DNA, 2.5 vol 100% ethanol
were added and the sample was left at -20◦C for at least 30 min. After centrifugation
for 20 min at 13,000 rpm at 4◦C, the pellet was washed once with 200µl 70% ethanol (3
min, 13,000 rpm), air-dried briefly and dissolved in 60µl RNase-free H2O. For in vitro
transcription, 20µl 5 x RRL transcription buffer, 12.5µl 25 mM rNTPs, 2.5µl RNasin
(40 U/µl) and 4µl T7 RNA polymerase (19 U/µl) were added to the purified DNA.
After incubation for 2 h at 37◦C, again 2µl of T7 RNA polymerase were added, followed
by another 2 h incubation at 37◦C. Transcription was terminated by addition of 6µl of
RNase-free DNase (1 U/ml)) for 30 min at 37 ◦C. For purification of the RNA, 60µl
(1/10) 2 M sodium acetate (pH 4.5), 440µl H20 and 400µl water-saturated phenol were
added. The sample was mixed with a vortex, left on ice for 10 min and centrifuged at 4
◦C for 10 min at 13,000 rpm. The upper phase was transferred to a new Eppendorf tube
and extracted again with 1 vol chloroform (vortex, 5 min at 13,000 rpm). RNA was
subsequently precipitated with 0.7 vol isopropanol (15 min at 13,000 rpm), washed once
with 70% ethanol (3 min at 13,000 rpm) and dissolved in 50µl RNase-free H2O. Agarose
gel electrophoresis was used to determine the RNA integrity and the concentration was
calculated by measurement of the optical at 260 nm.
10.7 Cell culture and virological methods
10.7.1 Culture of cell lines
All cell lines used in this work were cultured as monolayers on cell culture dishes or
flasks, using DMEM complete and the respective selection drug, if needed (see Materials
section 9). In general, cells were split twice a week 1:4 to 1:6, depending on the cell
line and the momentary growth. To this end, cells were washed with PBS, detached
by incubation in trypsin solution (2 min at 37◦C), sheared by pipetting up and down
through a 1000µl tip to yield a single cell suspension and a fraction of the cells was
transferred to a new dish. For long-term storage cells were frozen in liquid nitrogen.
Therefore, usually cells of a confluent 15 cm dish were washed with PBS, trypsinized,
resuspended in 10ml DMEM complete and centrifuged for 5 min at 700 rpm. Cells
were then resuspended in 9 ml ice-cold DMEM supplemented with 20% FCS and 10%
DMSO and frozen in five 1.8 ml aliquots in pre-chilled tubes for 24 or 48 h at -70◦C
before storage in liquid nitrogen. For thawing, cells of one aliquot were incubated at
37◦C, washed with 10 ml DMEM complete (5 min at 700 rpm), resuspended in 5ml
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and seeded into a T25 flask. Selection marker(s) were added immediately or 24 h after
seeding.
10.7.2 Cell line for trans-complementation assay
Huh-7 cells were cotransfected by electroporation as previously described with 5µg of a
neo-replicon as helper RNA and 1µg of a replication-deficient luciferase reporter repli-
con. After addition of 12ml of complete DMEM, 1ml aliquots of the cell suspension were
seeded into a 10 cm2 culture dish and harvested at the time points given in Results.
For determination of luciferase activity, cells were washed three times with phosphate-
buffered saline and scraped off the plate into 350µl of ice-cold lysis buffer (1% Triton
X-100, 25mM glycylglycine, 15mM MgSO4, 4mM EGTA, and 1mM DTT). One hun-
dred microliters of lysate was mixed with 360µl of assay buffer (25mM glycylglycine,
15mM MgSO4, 4mM EGTA, 1mM DTT, 2mM ATP, and 15mM K2PO4 [pH 7.8]) and,
after addition of 200µl of a 200µM luciferin stock solution, measured in a luminometer
(Lumat LB9507; Berthold, Freiburg, Germany) for 20 seconds. Values obtained with
cells harvested 4h after electroporation were used to determine the transfection efficiency.
(2)
pWPI_NS3-5A_Y93H_BLR
(1)
pWPI_NS3-5A_BLR
Figure 10.1: Cell Line
Western Blot showing NS5A for the cell line generated. (1) Assembly mutant:
pWPI-NS3-5A-BLR and (2) Resistant mutant: pWPI-NS3-5A-Y93H-BLR.
10.7.3 Lentivurs transduction of cells for new cell line production
293T cells 6X(1.2X106) were seeded in a 6 cm dish in a volume of 4 ml DMEM complete,
24 h after seeding cells were replaced with 4 ml of fresh medium and transfected with
the CalPhos mammalian transfection kit (Becton Dickinson R©). All transfection solu-
tions were calibrated at RT. For transfection, 6.4µg packaging plasmid (psPAX2), 6.4µg
transfer vector encoding the respective shRNAmir and puromycin resistance (pAPM)
and 2.1µg VSV envelope glycoprotein (pMD2.G) were mixed and diluted to a final vol-
ume of 438µl in H2O. Then, 62µl 2 M CaCl 2 and 500µl 2X HBS buffer were added and
mixed well by pipetting up and down. The mixture was immediately added to the cell
culture dish in a drop-wise fashion and the plate was gently swirled to evenly distribute
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the transfection mix. After 3 to 4 h, a fine precipitate formed which could be easily
confirmed under the microscope. After 6 to 24 h, the trasnfection mix was replaced 5
by 5 ml of fresh complete DMEM. On the next day, 2X106 of Huh7.5 target cells were
seeded in a 6-well plate. Twenty-four hours later (48 h post transfection), the lentiviral
particles containing supernatant from the 293T cells were harvested and replaced by
another 4 ml fresh DMEM complete. The supernatant was filtered through a 0.45µm
filter and 1.5 ml was used to infect the target cells. After 12 h, fresh 1.5 ml infectious
supernatant was used to infect the target cells a second time. On the next day, the
medium from the 293T cells was harvested and filtered a second time and pooled with
the infectious supernatant from the previous day. Target cells were infected a third
time with 1.5 ml of infectious supernatant for 4 to 6 h and were then supplied with
fresh DMEM complete containing 0.4µg/ml puromycin. As soon as possible, cells were
expanded to a T25 flask and 1µg/ml puromycin was added. Cells were expanded and
amount of selection antibiotic was increased up to 2-5µg/ml puromycin.
10.7.4 Electroporation
Monolayer of cells were washed once with PBS, trypsinized and sheared by pipetting
up and down through a 1 ml tip to get single-cell suspensions. After washing once with
DMEM complete (5 min at 7, 700 rpm) and once with 50 ml PBS (5 min at 700 rpm)
Huh7-Lunet cells were resuspended at 1X107 cells per ml in cytomix, whereas Huh7.5
cells were resuspended at 1.5X106 cells per ml. Unless otherwise stated, 5-10 µg of in
vitro transcribed RNA were mixed with 400µl cell suspension and electroporated with
a Gene Pulser system (Bio-Rad R©, Munich) in a cuvette with a gap width of 0.4 cm
(Bio-Rad) at 960 µF and 270 V. Cells were immediately transferred to DMEM complete
and seeded as required for the indicated experiment.
10.7.5 TCDI50 by VIRAPUR (Virus Purification)
The procedure is performed to determine the infectious titer of any virus which can
cause cytopathic effects (CPE) in tissue culture over a reasonable period of 5 to 20 days
while cells in culture remain viable. This procedure is performed to quantify how much
infectious virus is in a preparation by visual inspection of cell morphology or cytophatic
effect (CPE). Not all virus types cause CPE in tissue culture, and the cell line and
virus must be carefully matched in order to see a cytopathic effect. The TCDI50 is
determined in replicate cultures of serial dilutions of the virus sample. The titer of
the virus stock is expressed as the TCDI50 which can be calculated using a statistical
Excel program and is more accurate than a negative end-point. Previous to infection,
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prepare 48-well dishes by seeding each well with 7104 cells in 0.5ml DMEM plus 7.5%
fetal bovine serum, 4mM glutamine, antibiotics. Alternatively another cell density may
be required, based on the cell line required for viral growth. On the day of infection,
make dilutions of virus sample in PBS. Make a series of dilutions at 1:10 of the original
virus sample. Fill first tube in series with 2 ml of PBS, fill the remaining 6 tubes in
series with 1.8 ml of PBS. Vortex virus sample, transfer 20µl of virus to first tube,
vortex, discard tip. With a new tip, transfer 200µl of first dilution to next tube. Vortex,
discard tip. Repeat series of dilutions through the last tube. Calculate the TCID50 titer
using the Excel spreadsheet available for download from Yale School of Medicine at the
following url: www.med.yale.edu/micropath/pdf/Infectivity%20calculator.xls or
in our case use Excel file by Dr. Marco Binder available for laboratory users.
10.7.6 Determination of virus titres in cell culture supernatants and
cell lysates
Virus titers in cell culture supernatants were determined as described in a publication of
Lindenbach and coworkers [5] with slight modifications. Huh7.5 target cells were seeded
at a density of 1.1104 cells/well in 96-well-plate in a total volume of 200µl DMEM
complete. Twenty-four hours later, serial dilutions of virus supernatant were added
with 8 wells per dilution. Three days later, cells were washed with PBS, fixed for 20 min
with ice-cold methanol at -20◦C, washed once with PBS. After three washes with PBS,
NS3 was detected with 30µl/96-well of a 1:100 dilution of antibody 2E3 or NS3-49 1:1000
in PBS for 1 h at RT or o/n at 4◦C. Cells were washed three times with PBS and bound
primary antibodies were detected by incubation with 30µl/96-well peroxidase conjugated
anti-mouse or rabbit antibody diluted 1:200/500 in PBS. After 1 h incubation at RT
cells were washed three times with PBS and peroxidase activity was detected by using
30µl/96-well of a home made TCID50 see 10.7.5 detection substrate (1.5 ml solution 1
plus 5 ml solution 2 and 20µl H2O2; see Chemicals Table at section 9). Virus titers
(50% tissue culture infective dose [TCID50/ml]) were calculated based on the method
of Spearman and Ka¨rber. Intracellular infectivity assays as determined with freeze-
thaw lysates of transfected cells were at 48 h post transfection. Huh7-Lunet cells were
extensively washed with PBS, scraped off the plate and centrifuged for 5 min at 700xg.
Cell pellets were resuspended in 1 ml of DMEM containing 5% FCS and subjected to
three cycles of freezing and thawing using liquid nitrogen and a thermo block set to 37
◦C. Samples were then centrifuged at 10,000Xg for 10 min at 4 ◦C to remove cell debris,
and cell-associated infectivity was determined by TCID50 assay. Culture supernatants
from transfected cells were treated in the same way and infectivity was determined in
parallel. Importantly, establishment of 4 h post electroporation comes as a result of
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translation of transfected RNA and indicates transfection efficiency. This is why 4 h
time point is used in the present study as a threshold for transfection efficiency.
10.7.7 Luciferase viral reporter assays
Quantification of luciferase reporter activity (Firefly or Renillla-Luciferase) was used to
determine transient HCV RNA replication of subgenomic or full-length virus constructs.
Transfected or infected cells were harvested at the appropriate time points (see individ-
ual experiment description) by washing once with PBS and addition of ice-cold luciferase
lysis buffer (350µl per 6-well, 200µl per 12-well and 100µl per 24-well).
(A) Firefly-Luciferase assay. For measurement of cells out of 6 or 12-wells 150 or
50µl lysate were mixed with 360µl luciferase assay buffer and, after addition of 200µl
of luciferin substrate solution, measured for 20 sec in a luminometer (Lumat LB9507 R©;
Berthold, Freiburg, Germany).
(B) Renilla-Luciferase assay. For measurement of cells out of 12 or 24-wells 20µl
lysate were mixed with 100µl Renilla-Luciferase substrate solution and measured for 10
sec in a luminometer (Lumat LB9507 R©; Berthold, Freiburg, Germany). Cells in 24-well
plates measured after addition of 400µl Renilla-Luciferase substrate solution for 10 sec
in a plate luminometer (Mithras LB 940 R©, Berthold Technologies, Freiburg, Germany).
Each well was measured in duplicates. Kinetics of replication were determined by nor-
malizing the relative light units (RLU) of the different time points to the respective 4 h
value. Established 4 h post electroporation is the threshold for HCV infection to be sta-
bilized in the cells, this is why we use 4 h post-electroporation as the normalizing value
for every assay containing HCV electroporation. If replication of viral constructs was
compared in cells treated with different siRNAs then replication was normalized to cells
treated with the negative control siRNA, or with Hiperfect R©(unique blend of cationic
and neutral lipids that enables effective siRNA uptake and efficient release of siRNA in-
side cells, resulting in high gene knockdown even when using low siRNA concentrations)
from QIAGEN R©.
10.7.8 Transcomplementation assay
Huh7-Lunet cells were co-transfected with 5µg of Jc1 genomes and 0.5µg of helper RNAs
containing a Renilla luciferase (RLuc) reporter gene (corresponding to a 1:0.1 molar ra-
tio, respectively). Electroporated cells were resuspended in 20 ml culture medium. Two
ml aliquots were seeded per well of a 6-well plate and replication was determined by
measuring luciferase activity at 4, 24, 48 and 72 h post-electroporation. Transient repli-
cation of helper RNAs was determined by luciferase assay at 4, 24, 48 and 72 h after
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electroporation. Values obtained 4 h post electroporation were used to determine the
transfection efficiency. Supernatants were harvested 24, 48 and 72 h after electropora-
tion and concentrated three times by using Amicon columns (Millipore R©, Schwalbach)
according to the instructions of the manufacturer. Release of infectious particles from
co-transfected cells was determined by TCID50 assay by using the concentrated culture
supernatants. Replication of trans-packaged subgenomic helper RNA was determined
by luciferase assay performed with lysates of Huh 7.5 cells that had been inoculated
with the concentrated culture supernatants of co-transfected cells. See generated cell
line 10.7.2 and Figure 10.1.
10.8 Drug addition experiments
10.8.1 Dose-response assay using stable replicon cell lines and JCR2a
reporter virus
For dose-response LucUbiNeo Con1ET, using stable replicon cells, LucUbiNeo JFH1,
were seeded into a 12-well plate at a density of 4X104 cells/well. One day later, Sofos-
buvir (SOF) or BMS-790052) (DCV) was added at different concentrations. As mock
control, DMSO was added according to the highest inhibitor concentration used in the
assay. After 72h of treatment, cells were washed, lysed and analyzed by luciferase activ-
ity using Luminometer measurement. EC50 and EC90 values were calculated by using
GraphPad Prism R©(version 5.03). For dose-response assays using reporter virus JcR2a,
Huh7 cells were seeded one day prior to infection in a 12-well culture dish at a density of
4X104 cells/well. Eight hours post infection (five TCID50/cell) cells were incubated with
indicated concentrations. As mock control, DMSO was added according to the highest
inhibitor concentration used in the assay. After 72h of treatment, cells were washed,
lysed and analyzed by luciferase activity assay, EC50 and EC90 were calculated.
10.8.2 Full-length reporter virus JCR2a kinetics after DCV or SOF
treatment
Huh7 cells transfected by electroporation with in vitro transcribed RNA of HCV JCR2a
full-length reporter virus were seeded in 12-well culture plates. Two days later DMSO,
SOF or DCV was added at a concentration of 5X EC90 . Cell lysates were harvested
after 0, 10, 24 and 48h of treatment and analyzed by luciferase activity assay. Huh7.5
FLuc cells were seeded in a 12-well culture plate at a density of 1X105 cells/well. One
day later they were infected with JCR2a virus (1 TCID50/ml) for 48h before DMSO,
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SOF or DCV was added at a concentration of 5XEC50 . After 6, 12, 24 and 48h cell
lysates were harvested and used for luciferase activity assay. Note that in this case
Renilla Luciferase activity as well as firefly luciferase activity was determined to study
virus replication and cell growth, respectively.
10.8.3 Full-length reporter virus JCR2a kinetics and DCV pre-treatment
For replication kinetics of reporter virus JcR-2a (pFK i389RLuc2A Core-3-Jc1), Huh7.5
cells were seeded into a 12-well culture plate at a density of 1X104 cells/well. One
day later cells were infected with JCR2a with one TCID50/cell. After 48h inoculation,
medium was replaced by fresh medium. In case post-treatment, cells were subsequently
treated with DCV, SOF or DMSO (mock control). In case of pre-treatment, cells were
additionally incubated in DCV or SOF containing medium (50X EC90) for 2h prior
to inoculation with JCR2a. Directly prior to infection, medium was replaced by fresh
DMEM. Forty-eight hours post infection, inhibitor was added. After 6, 12, 24 and 48h
of treatment cells were washed, fixed and analyzed by luciferase activity assay.
10.9 Protein analysis
10.9.1 Proteinase K Protection Assay
Protease digestion assay. A membrane protection assay was performed as previously
indicated [153–155]. For analysis of proteins expressed in cells, transfected Huh 7.5
cells, transfected with JFH1 or Jc1 RNA. The post-nuclear supernatants or samples
obtained from in vitro synthesis were divided into three portions. One portion received
no treatment. The second portion was treated with Proteinase K 150µg/ml. The third
portion was solubilized with a final concentration of 1% Triton X-100 before Proteinase
K treatment. After incubation on ice for 1h, samples were analyzed by SDS-PAGE
followed by Western blotting.
10.9.2 SDS-Polyacrylamide-Gel-Electrophoresis (SDS-PAGE)
The cells were washed in PBS and lysed by addition of SDS-PAGE sample buffer. The
viscosity of the samples was reduced by sonication in a cup-horn Sonifier (Brandson
450 R©), which shears the genomic DNA. The sample was then heated to 95◦C for 3
min and cooled to RT. The polyacrylamide gels were prepared according to standard
protocols and gel electrophoresis was carried out at constant current of 200V for 3-4h
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(15x15cm gels). Pre-stained protein markers (New England Biolabs R©) were used as
molecular size marker.
10.9.3 Western Blot
Following gel electrophoresis the proteins were transferred to PVDF membranes using a
semidry blotter 2 (BioRad) for 90 min at a constant current of 1mA/cm . The membrane
was blocked with blocking buffer (5% milk powder in PBS 0.5% Tween20 (PBST)) for
1h at RT or overnight at 4 ◦C. The membrane was incubated with the primary antibody
diluted in blocking buffer for 1h at RT or overnight at 4 ◦C followed by three washes
for 10 min with PBST. Similarly the secondary antibody diluted in blocking buffer was
incubated for 60 minutes and washed thrice with PBST. The chemiluminescence signal
was revealed using ECL Home Made Kit R©according to the instructions and detected
by INTAS machine.
10.9.4 Paraformaldehyde oligomerization
Formaldehyde solution was obtained by dissolving 0.4% to 4% paraformaldehyde Fisher
Scientific in PBS for 2 h at 80 ◦C. The solution was filtered in 0.22 µm filters, stored in
the dark at RT and discarded after 4 weeks. For cross-linking, Lunet cells were pelleted
in a 50 ml reaction tube, resuspended in PBS and counted. Cells were centrifuged again
and resuspended to 1X 107 cells/ml in formaldehyde solution. Cells were incubated
with mild agitation for 7 min at RT and then pelleted at 1800xg and RT for 3 min,
resulting in 10 minutes exposure to formaldehyde. The supernatant was removed and the
reaction was quenched with 0.5 ml ice-cold 1.25 M glycine/ PBS. Cells were transferred
to a smaller tube, spun, washed once in 1.25 M glycine/PBS and lysed in 1 ml RIPA
buffer (50 mM Tris HCl, pH 8.0, 150 mM sodium chloride, 1% NP40, 0.5% sodium
deoxycholate, 0.1% SDS, 1 mM EDTA, protease inhibitors (Complete mini, EDTA-free,
Roche Diagnostics)) per 1X108 cells for 60 minute on ice. Incubation for 20 min at 65
◦C or 99◦C. Lysates were spun for 30 minutes at 20000 g and 4 ◦C to remove insoluble
debris. The supernatant was either used directly or stored at 80 ◦C. Control cells were
treated exactly the same way, except that they were resuspended in PBS instead of
formaldehyde solution. When platelets were used for cross-linking, 1.5X109 cells were
resuspended in 10 ml formaldehyde solution and lysed in 1 ml RIPA buffer. Protocol
taken from [156].
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10.9.5 BRET assay
293 T cells were seeded in a 24-well plate (1.5105 cells/well). Day after, transfected
with the YFP-construct (500ng) together with the Renilla Luc construct (500ng). Re-
move medium from cells, then added 500µl/well of fresh DMEM at least 30 min before
transfection, return cells to incubator. In the meanwhile prepare DNA mixtures: JetPEI
transfection reagent PolyPlus Transfection R©standard protocol was used. DNA/transfec-
tant mixture was added to a 150nM NaCl solution for a final volume of 50µl/transfection.
The mix was vortexed and incubated for 20 minutes, then added to the wells in a drop-
wise manner. The day after cells are checked for transfection efficiency (70-80% cells
expresses), the cells are washed with 1X PBS. The plate then is read by a spectrometer
for YFP expression before adding RLuc substrate (necessary for Saturation Curves).
Add 10µl/well of 1:20 dilution of Coelenterezine (1:200 final dilution), swirl plate gently,
check for absence of visible air bubbles. Incubate in the dark for 5 min to 40 min at
RT. Read the plate at Spectrometer (5 min to 40 min post-coelenterezine addition by
measuring YFP emission and RLuc emission (respectively 535 and 485 nm; 0.5” each
channel). Finally calculate data as follows in Figure 11.26, where long-wavelength is
YFP signal and short-wavelength is Rluc signal. The background is the same ratio
calculated in wells were only the Rluc-tagged protein at the same concentration was
trasfected.
Figure 10.2: BRET calculation method
Taken from [157].
10.10 Imaging
10.10.1 Immunofluorescence
Transfected Huh7-Lunet cells were seeded into 24 well-plates containing glass coverslips.
Seventy two hours after electroporation, cells were washed twice with PBS, fixed with 4%
PFA in 150 mM sodium cacodylate buffer [pH 7.5] for 15 min at RT and permeabalized
with digitonine (50µg/ml) for 5 min at RT. Permeabilzed cells were washed twice with
PBS and blocked with PBS containing 5% (w/v) bovine serum albumine for 30 min at
RT. Viral proteins were detected with specific primary antibodies see Table 9.1. After 1
h at RT, cells were washed three times with PBS and incubated with a 1:1,000 dilution
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of Alexa 488, 546 or 647- conjugated secondary antibody (Invitrogen R©, Molecular
Probes), shown in Antibodies Table 9.1 in PBS 5% BSA for 1 h in the dark.
10.11 Computational models and simulations
All proteins structures were downloaded from Protein Data Bank and completed with
MOE software R©. Maestro software R©was used for Protein Preparation, System Builder
and Molecular Dynamics (MD) (using Desmond tool). All proteins have energy min-
imised and analysis of its structure was performed previously to ensure analysis. For
NS5A protein, PDB number: 1ZH1, clam like structure taken from [38].
10.11.1 Proline analysis in NS5A structure
Analysis of Proline residues located in the linker structures of NS5A protein were anal-
ysed using MOE. The missing residues connecting linker AH-DI were added and energy
minimized with AMBER99 force field 0.001 gradient. This procedure was applied to all
the Proline residues present in the different linkers. Following analysis using MOE was
performed to measure and predict conformational changes in NS5A structure. See Table
11.1.
Linkers:
• AH-DI: 29-PKLPGLP-35
• DIa-DIb: 97-QCAPKPPT-104
• DI-DII: 189-PCEPEP-194
To explore the role of Proline residues in the linkers, we selected the residues and explore
the interactions within NS5A structure by visualization with MOE. Further, we wanted
to investigate whether they have a role in the binding of DCV or NS5A interactions
which might be important for the drug activity. Using MOE tool, DCV interacting
residues were analysed by visualisation.
10.11.2 Proline analysis in NS5A structure and DCV interaction
Prolines identified after site-directed mutagenesis of Proline residues in the linker con-
nection between amphipathic helix and domain Ia and domain Ib were situated in NS5A
structure from Nettles et al. 2014 [1]. Later, we mutated in silico to the corresponding
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amino acid and explore the different conformation of NS5A structure itself and inter-
action with DCV. We used Molecular Dynamics (conditions mentioned in 10.11.2), to
analyse in time, the conformational changes of DCV with the different Proline residues.
• Protein Preparation Wizard: for protein preparation
• System Builder:
a) Solvent model: TIP3P
b) Box shape: Cubic, different distances used to minimize volume for dynamics
(distances, very close to the membrane a=5; angles 90 degrees all).
c) Minimize volume: Force filed: OPLS 2005
• Molecular dynamics:
a) Simulation time: 300ns;
b)Frames: 625, Trajectory: 320
c) Energy: 16
Relaxation of model before simulation
Advanced: seed: random
10.11.2.1 Analysis of interaction with DCV
Docking with GLIDE R© The analysis was performed by re-docking DCV into NS5A
structure with the correspondent Proline mutation made 11.1. To select the best confor-
mation given by the docking program, i.e minimum energy of the protein-ligand complex
and maximum binding affinity should be selected for molecular dynamics study. Further-
more, MD was performed on selected poses to explore the stability of the conformation
and the possible changes in the DCV interaction sites.
Molecular Dynamics After docking DCV to the selected pose into the NS5A dimer
structure with the Proline mutations, we run Desmond MD, to explore the different
conformations DCV might take due to the Proline mutation. The MD conditions were
the same as established for all studies 10.11.2.
10.11.3 Amphipathic helix studies on POPE membrane
To start up with the analysis of the systems, protein preparation was performed using
Protein Wizard in Maestro (removal of water molecules and adding hydrogen missing
atoms). Considering a temperature of 300K a pH of 7 and salt concentration of 0.1M.
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The energy was minimized and then proceeded with the System Builder in Maestro,
were the membrane was loaded from workspace. Membrane used was large POPE bi-
layer with 340 lipids downloaded from the following url: http://people.ucalgary.ca/
~tieleman/download.html.
10.11.4 Molecular dynamics on Amphipatic Helix (AH) and mem-
brane studies
The previous set up was used to run Desmond set up of the system, then, the output
file was used to run Desmond Molecular Dynamics. The structure of amphipatic helix
was manually placed either horizontally or vertically from the membrane, both confor-
mations were minimize at MOE, prepared by Protein Preparation Wizard and analysed
by molecular dynamics from Desmond in MAESTRO. The following parameters were
used:
• Protein Preparation Wizard: for protein preparation
• System Builder:
a) Solvent model: TIP3P
b) Box shape: Cubic, different distances used to minimize volume for dynamics
(distances, very close to the membrane a=1, b=1, c=1; angles 90 degrees all).
c) Minimize volume: Force filed: OPLS 2005
• Molecular dynamics:
a) Simulation time: 200 ns or 500 ns (horizontal)
b) Frames: 625, Trajectory: 320
c) Energy: 16
Relaxation of model before simulation
Advanced: seed: random
Part III
Results
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Chapter 11
Experimental Results
Some of the big remaining questions regarding HCV field, are the precise mode of action
of the NS5A inhibitors, other types of DAAs have been widely studied and have now, a
well described mechanisms of action. However, NS5A is a multifunctional protein, that
is involved in many key points of HCV life cycle, as the full picture of all the activities
NS5A performs is not yet finished, the mechanism behind NS5A inhibitors is not fully
understood. In recent years, many and joint efforts have been made in getting a better
and clearer picture of the mode of action. The present study aims to contribute to the
full picture in a detail manner to elucidate the NS5A inhibitors mode of action by using
the best of two approaches to research, experimentally and computationally.
Furthermore, we wanted to focus on aspects that have not been fully studied on the
structure of NS5A, where important binding and interaction sites are located. Some
studies have looked into this aspect trying to reveal what are the key aspects on NS5A
structure that could explain the mechanism of action of the inhibitors [1, 117, 158].
First, we wanted to elucidate the importance of Proline residues located in the linker
structures of NS5A and their impact in HCV replication and infection. Additionally,
we evaluated the effect of this mutations in relation with DCV inhibitor in silico, see
Computational Results section 12. Second, we evaluated the role of DCV inhibitor
during the assembly process of HCV viral particles. Third, we look at the role of the
Amphipathic helix of NS5A in membrane interaction and thus, the impact of DCV-
membrane interaction in silico. We briefly look at the oligomerization state of NS5A
to look further into the multifunctionality of the protein. Lastly, we put together the
results to describe the mechanism of action of NS5A inhibitor DCV.
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The following chapter describes the experimental results and the next chapter describes
the computational results in section 12. Later in the discussion, these results are com-
mented and discussed as one topic itself, as the purpose of this study was to use both
tools to further elucidate and understand the mechanism of action of NS5A inhibitors.
11.1 Key role of NS5A Proline residues
To further understand the mode of action of DCV, we performed studies together with
collaborators (Cristoph Combet, at Lyon University) on the role of Proline residues
in the linker structures connecting the different domains of NS5A, see Appendix A.1.
The amphipatic helix is connected to Domain I via a Proline rich linker (linker AH-
DI), which promotes membrane association through an interaction of the AH with the
membrane. This linker might be key, not only for the binding of NS5A protein to the
cellular membrane but additionally the binding of DCV. Because as mentioned in the
introduction, it contains most of the resistance mutations and we do not have structural
data on this linker. Thus, we decided to study Proline residues in this linker which confer
conformational changes that will allow us to know the key role of the Proline residues
maintaining the structure of such linker in a functional position. The next linker is the
one between Domain I subdomain a connecting to Domain I subdomain b, (DIa-DIb),
the Prolines contained in this linker will maintain the structure of Domain I in position
regarding the membrane and the inhibitor binding, which is why it was also chosen for
mutational analysis. Finally, Domain I linker connecting Domain II (DI-DII), this linker
was studied because of its relevant interactions with PKR, PI3K, as well as NS5B, which
might be of importance keeping NS5A structure and function see Figure 11.1.
Domain I of NS5A is required for RNA replication, protein and membrane interaction,
its crystal structure is solved by the PDB entry: 1ZH1 and 3FQQ see Figure 2.7. NMR
structure is also solved for AH is solved in PDB: 1R7G, see Figure 2.5. However there
is no information available for the linker connecting AH and DI, where most of the
resistance mutations are clustering and where NS5A associates to the membrane [60,
129, 130]. Therefore the first thing to perform was to directly target Proline residues in
the linkers via site-directed mutagenesis. The linker sequences are the following:
Linkers:
• AH-DI: 29-PKLPGLP-35
• DIa-DIb: 97-QCAPKPPT-104
• DI-DII: 189-PCEPEP-194
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11.1.1 Proline residues in linker structures are key for HCV replication
and infection
We performed site-directed mutagenesis to specific conserved Proline residues within the
linkers as you can see in the table 11.1. Cloning strategy in this fragment Nsil/SanDI
by double PCR was used to introduce the single point mutations in positions: P29, P32,
P35, P100, P102, P103. The next cloning strategy was using a digest vector to generate
2 fragments vector Luc-JcR2A, together with 1) Nsil/BsiWI and 2) SanDI/BsiWI, bind
together by a triple ligation, this method was used for Proline residues P189, 192,
and 194; for further details see section 10. Later, the RNA from these mutants was
electroporated into Lunet cells and collected at different timepoints. Furthermore the
supernatant was used to infect Huh 7.5 cells and the read out was Renilla Luciferase
(RLuc) as the constructs contain the reporter gene, as negative control we used ∆GDD,
which is deficient in the nucleotidyl transfer reaction during HCV translation. As a
positive control of transfection efficiency we used the 4 h normalization value. The
following table contains the mutations made for each Proline residue within the linker
structures.
Table 11.1: Site directed mutagenesis of conserved Prolines to Alanine (Ala), Glycine
(Gly) or a Valine (Val)
AH-DI linker
P29 Ala Gly Val
P32 Ala Gly Val
P35 Ala Gly Val
DIa-DIb
P100 Ala Gly Val
P102 Ala Gly Val
P103 Ala Gly Val
DI-DII
P189 Ala Gly Val
P192 Ala Gly Val
P194 Ala Gly Val
The site directed mutagenesis of conserved Prolines was performed to Glycine (G), to
mimic the different conformations of Proline (P) cis-trans isomer, which would in turn
have a deleterious effect that would indicate a strong structural role of that Proline
residue. Mutations to Alanine (A), to mimic the cis-trans isomer of Proline, which
if there is no cis-trans isomerisation would mean that such mutant is functional. At
last, mutations to Valine (V) has no effect, means the Proline residue has no essential
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role. The next Figure 11.1 contains the mutations made to each Proline residue in the
linkers, showing the structure of Domain I of NS5A protein as a monomer. The linker
connections are located in between AH-DI, DI-DII, and DII-DIII, with the correspondent
sequence, where each sequence is shown in colour coding according to the correspondent
linker structure dividing each of the segments in Domain I.
Figure 11.1: Domain I of NS5A with linker connections
Amphipathic helix (AH), Domain I subdomains a and b. Sequences containing Proline
residues are also shown, in line with the linker structure dividing each part. Courtesy
by Critoph Combet.
After transfecting the HCV RNA via electroporation into the Lunet cells, we harvested
the cells at 24, 48 and 72 hours post-infection (hpi), we collected the supernatant.
The following Figure 11.2 shows first read out by RLuc, of the replication results of the
Proline residues located at the linker AH-DI. In Figure 11.2 panel A, AH-DI linker shows
a complete inhibition of replication with the exception of P29G, P35G and P35V. No
inhibitory effect during replication was observed in P35A, as expected P35A mutation
has a comparable effect to JCR2a wt (genotype 2a wildtype), which was used as a HCV
replicon positive control. The supernatant collected from the replication samples was
used to further infect Huh 7.5 cells, then RLuc was measured. In the case of Figure panel
B 11.2, where the same linker is shown, where the mutations seem to have a defective
phenotype during assembly/release of viral particles.
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The same procedure was performed for the DIa-DIb linker and DI-DII. Where Lunet
cells were transfected with the following Proline mutations to Glycine, Alanine or Valine
accordingly. Mutations in linker DIa-DIb: P100A, P100G and P102A show complete
inhibition of the HCV replication, as compared to the negative control (∆GDD). As for
linker DI-DII, mutations did not show any effect, as the replication an infection was as
wt (JCR 2a, positive control). Mutations P194A and P194V, did not show replication
or particle production, resulting in essential Proline residue at the site to achieve NS5A
functionality. However, the rest of the mutations in both linkers were able to replicate
as the wt values. When infection was analyzed by using the supernatant and infecting
Huh 7.5 cells, the mutants showed the same pattern as HCV replication, with or without
any additional effect on the viral particle production as compared to the wt, see Figures
11.3 and 11.4.
Some of these Proline residues showed a critical role when mutated to another amino
acid (G, A or V), showing that their role in maintaining structure by cis-trans iso-
merisation or by changes in the conformation due to the different interaction pattern.
These results give a detail perspective on how the linkers on DI of NS5A are key for the
functionality of the whole protein. In addition, the changes in the conformation due to
the cis-trans isomerisation can be critical to HCV life cycle as shown in the deleterious
effect on replication and infection of viral particles. Moreover, the linker structures are
known to be essential for NS5A inhibitors binding site, which makes these results key
to understand how Proline residues can affect NS5A and thus, the mechanism of action
of NS5A inhibitors.
Along the same lines, Proline mutations were shown to affect each of the linker structures,
due to the change in the amino acid conformation and interaction pattern. In the
following Figures, each linker is shown with the correspondent Proline mutations. Renilla
Luciferase (RLuc) was normalized to 4 hpi in the replication assay, positive control
JCR2a (wildtype HCV virus) and as negative control ∆GDD, which is the motif of
HCV NS5B RNA-dependent RNA polymerase. Luciferase activity at 4 hours after
electroporation correlates with the translation of input transcripts prior to onset of
replication and subsequent time points were normalized to 4hpe signal to account for
electroporation efficiency.
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Figure 11.2: Proline mutations on linker AH-DI effects on HCV life cycle
P29-35V showed complete inhibition of replication, as compared to the negative
control (∆GDD, which is the motif of HCV NS5B RNA-dependent RNA polymerase).
Mutations P29G, P35G, and P35V were able to replicate however their replication was
strongly reduced as compared to WT. No inhibitory effect during replication was
observed for P35A mutant. As expected P35A mutation had a comparable replication
and particle production kinetics to WT, panels A and B, respectively. Marked with *,
samples that are below detection.
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Figure 11.3: Proline mutations on linker DIa-DIb effects on HCV life cycle
Mutations at P100A, P100G and P102A, showed complete inhibition of replication, as
compared to the negative control. Whereas the rest of the mutants in this linker were
able to replicate as WT. The rest of the mutants did not show any additional effect on
particle production when compared to WT. Marked with *, samples that are below
detection.
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Figure 11.4: Proline mutations on linker DI-DII effects on HCV life cycle
Mutations within this linker did not show any effect on replication and particle
production, except for P194A and P194V mutants, which did not replicate and
therefore there was no particle production, when compared to negative control ∆GDD.
75
Results of this experiment show that in each of the 3 linkers at least one Proline is crucial
for replication (P29 P32, P100 P102 and P194). Moreover, the crucial Proline residues
seem to be involved in cis-trans isomerisation. Together, these data indicate that NS5A
domain 1 changes conformation, which is needed to acquire precise conformation to be
activated by isomerisation to achieve its function, the crystal structures of domain 1 are
only one picture of the changes in the conformation. Other conformational changes can
be taking place in:
• between AH and domain 1, which could be the most crucial, taking into account
the membrane proximity, reinforced by location of resistant mutations.
• between subdomains 1a and 1b, which might involve the opening of D1a-D1b
probably by domain swapping in dimers.
• between domain 1 and 2, which might be crucial for host interactions.
This leads to the involvement of cis-trans Proline isomerase as many have shown before
[159, 160]. Hence, these results show the role of key Proline residues in the linker
structures of NS5A, which might have a role maintaining not only in HCV replication
or infection, but additionally the binding or interaction site with DCV. Computational
studies to explore and visualize the conformational changes of the NS5A protein and
the DCV binding site could elucidate the role of this key Proline residues, to further
improve or develop new antiviral agents. In the section 12, we explore this possibilities
and analyse the Molecular Dynamics of NS5A inhibitor DCV interactions with NS5A
dimer structure.
Furthermore, inhibitors targeting NS5A affect HCV replication by inhibiting conforma-
tional changes in NS5A protein or protein complex formation that occur in the context of
HCV polyprotein expression and in the replication compartment formation [161]. Oth-
ers have observed the effect of DCV, blocking HCV replication by preventing formation
of the membranous web, which was not linked to an inhibition of phosphatidylinositol-4
kinase IIIα [118].
However NS5A protein has a key role during the assembly process. As it is proposed by
Zayas et al [162], where a highly conserved basic cluster (BC) of Domain III was found
to play a key role during the assembly of viral particles. During the assembly process of
HCV, NS5A plays several key roles [163, 164]:
• it interacts with core protein via NS5A DIII [26, 165].
• NS5A is recruited to cLDs where core protein accumulates [26, 165, 166].
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• assembly requires the phosphorylation of a serine residue in NS5A DIII by casein
kinase IIα [51].
• NS5A facilitates the association of core protein with the viral RNA genome [165].
• NS5A interacts with the p7-NS2 complex that is required for the envelopment of
the HCV particles [167].
• NS5A also interacts with apolipoprotein E that is incorporated into the virion and
with Annexin A2, which is a host cell membrane sorting protein enhancing HCV
assembly [20, 43, 168–171].
Consequently, assembly of HCV particles requires a spatio-temporally coordinated as-
sociation of the replicase, NS3 helicase and NS5A together with the Core protein allow
packaging of the RNA genome into the virion. To determine whether DCV, NS5A in-
hibitor has an effect at some point during the assembly process we first wanted to ruled
out the specific effect on assembly by using another inhibitor of NS5B protein, Sofos-
buvir. The results from the experiment will show the specific effect of NS5A inhibitor
during assembly as an inhibition of NS5A protein activity.
11.2 Effect of Sofosbuvir and Daclatasvir treatment
We started with the titration of both drugs DCV and SOF, in order to have both EC50s
that could correlate to each other and have the precise drug concentration at which
both drugs inhibit HCV infection. We first electroporated HCV RNA from the JCR2a
(wt) genotype in Lunet cells and as a control included untransfected cells (MK cells).
The drugs were added 12 hours post electroporation (hpe) and 24 hpe. We recover the
supernatant at 24, 48 and 72 hours post infection (hpi), this means when we infected
the cells using the supernatant of the eletroporated cells, for more details see diagram
on Appendix A.2. We lysed the plates and store them at -20 ◦C, this plate was further
used to perform a Renilla Luciferase (RLuc) assay. The supernatant was used to infect
Huh7.5 cells where we also included MK cells. After 72 hpi, we harvested the cells
and perform RLuc assay. The results of the plate reader were all normalised to 24 hpi.
Results gave us the optimal concentration to use of SOF with comparable effect to DCV
for further experiments, see Figure 11.5 and 11.6.
Figure 11.5 shows the EC50 values for DCV are extremely low, which gives NS5A in-
hibitor its high antiviral potency. A decline in viral protein upon treatment was observed
for replication and reinfection measurements, in comparison to the mock cells. When
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using SOF Figure 11.6, we observed a faster effect of the drug upon infection and repli-
cation compared to Mock cells and DCV treatment. In the corresponding tables we
have the data needed to calculate the IC50 , which is the concentration of an inhibitor
where the response (or binding) is reduced by half. We continue taking the IC50 as
EC50 , because EC50 is the concentration of a drug that gives half-maximal response, in
this case both concepts give the same number. This result gave us the exact number by
which both drugs act effectively on HCV infection.
Figure 11.5: Established EC50 values for NS5A inhibitor, Daclatasvir (DCV)
Logarithmic inhibitor vs response in a variable slope graphic showing EC50 values for
DCV titration. Table above shows logarithmic calculation of EC50 data on time points
24, 48 and 72 hpe.
11.3 Daclatasvir and Sofosbuvir kinetics
Once we found the EC50 values for both drugs, we use this to formulate a kinetic ex-
periment with different time points of drug addition. The goal was to find the optimal
concentration by which both drugs inhibit HCV replication at the same time post-
infection. For this purpose we use the same conditions of previous experiment, but in
a dose-response set-up. We achieved this by adding a range of concentrations around
the optimal EC50 value, as shown in Figure 11.5 and 11.6. Thus, SOF and DCV were
added to Lunet cells 12hpe and 24hpe, and the supernantants (SN) were recovered and
used for infection of new Huh 7.5 cells, measuring RLU at points of 24, 48 and 72 hpi
(as described in Appendix A.2). In the following, Figures 11.7 and 11.8, we show the
last experiment data (n=1), where the concentration is related to the the percentage
of untreated cells (RLU normalisation to 4hpi was set to 100% or 1%). Where we use
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Figure 11.6: Established EC50 values for NS5B inhibitor, Sofosbuvir (SOF)
Logarithmic inhibitor vs response in a variable slope graphic showing EC50 values for
SOF titration.Table above shows logarithmic calculation of EC50 data on time points
24, 48 and 72 hpe.
some concentrations around the EC50 values (DCV 0.0062nM and SOF 56.56nM) to
determine the concentration at which both drugs have and effect on HCV infection, ob-
served by calculating the ratios between replication and reinfection (infection with SN).
An early inhibition with a lower concentration of 0.097nM DCV can inhibit replication,
an effect in assembly is shown when the EC50 value is reached at 0.0062nM as shown
in Figure 11.7. This concentration was then use to further evaluate the effect of DCV
on assembly process, as this experiment pointed that its effect could be in addition to
its effect in HCV replication. In Figure 11.8, the results of the last experiment (n=1),
showed that Sofosbuvir has an effect just on replication (as expected because is a NS5B
inhibitor), using its EC50 concentration of 56.56nM, which is why this drug was used as
a positive control of solely replication inhibition.
Additionally, we wanted to establish the time of drug addition, to rule out any other
effect on HCV cycle, but assembly. For this we use the values obtained in the experiment
and did a logarithmic graph, were the shift in plotting replication or reinfection could
be interpreted as a drug-related effect 11.9, as for SOF, 11.10; (see Appendix A.5, for
details on n=3 of the drug titrations). We then use 24 hours post electroporation to
add the drug and 24 after drug addition we electroporated the cells with HCV genome
JCR2a. Together this experiments gave us the exact concentration and time, at which
both drugs inhibit HCV infection, but more important, the ratios showed already an
effect of DCV on assembly steps, which we continue to investigate.
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Figure 11.7: Daclatasvir dose-response effects on HCV life cycle
Different concentrations of DCV were chosen and normalized to untreated cells
(uninfected, no electroporated HCV RNA). DCV effects on HCV replication and
reinfection are shown. In addition, the ratio between the replication and the
reinfection values is shown to underline DCV effect. The line shows the 100% of
inhibition. Readout by RLuc measurement (n=1). All samples were treated to RLU %
to untreated cells.
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Figure 11.8: Sofosbuvir dose-response effects on HCV life cycle
Different concentrations of SOF were chosen and normalized to untreated cells
(uninfected, no electroporated HCV RNA). SOF effects on HCV replication and
reinfection effects are shown. In addition, the ratio between the replication and the
reinfection values are shown to underline SOF effect. The line shows the 100% of
inhibition. Readout by RLU measurement (n=1). All samples were treated to RLU %
to untreated cells.
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Figure 11.9: DCV drug addition at different time points
Drug addition 24hpe and harvesting time points 24, 48 and 72hpi with different DCV
concentrations for HCV replication (rep) and reinfection (rei) are shown. Normalized
to 4hrs of untreated cells. Readout by RLU measurement(n=1). All samples were
treated to RLU % to untreated cells. (see Appendix A.5, for details on n=3 of the
drug titrations).
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Figure 11.10: SOF Drug addition at different time points
Drug addition 24hpe and harvesting time points 24, 48 and 72hpi with different SOF
concentrations for HCV replication (rep) and reinfection (rei) are shown. Normalized
to 4hrs of untreated cells. Readout by RLuc measurement (n=1). All samples were
treated to RLU % to untreated cells. (see Appendix A.5, for details on n=3 of the
drug titrations).
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11.4 Daclatasvir has an inhibitory effect on envelopment
of viral particles
Until the moment of the present experiments, direct-acting antiviral DCV mode of action
was not fully understood and strong evidence from various groups have shown that this
drug might have an effect in assembly of the virus [26, 126, 165].
Nonetheless, NS5A participates in various ways during assembly. It is known it regulates
the coordinated packaging which is required for viral RNA to get into the nucelocapsid.
Also, during assembly of infectious virus particles, NS5A appears to be colocalising
with core protein in lipid droplets which seem to be required [26]. Finally, it has been
suggested that NS5A is regulating the switch between replication of the viral RNA
and its packaging into virions [162]. All together these experiments pointed into NS5A
activities also being inhibited by NS5A inhibitor, DCV. However, the role of DCV in
assembly of HCV viral particles remained unclear. To investigate further on the role of
DCV in assembly and decipher the MOA, we performed the following experiments.
We use then the established conditions in the previous experiments. Lunet cell culture
was treated with DCV or SOF after 24h post electroporation of JCR2a HCV genome.
We added the established EC50 values: 0.06nM and 56.56nM, respectively. As we can
see in Figure 11.11, the effect was observed only in the cells treated with DCV compared
to SOF treated cells, which main target is NS5B and has no effect on the assembly of
the viral particles. This was the first evidence that was indeed affecting the assembly
process and not only the replication of HCV viral particles, as shown in Figure 11.11.
This Figure represents the ratio calculated between replication values and reinfection
values when samples were treated with both drugs SOF and DCV. As shown in Figure
11.9, by one time experiment, the shift was observed when samples were treated 24
after drug addition, so this effect was also observed when the ratios where calculated for
reinfection values at 24 hours post drug addition.
Once we observed the effect of DCV treatment in HCV assembly, we continued to
investigate at which step of the assembly process DCV is inhibiting NS5A activities.
The assembly process is divided into distinct steps such as core trafficking to the lipid
droplets, core oligomerization, capsid formation and finally envelopment. We first look
into the envelopment of the viral particles and if it was interrupted by the drug. For
this purpose, we used the same conditions in which we electroporated Lunet cells with
HCV RNA, after 24 hpe, we added the different treatment of drug SOF or DCV, using
EC50 values and use control cells as untreated without a drug. After 24, 48 and 72 hpi,
we harvested the cells collecting the supernantant and the debris.
84
Sofosbuvir
Replication Reinfection
0
20
40
60
80
100
24hr
48hr
72hr
[nM: 39.06]
%
 o
f u
nt
re
at
ed
Daclatasvir
Replication Reinfection
0
20
40
60
80
100
24hr
48hr
72hr
[nM: 0.0061]
%
 o
f u
nt
re
at
ed
EC50: 56.56nM EC50: 0.0062nM
*
Figure 11.11: SOF and DCV effect on replication and reinfection processes
DCV and SOF ratios and the effect of the drug addition after 24hpi. Underneath each
drug treatment the EC50 value selected for treatment at 24 hpe is shown. Then the
cells were harvested at 24, 48 and 72 hpi. Replication and reinfection values are shown.
All the values were normalised to the untreated cells. Results are shown in percentage.
11.4.1 Proteinase K Assay
First, we assessed if core protein was protected against the proteolytic digestion with
proteinase K, to ensure the envelopment of the protein into membranes as the assembly
of HCV viral particles. The residual core protein was quantified by Western blot and
the data was normalized to the amount of core protein in the untreated sample. As a
control, cell lysates were preteated with Triton X-100 to solubilize all membranes before
proteinase K digestion. Under these latter circumstances, all core proteins are expected
to be sensitive to proteolytic digestion, ensuring that the proteinase K concentration
was not limiting in the assay. The core amount detected under these conditions was
used for background subtraction. A representative immunoblot stained for HCV core is
shown in Figure 11.12. This method is also described in 10 as it was published by [162].
Accordingly, in samples treated with SOF, quantification of signal intensities revealed
that all of intracellular core protein was resistant to protease digestion and thus, had
already acquired a membrane envelope and proceeded to a post-budding step see Figure
11.12. In contrast, samples under the treatment with DCV showed a highly significant
reduction in amount of protected core, indicating that most core species present were
digested shown in Figure 11.12, the quantification shows the more evident reduction on
the envelopment of viral particles. Together, these data suggest that treatment with
DCV confer a defect in infectious particle production occurring at, or prior to, core
envelopment. As already mentioned, assembly of infectious HCV particles requires the
acquisition of a lipid membrane containing the envelope glycoproteins and as previously
reported [162], this process can be monitored in a time-resolved manner by determining
the sedimentation profile of core protein using rate zonal centrifugation [155].
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Figure 11.12: Envelopment assay experiment
Jc1 cell lysates were subjected to a proteolytic digestion protection assay as follows:
Lysates were separated into three aliquots which received different treatments: (i) left
untreated (-), (ii) treated with 150 g/ml proteinase K (PK) for 1 h on ice, or (iii) lysed
in 1% Triton X-100 prior to PK treatment (condition used for background correction).
The amount of protease-resistant core was determined by Western Blot both blots
stained for HCV core.
Western Blot signal intensities were quantified with LabImage 1D and values obtained
for the proteinase K-treated sample were background-corrected and normalized to
untreated control. Mean values and standard deviations of 3 independent experiments
are shown.
11.4.2 Rate Zonal Centrifugation Assay
Secondly, we use rate zonal centrifugation which separates particles by size, using dif-
ferent concentrations of sucrose in different densities (gradients). Larger particles to the
bottom (more viscous) and small on the top (not enough mass to go through gradient).
To this end, we prepared lysates of the Lunet cells at 24h after electroporation of JC1
HCV genome into Lunet cells and 24h after drug addition (SOF and DCV) as previously.
Post nuclear supernatants were loaded on top of a linear sucrose gradient (0-30%) and
separated by rate zonal centrifugation [155]. Gradients were fractionated and core pro-
tein amount in each fraction was determined by CMIA (Chemiluminescent microparticle
immunoassay). Fractions are collected after centrifugation, see Figure 11.13.
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Figure 11.13: DCV treatment gradients show no Core envelopment particles
Rate zonal centrifugation. Post-nuclear supernatants of cell lysates obtained by
repetitive cycles of freeze and thaw 48 h post-transfection were layered on top of a
preformed continuous 0 to 30% sucrose density gradient and subjected to rate zonal
centrifugation for 1h at 270,000xg. Core content was measured along the gradient by
ELISA and normalized to the total core amount in the lysate. Experiment 1, shows
one repetition and the average data come from 3 independent experiments where we
performed separation by 030% linear sucrose gradient, the collected 11 fractions are
shown.
At 48hrs post transfection we observed all complexes are sedimented slower in SOF
treated samples than in DCV treated samples. The samples under DCV treatment
showed the first peak at fraction 4-5, and a second one between 7-9, this shows the dual
mode of action. Hereby, DCV shows an inhibition of the envelopment of viral particles,
shown by the first peak, which refers to its effect at slow sedimenting fractions 4-5. In
contrast, SOF treated samples were a large proportion of core protein has assembled into
fast-sedimenting complexes that accumulated in fractions 6-9, which have no effect on
the envelopment of HCV viral particles. Therefore, this experiment shows that samples
treated with SOF had the Core protein fully enveloped by 48hrs after transfection mainly
because the samples pass through the gradient showing highest peak at fraction 6-9. In
contrast, samples with DCV, did not pass rapidly though the gradient and accumulated
in first fractions 3 to 5 having a significant peak at fraction 8 to 9. This last point
shows that in samples treated with DCV the Core protein appears not to be enveloped
as shown in Figure 11.13. We suggest then, that DCV treatment can block the assembly
at the envelopment stage.
However further experiments using different time points could be useful to determine
if the process of envelopment is blocked prior to assembly of the HCV viral particle.
Thus, performing the experiments prior to the 24hpe and 24 post drug addition of our
settings, could elucidate this question (for example, 12h as previously reported in [162]).
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11.4.3 Immunofluorescence Assay
NS5A inhibitors interfere with the assembly of infectious virions and at the same time
block the membrane rearrangements that are essential to build up the viral replica-
tion factory [126]. Accordingly, we wanted to analyse the same samples by confocal
microscope to determine the co-sedimentation of core protein with the HCV envelope
glycoproteins, which could show a relevant effect of DCV on membrane rearrangements
or on NS5A sub-cellular location. We found that HCV Core colocalizes with NS5A, this
is because core protein is directed to LDs whereas RNA replication most likely is medi-
ated by a replicase complex associated with ER or ER-derived membranes as previously
reported [162].
Moreover, during virus assembly the RNA genome is transferred from the replicase
complex to the core protein. This process will require the action of NS5A to mediate
the interaction between the core protein and the replicase complex, giving NS5A a
clear role during assembly. Using microscopy data we analysed the co-localization of
core and NS5A in Huh7-Lunet cells transfected with HCV JCR2a and then treated the
samples with DCV or SOF. As shown in Figure 11.14 and Figure 11.16, we observed
co-localization between NS5A and core proteins and glycoprotein E2. Moreover, the
ring-like staining pattern of NS5A indicates that this protein also associates with LDs.
The drug treatment with SOF or DCV, did not alter the colocalisation with glycoprotein
E2 or to LDs see Figure 11.15 and Figure 11.17.
This results could suggest that the differences in core-NS5A (replicase complex) inter-
actions are not detectable for the different level of virus production. Moreover the drug
addition treatment apparently did not affect the localisation of HCV Core protein or
E2 glycoprotein. When treated with DCV samples show the same pattern as SOF and
NS5A colocalization with LDs suggests no additional relocalisation of the proteins due
to the drug treatment. Anyhow, additional time points could help elucidating the effect
of the drug on this step of the assembly, because the effect of the drug might be in the
early or late steps of the assembly process.
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Figure 11.14: NS5A and E2 localisation
NS5A localisation in relation to glycoprotein E2 in samples treated with DCV. JCR2a
genome was transfected into Huh7-Lunet cells which then were fixed after 48h and
subjected to immunofluorescence staining of E2 (AP33, 1:300 mouse monoclonal
antibody, green) and core (C830 1:200 rabbit polyclonal antibody, red). Nuclei were
counterstained with DAPI (blue), not shown. Representative transfected cells were
counted for each construct. To the right, a quantification of samples performed by R
pearson in ImageJ.
Figure 11.15: NS5A and E2 localisation
NS5A localisation in relation to glycoprotein E2 in samples treated with SOF. JCR2a
genome was transfected into Huh7-Lunet cells which then were fixed after 48h and
subjected to immunofluorescence staining of core (C830) 1:200 rabbit polyclonal
antibody, red) and E2 (AP33, 1:300 mouse monoclonal antibody, green). Nuclei were
counterstained with DAPI (blue), not shown. Representative transfected cells were
counted for each construct. To the right, a quantification of samples performed by R
pearson in ImageJ.
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Figure 11.16: NS5A and Core protein localisation
NS5A localisation and Core protein in samples treated with DCV. JCR2a genome was
transfected into Huh7-Lunet cells which then were fixed after 48 h and subjected to
immunofluorescence staining of core (C830 1:200 rabbit polyclonal antibody, red) and
NS5A (9E10 1:1000, mouse monoclonal antibody, green). Nuclei were counterstained
with DAPI (blue), not shown. Representative transfected cells were counted for each
construct. To the right, a quantification of samples performed by R pearson in ImageJ.
Figure 11.17: NS5A and Core protein localisation
NS5A localisation and Core protein in samples trated with SOF. JCR2a genome was
transfected into Huh7-Lunet cells which then were fixed after 48h and subjected to
immunofluorescence staining of core (C830 1:200 rabbit polyclonal antibody, red) and
NS5A (9E10 1:1000, mouse monoclonal antibody, green). Nuclei were counterstained
with DAPI (blue), not shown. Representative transfected cells were counted for each
construct. To the right, a quantification of samples performed by R pearson in ImageJ.
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11.4.4 Transcomplementation Assay
Moreover, replication-incompetent NS5A mutants could be rescued by transcomplemen-
tation assay [26], knowing now that NS5A inhibitors could interfere with the assembly
of viral particles, we were interested whether this NS5A function can also be restored
by trans-complementation and/or if NS5A inhibitors could interfere with the rescue
of assembly. To this end we established a trans-complementation assay based on the
co-transfection of a JCR2a genome carrying the deletion in domain III of NS5A (∆2328-
2435), with or without a resistant mutant Y93H and an HA-tag, into two different cell
lines containing a subgenomic luciferase-helper RNA that lacks the region encoding core
to the C-terminus of NS2 and in case of the resistant mutant, contains the mutation on
Y93H, as shown in Figure 11.18. Replication of this helper RNA was determined by
luciferase assay. The final aim of the transcomplementation assay was to uncouple the
assembly function of NS5A by deleting its DIII and treatment with or without drugs
to rescue its function by transcomplementation assay. This assay utilizes the transfec-
tion of selectable replication-deficient HCV replicons into cells that harbour replicons
expressing the trans-complement. We transfected the following helper RNA constructs,
see 11.18 into Huh7-Lunet NS3-NS5A (wildtype) and Y93H (resistant mutant) cell lines
previously prepared as described previously in section 10.7.2.
JcR2a DDIII NS5A-HA JcR2a Y93H DDIII NS5A-HA
(1) (2)
(A) (B)
(1) (2)
Figure 11.18: Trans-complementation constructs and cell lines
Constructs used for the trans-complementation assay. Cell lines (1)
pWPI-NS3-5A-BLR. (2) pWPI-NS3-5A-Y93H-BLR (yellow star marking the drug
resistant mutantion on NS5A). Right side panel shows the cell lines detection by WB:
(1) pWPI-NS3-5A-BLR and (2) pWPI-NS3-5A-Y93H-BLR, respectively. Constructs
containing JCr2a HCV genome used for assay were (A) JCR2a ∆DIII NS5A-HA and
(B) JCR2a Y93H ∆DIII NS5A-HA.
Depending on the particular combination of the constructs, different outcomes were
possible. Upon transfection of cells with the helper RNA constructs we expected different
rescue patterns as shown in Figure 11.19. The first (A) JCR2a construct was used as
a marker for assembly blockage -assembly mutant- and the second, (B) construct was
used to evaluate the effect of the drug in the resistant mutation Y93H -resistant mutant-.
Treatment with DCV or SOF will help or not in the recovery of the assembly of viral
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JcR2a DDIII NS5A-HA 
Rescue assembly
JcR2a DDIII NS5A-HA 
+
DCV
NO rescue assembly
Rescue assembly
SOF JcR2a  Y93H DDIII NS5A-HA 
JcR2a  Y93H DDIII NS5A-HA 
JcR2a DDIII NS5A-HA Rescue assembly
JcR2a  Y93H DDIII NS5A-HA 
NO rescue assembly
+
+
Figure 11.19: Transcomplementation assay hypothetical results
Expected results from different combinations of constructs and cell lines, to observe
the recover effect of each trans-complementation. DCV or SOF treatment in each
combination is crucial for the recovery or not of assembly.
particles. We expected that combination of both cell lines and both constructs under
the treatment of SOF, would recover the assembly, because SOF treatment will not
interfere with the assembly process. In contrast, using the assembly mutant construct
together with either of the cell lines will result in no rescue of the assembly, due to the
effect of DCV on assembly of the viral particles. However, when using the cell line with
the resistant mutant (2) and constructs (A) or (B), assembly will be recover, due to the
resistance phenotype, as shown in Figure 11.19.
However the experiment did not show exactly the results as we expected. The combi-
nations of constructs (JCR2a wt, JCR2a∆III and JCR2a∆III-Y93H) are shown in the
y axis together with cell line types: Lunet, Lunet wt (pWPI-NS3-5A-BLR), and Lunet
Y93H (pWPI-NS3-5A-Y93H-BLR), on the x axis, RLuc measurement normalized to
4hrs hpe, as shown in Figure 11.20. Instead, the combinations showed the following:
• When using JCR2a (wt) construct and the three different cell lines, HCV repli-
cation showed a normal infection curve where we have 1.0X104 RLuc counts after
24hrs for HCV replication time-point, as this was used as positive control.
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Figure 11.20: Trans-complementation of constructs on time line.
Combinations of three different constructs (JCR2a wildtype, JCR2a∆III and
JCR2a∆IIIY93H and three different cell lines: Lunet, Lunet (wildtype:
pWPI-NS3-5A-BLR) and Lunet Y93H (resistant mutant: pWPI-NS3-5A-Y93H-BLR).
RLuc measurement at different time points of HCV replication, normalized to 4hrs.
• When using JCR2a∆III construct and the three different cell lines, resulted in a
lower HCV replication. And in when using the Lunet wt cells (1) pWPI-NS3-5A-
BLR, showed no detectable counts at 4hpi, which we could not develop further.
When using Lunet Y93H cell line, at 24hpi, HCV replication was not yet estab-
lished, but at 48hpi, HCV replication was observed, but not as wildtype.
• When using JCR2a∆III-Y93H construct with Lunet cells, we did not detect any
RLuc counts on the plates, which we account for a defect on the trans comple-
mentation assay. When using Lunet wt cells, we observed a reduction on HCV
replication after 4hr infection, which showed that trans-complementation was not
established and when using Lunet Y93H cell line, the construct JCR2a∆III Y93H,
the HCV replication RLuc counts could not be enough to use this combination for
a established trans-complementation assay.
Unfortunately, we could not use this combination set-up as expected due to the non
recovery of the trans-complementation assay between constructs and cell lines. The
future plan was to recover the supernatant and infect new Huh7.5 cells with it, then
further treat with DCV or SOF. Nonetheless, we could improve the set-up by addition of
double mutants, addition of a antibiotic resistance, or different helper RNA constructs
to have a precise cis or trans complementation of each part of the assay, as further
discussed in section 13. Regardless, the results were conclusive to build the cell lines and
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constructs needed for such experiments and improvements can be taken from previous
reported transcomplementation assays in other studies [172–174].
11.5 NS5A oligomerization state
Among other unsolved questions regarding the multifunctionality of NS5A is the oligomer-
ization state of the protein. Controversially, it has been reported that NS5A forms a
dimer [37–39], but even these studies suggest the formation of high oligomer formation
during NS5A functions. A more recent report suggests there is a higher oligomer forma-
tion [62], which is crucial for NS5A multifunctionality and so for the inhibition by NS5A
drugs. It has been hypothesized that the oligomer must be present for the inhibitor to
attach to the binding site. Moreover, high resolution structural studies of NS5A protein
reveal that the protein forms a dimer via contacts near the N-terminus, and the Y93H
resistant mutation lies at the interface between two NS5A proteins [37], which is why
we used both constructs (wildtype and resistant mutant Y93H). Although other reports
claim that drug treatment does not seem to affect dimerization process [161]. In the end
we wanted first, to investigate whether NS5A forms high oligomers during HCV infec-
tion. Second, to investigate if this can be disrupted by the addition of NS5A inhibitors.
And lastly, to see if the oligomerization state affects the efficacy and efficiency of NS5A
inhibitors. To approach this matter and study the presence of higher oligomer formation
of NS5A, we used PFA (Paraformaldehyde) cross-linking assay [156]) and using BRET
(Bioluminescence Resonance Energy Transfer) assay [118]. This last assay results are
undergoing which is why results are not all shown in the present study.
11.5.1 PFA cross-linking
In order to confirm the detection of PFA cross-linked complexes. Lysates were incubated
at 65◦C and 99◦C, respectively and analyzed by western blot using the antibody against
NS5A protein (9E10), as described in 10.9.4. As seen in Figure 11.21, the assay’s prin-
ciple is that at 65◦C, the oligomer would continue in a oligomer conformation, whereas
at 99◦C, the oligomer would loose its conformation, thus, being able to detect different
parts of it.
We use the following constructs to transfect Lunet-T7-puromycin cells:
• pTM-NS3-3’ JFH1
• pTM-NS3-3’-NS5A-gfp Y93H-JFH1
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• pTM-NS3-3’-NS5A-gfp ∆DI-JFH1 (aa28-213) (data not shown)
Later, we prepared formaldehyde as cross-linking reagent at different concentrations
0.4% to 4%, then Lunet cells were suspended under the different PFA concentrations
and incubated at different temperatures 65◦C or 99◦C and then lysed with RIPA buffer
for later analysis by western blot, as shown in 11.22 and 11.23.
Figure 11.21: PFA cross-linking assay principle
Schematic model. Formaldehyde derived cross-links are preserved, if samples are only
incubated at 65◦C, whereas most of the cross-links are reversed at 99◦C. Proteins are
depicted as oval shapes, formaldehyde cross-links as black triangles. Taken from [156]
Under this circumstances we could recognize a higher molecular weight complex (a
smear) containing NS5A, in samples treated for 5 min at 65◦C and 99◦C. In Figure
11.22, samples showed a clear band at 56 kDa using both constructs (wt and Y93H
resistant mutant). PFA concentration 0.4, 0.8 and 2%, in samples including the wt con-
struct, showed a smear and a band at around 75 kDa, which can correlate to a higher
molecular weight NS5A oligomer formation. In contrast to samples with Y93H resistant
mutant, a smear was lightly detected at 0.4-0.8% PFA concentration, but a clear band
was detected at 2% PFA concentration. This suggested that using 2% of PFA concen-
tration we could detect an cross-linked complex containing non-structural protein 5A.
In Figure 11.23, NS5A was detected at 58 kDa using 0.2, 0.4, 0.8 and 1% PFA for the wt
construct. Additionally, at 0.8, 1 and 2% PFA, we could detect three different molecular
weight bands, at approx 70, 90 and 130 kDa, indicating that using 99◦C, can separate
the oligomer in separate molecular weight protein parts, as shown in Figure 11.21. As
for the resistant mutant, we could detect NS5A at 58 kDa using 0.2, 0.4, 0.8% PFA
concentration. Additional bands were observed at 70, 90 and using 1.8 and 2% bands
detected at 130 kDa, indicating that the resistant mutation does not seem to affect the
oligomer formation of NS5A.
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Figure 11.22: NS5A oligomerization state detected at 2% PFA concentration
Samples incubated at 65◦C for 5 minutes under different PFA concentrations. Different
molecular weights are shown. Western Blot for NS5A (using 9E10 antibody).
Figure 11.23: NS5A oligomerization state detected at 2% PFA concentration
Samples incubated at 99◦C for 5 minutes under different PFA concentrations. Different
molecular weights are shown. Western Blot for NS5A (using 9E10 antibody).
However, NS5A was also found in the monomeric form at approximately 58 kDa after
incubation at 65◦C, as shown in Figure 11.22, which was detectable at different PFA
concentrations treating the samples at the higher temperature, which correlates with
what we were expecting from this assay. This could be due to incomplete cross-linking,
as the conditions applied during formaldehyde cross-linking do not lead to a high extent
of protein cross-linking, leaving a large fraction of NS5A non cross-linked. Alternatively,
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incubation at 65◦C may lead to partial reversal of formaldehyde cross-links and release
of NS5A even at a lower temperature. Moreover, samples at 99◦C show less smear than
the samples treated at 65◦C, this could also suggest the presence of a high oligomer
formation, as shown in Figures 11.22 and 11.23. Interestingly the resistant mutant
construct did not show significant differences at 99◦C but at 65◦C boiling temperature,
samples showed a decreased in the smear, which suggests that it is less likely to form
oligomers of higher molecular weight. Ultimately, repetitions of this experiment must
be performed to have more conclusive data. Regardless, this experiment shows evidence
for a higher order complex formation at an optimal PFA concentration for cross linking.
11.5.2 BRET assay
Another technical tool to detect oligomer formation is using BRET (Bioluminescence
Resonance Energy Transfer), previously used in the laboratory. Unfortunately, the re-
sults generated in the laboratory did not work due to the construct preparation, so
we improve the set constructs using RLuc or YFP label and generated newly designed
constructs as shown in as shown in section 9, we use different linker lengths for each
construct. Each of the constructs contain two fragments of each reporter protein (F1
or F2), that could complement each other and reconstitute the whole Renilla Luciferase
or full YFP NS5A labelled, respectively. The aim was to reconstitute the BRET signal,
which we could interpret as having several of this constructs in close proximity, which
could strongly suggest the formation of a higher oligomers.
First, we designed 16 constructs with different linker lengths as shown in section 9, that
contained as the following Figure 11.24:
Figure 11.24: BRET constructs containing RLuc or YFP
Constructs and method are in detailed described in sections 9 and 10. In green, are
RLuc containing constructs and in orange YFP containing constructs, that were
selected. Diagram of each construct is illustrated (taken from DR. Berger data).
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Second we use in combination all 16 constructs and try to combine all of them, and
see which combination works best. The assay works as seen in Figure 11.25, where two
dimers of NS5A, each expressing a RLuc fragment, and another expressing full YFP, we
hypothesized that when this complex is in close proximity, we could recover BRET sig-
nal, as an acceptor-donor interaction. Furthermore, when NS5A inhibitors are present
we would observe no BRET signal, if NS5A inhibitors are blocking the formation of a
high molecular weight oligomer.
Figure 11.25: Principle of BRET experiment
NS5A is represented as a dimer (magenta and cyan), each containing a representative
of RLuc fragments or YFP full-length. Two hypothetical scenarios are shown: left,
shows a scenario where BRET signal can be recover due to the expression of each
construct (RLucF1 or RLucF2 together with YFP) and thus, the formation of the
oligomer. Right, shows the scenario where NS5A inhibitors interfere with this oligomer
formation by a steric clash or a blockage in the interaction via the binding site. DCV
chemical structure is shown.
Figure 11.26: BRET combination of RLuc constructs
Letter code stand for each RLuc fragment needed in each combination for BRET. F1
or F2.1, stands for the linker number, although also shown. Each fragment linker
number and length are shown.
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Third, we transfected each construct in Huh7.5 cells, obtain and quantify protein for
each one of the constructs. Later, we use this quantification numbers, to use the exact
amounts of each construct using western blot (data not shown) and then protein quan-
tification method using LabImage R©. Once we calculated protein concentration we were
able to express all constructs with the same amount of protein; this improved the assay’s
accuracy. Lastly, we use selected constructs in combination RLucF1 or RLucF2, as a
test before performing BRET final assay which will include one of the RLuc fragments
together with full YFP. Figure 11.26, shows the constructs which showed a significant
RLuc measurement (above 4hrs post transfection normalization). The last is undergoing.
Chapter 12
Computational Results
The following section describes the computational experiments based on the experimen-
tal results in order to complement and fully understand the mechanism of action behind
NS5A inhibitors and NS5A multifunctionality. First, we decided to look at the same
Proline residues used in our experimental data, to compare with using a computational
approach. Second, we wanted to look into DCV properties in relation to NS5A. Lastly,
we wanted to elucidate the role of the NS5A amphipatic helix in the cellular membrane
and its role using NS5A inhibitors. Together all these results could give us a slight
picture of how the inhibitor is working and how key aspects of NS5A are relevant for
DCV mechanism of action.
12.1 Proline residues in linker structures are key for DCV
binding
As described in the experimental results, see 11.1, we use the Proline mutations on the
linkers, as in 11.1, to investigate the impact of Proline mutations in the interaction with
DCV. We use our experimental data to identify the effects of this Proline mutations
on the interaction site with DCV inhibitor. For this, we use the NS5A dimer structure
described in [1] and analyse each identified site-directed mutagenesis Proline residue in
the linker connection between the amphipatic helix and domain Ia and domain Ib. We
analyse each mutation on the overall structure of NS5A by visual analysis. Then we
re-docked DCV inhibitor in the NS5A structure including each Proline mutation and
run molecular dynamics, All together to fully understand the binding mechanism in the
interaction site in addition to understand how the Proline mutations affect or promote
this interaction.
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Using MOE we introduce the Proline substitutions for the mutations performed experi-
mentally, we compared the position to the wildtype Proline residue in one of the linkers
as an example we used Proline residue 29 and 35, as shown in 12.1. We then performed
this visual analysis with all the Proline mutations (data not shown). But to demon-
strate that the mutation is having an effect on the binding with NS5A inhibitor, DCV
we performed Molecular Dynamics to study this in detail.
Pr
o 
29
Pr
o 
35
Mutation AlaWildtype Pro Mutation ValMutation Gly
Figure 12.1: Example Proline 29 and 35 mutations
Site-directed mutagenesis to Proline residues mutations on linker structures of NS5A.
Visual analysis of position in comparison to wildtype in MOE. DCV is shown in
yellow, Pro29 and Pro35 shown in cyan as wildtype and each of the substitutions for
Ala, Gly or Val are shown in orange.
The location of the Proline residues is shown in 12.2, were each of the Proline residues
found in the experimental results are colour coded to the impact they had in the HCV life
cycle. The site-directed mutagenesis experiments resulted in the highlight of key Proline
residues that showed an impact on HCV replication and thus on HCV infection. This
Proline residues were mainly in the linker connection between subdomain Ia and Ib or
in the connection with the domain II. While, the Prolines showing a more wildtype-like
(shown in example Figure 12.1 in cyan) behaviour were located in the linker connecting
AH and domain Ia, this might be related to the high conservation of this Proline residues.
Thus, their activity might be key for the binding to the cellular membrane through their
interaction with the AH. This was further investigated with molecular dynamics results
in results section (see 12.3). Furthermore, as you can observe in Figure 12.2, the location
of the Proline residues as wt (shown in cyan), are in close proximity to the AH, and
located in the binding site of DCV, this interesting correlation might indicate that the
Proline residue might have a key role in maintaining the linker structure for further
stability of the protein. Hence, this conserved activity might be key for the mechanism
of action of DCV.
For the next step we use the same generated Proline substitutions and re-docked the
DCV inhibitor into the structure of NS5A taken from [1] as mentioned before. This
resulted in the selection of a re-docked poses of DCV that best fitted to the system,
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Figure 12.2: NS5A dimer with highlighted Proline residues
Proline residues in NS5A structure. Using the model from [1], we inserted the Proline
residues that were mutated and we analysed their structure relative to their effects
during replication and/or particle production. We added DCV to analyse the possible
effect during inhibition of NS5A. DCV is shown in yellow. Proline residues influencing
HCV replication or infection are shown in green and in cyan are shown the Proline
residues as the wildtype.
then the selected pose was prepared by MAESTRO and molecular dynamics were run in
MAESTRO by Desmond program. Thus, in the following Figures the data generated for
each MD is shown within the corresponding Proline mutation, docked DCV and NS5A
dimer, these key aspects of the MD are detailed described.
To analyse further each linker we looked at the previously explored Proline mutations. In
the following Figure we took some snapshots of the MD ran for the generated constructs.
The constructs include NS5A with the following predicted AH cited in [1] and each
Proline mutation with the re-docked inhibitor Daclatasvir. Each snapshot shows a key
movement of the key components (NS5A protein, Amphipathic helix, or the inhibitor
DCV). Each MD was run 300ns in total, snapshot were taken a different time points
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(as stated) and the major event was described in steps (bullet points). Additional MD
movies are further discussed in section 13. Each monomer is shown in a different colour.
We based our studies on the Proline mutation analysis of the AH-DI linker, which is of
major relevance.
12.1.1 P29A
The following sequence of snapshots describe the molecular dynamics for the system
containing NS5A, DCV and P29A mutation on AH-DI linker of NS5A structure. Figure
12.3 shows a representative snapshot. Molecular dynamics video is described in the
following steps.
• Step 1: beginning. The model with its starting position, were all components are
inserted as the previous re-docked position of DCV with NS5A.
• Step 2: 15ns, slight movement of the AH on one of NS5A dimers.
• Step 3: 30ns, the AH undergoes slight movements making DI on both dimers come
closer together.
• Step 4: 97ns, DCV looses contact with AH.
• Step 5: 135ns, DCV reconnects with AH.
• Step 6: 173ns, AH reconstitutes its original position, horizontally to where mem-
brane is located.
• Step 7: 202ns, AH and DCV are brought closer to NS5A via closed conformation
of linker.
• Step 8: 262ns, DCV changes configuration drastically, changing plane and location
of side chains.
• Step 9: 297ns, DCV changes conformation, in contact with AH and NS5A DI, and
has a closed conformation.
In conclusion, molecular dynamics on P29A showed major changes in the position of AH.
This might be due to the lack cellular membrane position, which stabilizes its position.
As a result of the AH movement we can see a movement in DI on each dimer, this might
also cause a disruption in important interactions between AH and DCV. In fact, this
observation can explain the experimental results, where we detect a reduction on HCV
replication as compared to wildtype. See Figure 11.2. In general, the structure of NS5A
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remains in same position while DCV changes conformation to fit into space between AH
and linker. This observation can predict that when P29A is mutated, DCV binding site
can change, thus, disrupting its activity.
Figure 12.3: P29A
. Representative snapshot is shown, where as described, AH undergoes changes that
provoke DI to rearrange. DCV fitting into interdomain region. Each monomer is
shown in cyan and green. DCV in orange. MD total time was 300ns.
12.1.2 P29G
The following sequence of snapshots describe the molecular dynamics for the system
containing NS5A, DCV and P29G mutation on AH-DI linker of NS5A structure. Figure
12.4 shows a representative snapshot. Molecular dynamics video is described in the
following steps.
• Step 1: starting position where DCV is re-docked to NS5A.
• Step 2: 7ns, AH comes closer to DCV.
• Step 3: 15ns, DCV almost gets to an overlapping position with AH.
• Step 4: 60ns, DCV core rings change plane (from horizontal to vertical), side
chains of DCV core are closer to the external amino acids chains of AH.
• Step 5: 109ns, AH looses contact with side chain of DCV, AH makes a turn.
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• Step 6:128ns, AH turns again facing DCV, which is closer to AH-DI linker, while
DCV core rings remain in the horizontal plane.
• Step 7: 148ns, AH last loop continues changing conformation while DCV changes
position relative to the AH-DI linker orientation (opening of the linker, by ex-
tension), provoking drastic conformational changes in the DI subdomains of both
NS5A dimers.
• Step 8: 168ns, AH last loop continues changing conformation together with DCV,
maintaining a tight interaction.
• Step 9: 273ns, AH looses last two loops, while DCV conformation changes accord-
ingly. AH-DI linker is in the closed position bringing closer interactions between
AH and DCV.
• Step 10: 291ns, AH without 2 of 5 loops, DCV changes conformation through the
last ns together with AH. Mainly changing last chain, the core remains in plane,
while the AH-DI linker opens and closes conformation bringing closer together the
AH to DCV which maintains the interaction.
Figure 12.4: P29G
Representative snapshot of molecular dynamics is showing the interesting position
DCV adapts after AH movement, as described. Each monomer is shown in cyan and
green. DCV in orange. MD total time was 300ns.
Consequently, the MD of P29G mutation showed a major movement of the AH which
impacts on the position of DCV. We observed drastic changes in the DCV position
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which relate to the experimental results which show that this mutation can still have
some replication at 72 hpe, in comparison to the other Proline 29 mutations, see Figure
11.2, where the values are not enough to reach wt. Additionally, the AH-DI linker main
function is to bring together the AH to the space in between two NS5A dimers where
the binding site of DCV is located, this happens when DCV is in a closed position, see
Figure 12.4.
12.1.3 P29V
As before, the following sequence of snapshots describe the molecular dynamics for sys-
tem the containing NS5A, DCV and P29V mutation on AH-DI linker of NS5A structure.
Figure 12.5 shows a representative snapshot. Molecular dynamics video is described in
the following steps.
• Step 1: beginning, starting position of DCV re-docked with NS5A.
• Step 2: 18ns, DCV structure is located in between the AH-DI linker and AH. Then
there is a conformational change and DCV moves into the interdomain space (this
term refers in this study to the area in between the DI of both NS5A dimers).
• Step 3: 28ns, DCV interacts with AH, this movement brings AH-DI linker to a
closed conformation and which in turn moves the AH closer to DCV.
• Step 4: 45ns, the last loop of AH looses its conformation. DCV interacts with AH
and the interdomain region, while AH-DI linker remains in a closed conformation.
• Step 5: 91ns, DCV changes conformation drastically and its position has almost
no interaction with AH or the interdomain region (where binding site is located).
• Step 6: 173ns, AH reconstitutes its original position, in a horizontal relation to
where cellular membrane is supposed to be located.
• Step 7: 202ns, AH plus DCV are brought closer to NS5A dimer via the closed
conformation of AH-DI linker.
• Step 8: 262ns, DCV changes configuration drastically, which makes a change in
its plane conformation and thus, in the location of the side chains.
• Step 9: 297ns, DCV changes conformation again, and it is in close contact with
AH. NS5A DI is in a closed conformation.
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Figure 12.5: P29V
Representative snapshot molecular dynamics of mutation at P29V, where we observe
DCV fitting into AH-DI linker and AH, as described. Each monomer is shown in cyan
and green. DCV in orange. MD total time was 300ns.
As can be seen, the results on P29V molecular dynamics showed that NS5A dimer struc-
ture remains in position while DCV changes conformation to fit into space between AH
and AH-DI linker. The connection with the AH changes through the MD, showing closer
interactions of the compound and DI, see Figure 12.5. When using the MD to explain
the experimental results, we found similarities with P29A, where both mutations showed
no HCV replication or infection (compared to wt), and MD showed drastic changes of
DCV, which correlates to the important role of this Proline residues in maintaining
NS5A functionality, see Figure 11.2.
12.1.4 P32A
To continue, the following sequence of snapshots describe the molecular dynamics for the
system containing NS5A, DCV and P32A mutation on AH-DI linker of NS5A structure.
Figure 12.6 shows a representative snapshot. Molecular dynamics video is described in
the following steps.
• Step 1: beginning DCV located in between linker and AH region.
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• Step 2: 6ns, DCV side chains and core moved to a closer proximity with AH, as
the AH-DI linker extends into an open conformation.
• Step 3: 20ns, DCV in close proximity to AH, AH-DI linker keeps extended position,
a side chain of DCV makes contact with the second AH (on the other NS5A
monomer).
• Step 4: 48ns, DCV in only in contact with AH, AH-DI linker is in a total open
conformation, full extension. AH looses the last loop conformation, and, thus, the
contact to second AH (on facing NS5A monomer) is lost.
• Step 5: 77ns, AH-DI linker is closer to AH, DCV remains in contact with AH.
• Step 6: 99ns, AH-DI linker in a full extension conformation, allows the opening of
the AH, which leads the side chains of DCV free into the interdomain region while
the core of DCV remain in contact with AH.
• Step 7: 123ns, DCV structure is in a conformation that allows the connection be-
tween the two AH located in both dimers. AH-DI linkers are completely extended
and both lost the last loop of the AH configuration, this movement brings the DI
of both subunits to collapse into each other.
• Step 8: 181ns, DCV undergoes an insertion into AH the AH-DI linker looses its
conformation into a complete extension. AH looses last loop and, thus, DCV lies
in AH horizontally but with no contact to the AH-DI linker.
• Step 9: 236ns, DCV core makes contact again with the AH-DI linker but continues
to lie in the AH in a horizontal position.
• Step 10: 273ns, DCV shifts to the interdomain region between AH-DI linker and
AH making contact with both structures. The last loop of AH is lost and the AH-
DI linker remains in an extended configuration. DI of both subunits are collapsing
into each other.
P32A mutation changes drastically the structure of the key components: AH, inter-
domain region and AH-DI linker, which stabilize DCV into the binding pocket. This
dramatic changes of the AH and the key components of the system lead to an over-
all change of the whole NS5A protein structure. When analyse in detail, the linker
seems to be several times in close contact with the interdomain region making the whole
structure shrink. This results correlate with the experimental data, where we observe
no HCV replication or infection (compared to wt), which might be explained by the
rearrangement of NS5A structure, see Figure 11.2.
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Figure 12.6: P32A
Representative snapshot of mutation at P32A, where we observe DCV in contact with
AH. AH looses loop structure. Additional changes in DI-DII linker of NS5A structure,
as described. Each monomer is shown in cyan and green. DCV in orange. MD total
time was 300ns.
12.1.5 P32G
In this section we have the sequence of snapshots which describe the molecular dynamics
for the system containing NS5A, DCV and P32G mutation on AH-DI linker of NS5A
structure. Figure 12.7 shows a representative snapshot. Molecular dynamics video is
described in the following steps.
• Step 1: beginning, DCV in the space between linker and AH.
• Step 2: 15ns, DCV structure is in contact with the AH-DI linker, into an extended
position where it interacts with the interdomain space.
• Step 3: 30ns, DCV is located in the interdomain region where it interacts with
AH-DI linker. There is no contact with AH.
• Step 4: 80ns, DCV is in close proximity with AH-DI linker located in the interdo-
main region, this opens DI structure on both subunits of NS5A. The AH-DI linker
is in a complete extension in an open conformation.
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• Step 5: 98ns, AH loops can change conformation and open into an extended con-
formation, this changes the location of DCV core which is interacting with AH-DI
linker and the interdomain region.
• Step 6: 142ns, DCV remains in contact with AH-linker and in the interdomain
region.
• Step 7: 168ns, DCV structure plane turns into a vertical position and interacts
with AH, the last loops of the AH are in a twisted position. DCV side chains are
located in the interdomain region.
• Step 8: 214ns, DCV returns to its starting position in between the AH-DI linker
and the AH. The last loop of AH looses its starting conformation.
• Step 9: 240ns, DCV interacts with the AH-DI linker, while the AH and the in-
terdomain region are all conforming the binding site for DCV. DCV in U-like
conformation, allowing interaction with all the key components of the binding
site.
• Step 10: 286ns, DCV remains in same position. AH twisted towards membrane
location.
Figure 12.7: P32G
Representative snapshot of mutation at P32G, showing the open conformation of
AH-DI linker, which can change the interacting points in the binding site of DCV.
Each monomer is shown in cyan and green. DCV in orange. MD total time was 300ns.
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Molecular Dynamics on P32G showed a rotational change on the AH which brings DCV
in close proximity to the interdomain region. This results in a opening of the AH-DI
linker. All together, this results correlate to the experimental results, see Figure 11.2,
because we can observe no HCV replication or infection due to the structure change of
NS5A or might be related to the overall mutation on the 32 position, as we observed
similar pattern with P32A mutation.
12.1.6 P32V
To continue, the following sequence of snapshots describe the molecular dynamics for the
system containing NS5A, DCV and P32V mutation on AH-DI linker of NS5A structure.
Figure 12.8 shows a representative snapshot. Molecular dynamics video is described in
the following steps.
• Step 1: beginning, DCV is located at the starting position.
• Step 2: 14ns, DCV structure moves into the interdomain region. The AH-DI linker
is in an extended configuration and the AH is interacting with DCV.
• Step 3: 34ns, DCV interacts with AH-DI linker in an open conformation, DCV is
located under the interdomain region, in the binding site.
• Step 4: 51ns, DCV remains in same position. AH looses the last loop on its
structure.
• Step 5: 72ns, DCV turns core structure into a vertical position and it shifts con-
figuration to interact with AH-DI linker, AH and the interdomain region, making
contact with all the key components on the binding site.
• Step 6: 100ns, DCV is in a cross position from AH where it remains through the
MD. The AH is in a twisted position interacting with the AH-DI linker and it is
located close to the interdomain region.
• Step 7: 120ns, DCV is closer to the AH. The AH-DI linker is in close position to
DCV, which remains close to the interdomain region.
• Step 8: 152ns, DCV is around the AH interacting with the AH-DI linker.
• Step 9: 213ns, AH-DI linker in U-like shape, this movement brings it closer to the
interdomain region where DCV locates in a crossed position.
• Step 10: an interesting insertion of AH into the interdomain region by AH-DI
linker movement. DVC interacts with AH-DI linker and remains located in the
interdomain region.
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Notably the AH-DI linker conformation is in an open or closed conformation, this move-
ment regulates the shift in the position of DCV. Additionally, both domains from dimers
are brought closer together or further apart from this movement. Together these move-
ments might influence the position of the AH in relation to the membrane location.
The MD showed that this movement of both AH-DI linkers is important for stabilizing
NS5A structure. Thus P32V mutation, as seen in the experimental data, has an impact
in HCV replication and HCV infection, which can be explained by the importance of
the dynamics in stabilizing NS5A protein.
Figure 12.8: P32V
Representative snapshot of mutation at P32V, open position of AH-DI linker, shifting
DCV position, as described. Each monomer is shown in cyan and green. DCV in
orange. MD total time was 300ns.
Overall what we observed with mutations on Proline 32, is that there is a direct impact
on HCV replication and infection as observed in experimental results. In addition, there
are extensive structure rearrangements which could be key to the mode of action of DCV.
This can be explained by the MD, as the binding pocket is located in close relation to
each of the key components in the system, the AH, inter domain region and AH-DI
linker positions respectively. Therefore, Proline 32 mutation is shown essential for HCV
NS5A protein.
112
12.1.7 P35A
The following sequence of snapshots describe the molecular dynamics for the system
containing NS5A, DCV and P35A mutation on AH-DI linker of NS5A structure. Figure
12.9 shows a representative snapshot. Molecular dynamics video is described in the
following steps.
• Step 1: beginning, DCV is located in the binding pocket making contact with the
key elements of the pocket: the AH-DI linker, AH, and the interdomain region.
• Step 2: 30ns, DCV moves into a closer contact position with to AH.
• Step 3: 51ns, there is a side chain on DCV which is inserted into the interdomain
region, the rest remains in contact with AH and linker.
• Step 4: 92ns, DCV remains in a stable configuration in the binding pocket between
DI of each NS5A subunits.
• Step 5: 139ns, very stable configuration of key components, DCV remains in the
same position, in contact with all the key elements in the binding and affinity
pocket.
• Step 6: 185ns, slight movement of DCV structure which brings closer together the
side chains and the core.
• Step 7: 196ns, DCV moves accordingly to AH-DI linker in a closed position which
brings DCV to a compact configuration, retaining the contact with the AH, AH-DI
linker and the interdomain region.
• Step 8: 200ns, DCV core changes plane to horizontal, the contact with the 3 key
elements remains.
• Step 9: 244ns, DCV remains in a horizontal position, DCV overall structure main-
tains contact with key elements.
• Step 10: 279ns, AH-DI linker shifts into an extended position away from AH in
a horizontal manner, into a slightly more vertical position maintaining interaction
with the key elements of the binding pocket.
This mutation does not show drastic changes in the conformation, and more impor-
tantly shows that DCV maintains a stable position in the binding pocket which allows
a continuous interaction and/or contact with the key elements of the system. This fact
is what keeps DCV in the key position for its activity efficacy. Therefore, this mutation
could have an impact in the replication of the virus as on the efficiency of DCV activity.
This MD observations correlate to the experimental data seen in Figure 11.2.
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Figure 12.9: P35A
Representative snapshot of mutation at P35A, showing DCV in the precise binding
site, making connections to the key elements in the pocket, as described. Each
monomer is shown in cyan and green. DCV in orange. MD total time was 300ns.
12.1.8 P35G
The following sequence of snapshots describe the molecular dynamics for the system
containing NS5A, DCV and P35A mutation on AH-DI linker of NS5A structure. Figure
12.10 shows a representative snapshot. Molecular dynamics video is described in the
following steps.
• Step 1: beginning, DCV and key elements of the system remain in beginning
position.
• Step 2: 46ns, DCV remains in close contact to key elements in the binding pocket.
• Step 3: 74ns, movement of AH towards DI on one of the dimers shifts location of
DCV closer to interdomain region.
• Step 4: 123ns, key elements maintain the structure, DCV moves towards the AH-
DI linker.
• Step 5: 141ns, DCV side chains and core do not undergo major changes and key
components are stable. DI shifts location according to AH.
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• Step 6: 186ns, DCV moves slightly closer to the interdomain region maintaining
contact with AH.
• Step 7: 202ns, key components maintain DCV structure in binding site.
• Step 8: 230ns, DCV does not shift plane and remains in binding pocket. AH-DI
linker moves into an extended position.
• Step 9: 267ns, AH remains horizontal to the cellular membrane position, keeping
DCV in line. AH-DI linker extension provokes movement of DI of NS5A.
• Step 10: 284ns, AH-DI returns to a less extended position, where key elements
maintain the binding site where DCV is located.
Figure 12.10: P35G
Representative snapshot of mutation at P35G, a slight opening of the AH-DI linker.
DCV remains in binding pocket making contact with key elements, as described. Each
monomer is shown in cyan and green. DCV in orange. MD total time was 300ns.
P35G mutation did not show major NS5A structure rearrangements, maintaining sta-
ble the binding pocket of DCV, which correlates to the stability of the mutation on
experimental results. When P35G is mutated there is a decreased in normal (wt) HCV
replication and infection, but the virus can still have a detectable level of HCV replica-
tion and infection. Molecular Dynamics on this mutation show that Proline 35 might
not have an essential role on HCV life cycle, but it is essential for the maintenance of
DCV’s binding pocket.
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Snapshots on mutation P35V are not shown due to problems in the re-docking process
of DCV into the NS5A structure. Furthermore, the molecular dynamics could not be
performed. Improvements on some amino acid interactions can be done to perform a
re-docking of DCV.
To conclude we have observe that: mutations on P29X: showed stability in DCV struc-
ture. Although no major changes on the conformation of NS5A DI subdomains was
seen. P29G, showed that the AH looses the conformation of the AH loops. Addition-
ally, DCV was not in contact with the interdomain region which is the key component
of the binding pocket. Mutations on P32X: This mutation showed more drastic confor-
mational changes that would challenge the conformation of the DI subunits in the dimer
formation. The AH showed drastic changes in conformation that could suggest the in-
sertion of this into the cellular membrane. Finally, mutations on P35X: This mutation
does not alter the structure of NS5A, this might be due to the stability of DCV into
its binding pocket and the stability through the dynamics in the contact with the key
elements which maintain the molecule in the correct position for its activity.
Altogether, this experiments show that Proline mutations significantly change the posi-
tion of DCV as seen by molecular dynamics, implicating a different binding site of the
drug to the protein, which can have a direct effect on the efficiency and efficacy of the
binding of the drug. Interestingly, some of this mutations have a higher impact than
others, as already mentioned this might be due to the steric clashes of the amino acid
itself or other interactions.
Ultimately, with this experiments we want to show the potential mutations on essen-
tial Proline residues that might not only change the position of DCV in its binding
pocket, but that might also change its properties. Therefore, we studied DCV essential
properties and its impact on the overall structure of NS5A protein.
12.2 DCV structural properties
The following studies are focused on the inhibitor, DCV, and its interactions with Proline
residues in NS5A protein. DCV structure ligand interactions showing close proximity
and key role of identified Proline residues. These observations show that the effects on
essential Proline residues 29, 32 and 35 can potentially change the binding pocket. As
our previous results show, this mutations not only change the position of DCV in the
binding pocket but its further interactions with the amino acids in the binding pocket.
As seen in Figure 12.11, P29, P32 and P35 have a receptor exposure to the interacting
zone of DCV. Additionally as previously shown, this Proline residues, showed also a
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reduction in HCV replication when mutated, which might be due to its essential role in
the stability of the binding pocket.
Figure 12.11: Daclatasvir interaction map generated in MOE R©, showing important
interacting residues. Symbols are characterizing the properties of the amino acids in
the proximity of DCV.
12.2.1 DCV binding pocket
Linker AH-DI is the anchoring region which is involved not only in the membrane as-
sociation but apparently also in the proper docking of DCV. The studies on Proline
mutations suggest that AH-DI linker structure is key to ensure the binding pocket of
DCV as well as its interaction with the cellular membrane. Our Molecular Dynamics
studies were limited, but we did not observe a major conformation change when studying
the NS5A dimer or the amphipatic helix alone with the cellular membrane. Re-ensuring
that the AH is the main anchor to the cellular membrane giving NS5A stability and DCV
a binding pocket. Together with the data on previous experiments in this study (Sec-
tion 11.1), we can suggest that Daclatasvir binding pocket is stabilized by the proper
membrane association. Thus, the AH has a key role in the mode of action of NS5A
inhibitors. Therefore, we analyzed the conformation of Daclatasvir binding pocket in
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NS5A structure via visual inspection of the interacting amino acids and close contacts
in NS5A dimer. In Figure 12.12, we observe the position of docked DCV in relation to
the Proline mutations positions.
Figure 12.12: NS5A dimer plus DCV binding pocket. A. DCV molecule is in yellow,
its binding site is in green and NS5A dimer in magenta and orange. Proline mutations
are marked in cyan.
Figure 12.13: NS5A dimer plus DCV binding pocket. B. Different angle, DCV
molecule is in yellow, its binding site is in green and NS5A dimer in magenta and
orange. Proline mutations are marked in cyan.
Although together all the results we gathered in the Proline mutation studies, are
strongly suggesting that this Prolines have an essential role in the stability of the binding
pocket and in the structure of the linker connecting the amphipatic helix with NS5A;
the cellular membrane in this whole picture is not taken into account. And regarding
the importance of NS5A functions, the cellular membrane must be a point of study to
complete the overview of the effects on NS5A inhibitors. Therefore, we studied the NS5A
protein in a dimer form together with the cellular membrane. For this purpose we use
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computational methods to predict and formulate the structure of NS5A on the cellular
membrane. By visual inspection we observed that NS5A dimer is positioned on top of
the cellular membrane being the AH the anchor to it. The Molecular Dynamics studies
showed that the dimer moves through but does not detach from the cellular membrane.
The linkers give flexibility to the whole protein providing a bridge-like structure which
could be useful for the DCV molecule to access the binding pocket.
Unfortunately, this system is too unstable to analyse via MD, and it is to big to predict
further interactions and conformational changes. For this reason, we decided to reduce
the system into the analysis of just the AH in presence of the cellular membrane.
12.3 Amphipatic helix and membrane simulations
As computational tools can be powerful enough to get big systems to be studied by
molecular dynamics, it has its limitations. The bigger the system the more powerful the
computational tools and so the more time the studies take. For the purpose of the present
analysis in here, we narrow our study to focus on the interaction of the amphipatic helix
containing the Proline rich linker, which is the main anchoring part of NS5A to the
ER-like membrane, taken from https://www.ucalgary.ca/tieleman/publications.
Figure 12.14: NS5A dimer containing AH and linker on cellular membrane.
NS5A dimer built with AH and Proline-rich linker on top of POPE cellular ER
membrane-like. Solvent water.
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12.3.1 Amphipatic helix orientation in cellular membrane
NS5A is tightly associated with the ER membrane and behaves as an integral mem-
brane protein, with a few more contacts besides the amphipathic helix. Likewise, the
hydrophobic and basic residues following the NS5A amphipathic alpha-helix could par-
ticipate in membrane association. Moreover, residues located downstream of amino acids
1 to 31 were determined to interact with the cellular membrane [175]. The amphipathic
helix is the main anchor, yet the region can be extended to ensure the membrane as-
sociation, creating a platform with hydrophilic resides and asymmetric distribution of
charged resides on the cytosolic side of the N- terminal [33].
As mentioned before in section 2.7.5.2, at the N-terminal region of NS5A contains 30
amino acid residues which serve as a membrane anchor for NS5A, forming an in-plane
amphipathic helix embedded into the cytosolic leaflet of the cellular membrane bilayer.
Previous studies [15, 175] on NMR data showed that the anchoring helix is five residues
from the N- terminus of the D1 structure which suggests it is close to the membrane,
where it can possibly interact with RNA. In the same study [175], it is suggested that
the interaction might be through the DI dimer groove which is facing away from the
cellular membrane. Interestingly, this groove can act as an RNA-binding pocket because
it is a highly basic region, making an electrostatic contact with the basic region of the
groove [37].
Figure 12.15: NS5A dimer with Proline-rich linker. AH-linker homology based on
PxxPxxP. Taken from Nettles et al 2014, [1].
So for our studies we decided to have the amphipatic helix together with the Proline-
rich linker together with the cellular membrane for the molecular dynamics. As shown
in Figure 12.16, orientation of AH could be vertical or horizontal, although previous
data have shown that the AH is in-plane from the cellular membrane, we explore both
structures on molecular dynamics to determine the system’s limitations. As predicted
before, the amphipatic helix structure lies on top of the cellular membrane, we ruled out
the vertical position because the molecular dynamics showed no systematical pattern
that would make sense with previous and experimental data. Thus, we continue with
the horizontal model of AH and cellular membrane.
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Figure 12.16: Amphipatic helix orientation
AH orientation with Proline-rich linker. a. Horizontal orientation and b. Vertical
orientation. Taken from [176].
12.3.2 Amphipatic helix and membrane association
The model was constructed manually including the AH in a horizontal position together
with the POPE cellular membrane (as described in 10.11.3). We ran molecular dynamics
with established conditions as shown in Methods section 10.11.3. The system looks like
in Figure 12.17, where the conditions were the same as set up for all the molecular
dynamics, to keep consistency.
Figure 12.17: Amphipatic helix and membrane
AH construct including Proline rich linker in starting position of built-up model in a
horizontal orientation from the POPE cellular membrane. This system was used as
set-up for Molecular Dynamics.
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The molecular dynamics ran by Desmond showed what others and us have predicted,
the amphipatic helix besides being the major anchor to the membrane it is flexible
and changes conformation during the 500ns of MD, Figures 12.17, 12.18, 12.19, and
12.20, where we can see that the AH-membrane association, undergoes several structure
changes. This changes are the basis to fulfill NS5A main functions, as the protein can
move to allow interactions and thus, open and close conformations that also allow the
binding of NS5A inhibitors, including DCV. Because of systems limitations we studied
only the association of AH to the membrane, but we can predict that the AH has a
flexibility that the linker provides, which can be crucial for the binding of DCV as seen
in the Proline-mutations molecular dynamics, following Figures. .
Figure 12.18: Molecular Dynamics of AH-Proline rich linker (AH-DI linker)
A. Snapshot taken at 72ns, showing AH on top of POPE cellular membrane. As
described in the text, AH is in close contact with the cellular membrane, amino acids
in loop are shown interacting with hydrophobic lipid groups on cellular membrane. B.
Snapshot taken at 244ns, where AH-DI linker (Proline-rich linker), is inserting in
cellular membrane.
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Figure 12.19: Molecular Dynamics of AH-Proline rich linker (AH-DI)
C. Representative snapshot taken at 331ns, where the majority of the AH is inserted in
the cellular membrane. D. Snapshot taken at 443ns, where AH is in contact with
cellular membrane via the Proline-rich linker (AH-DI), through the dynamics we
observe this movement of the AH.
However, molecular dynamics can just predict and model what we include in the system
and it might be that the whole protein undergoes several other conformational changes
which might also be the reason for the proteins functions. Regardless, our MD showed
that the linker plays a major role in maintaining the protein attached to the cellular
membrane via the AH. As mentioned previously, resistance mutations arise in this im-
portant part of the protein, the molecular dynamics show its relevant role in keeping
the membrane association, which has not been studied before. This results show that
the protein’s association to the membrane might be essential to the mode of action of
the inhibitor Daclatasvir.
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Figure 12.20: Molecular Dynamics of AH-Proline rich linker (AH-DI)
Representative snapshot taken at 481ns of molecular dynamics, where the amphipatic
helix sits on top of the membrane on a horizontal manner making contact with the
cellular membrane mostly via the Proline-rich linker (AH-DI).
Our studies generated a more precise model for the mechanism of action of NS5A in-
hibitor, Daclatasvir, where importantly Proline mutations showed an impact in HCV
life cycle. We could prove this by molecular dynamics where we followed each mutation
and by looking at HCV replication and infection. The correlation of these observations
suggest that some of the mutations might have an effect on HCV life cycle due to a
conformational change of the AH-DI linker. The mechanism behind this involves the
attachment of the AH to the cellular membrane, as seen from the AH and membrane
association results. Furthermore, we could follow this AH-membrane association via
molecular dynamics, where we could predict the importance of the Proline-rich linker
not only in the maintenance of NS5A structure but additionally in the binding of DCV
inhibitor, which can be use for the improvement of future antiviral development. More-
over, to our understanding and already proven by others [117], we observed the inhibitory
effect of DCV on the envelopment of HCV viral particles. In addition to the already
know efficacy of NS5A inhibitor, DCV, we could explain its high potency is due to the
major conformational changes that NS5A undergoes which are crucial for its mode of
action. Particularly, we reveal the importance of key elements (amphipatic helix, AH-DI
linker and the interdomain region) in the binding site, that could be target of future
antivirals against HCV. Altogether the present studies, result in a better understanding
of the mechanism of action of NS5A inhibitor DCV, plus expanding the knowledge on
the infection dynamics.
Chapter 13
Discussion
13.1 HCV assembly impaired by DCV activity
Chronic hepatitis C infection remains a major public health threat, requiring research
and development of more specific and effective inhibitors. The emergence of resistance
mutations and the divergence in HCV variant genotypes, makes this task significantly
difficult [60, 127, 177]. However, cell-based HCV replicon, and the discovery of highly
potent direct acting antivirals are now the best antiviral therapy for HCV infection [82].
The pico-molar activity of NS5A inhibitors was discovered in 2009, since then several
underlying mechanisms of action had been proposed. Mainly two hypothesis have now
been confirmed: first, the antiviral mechanism targets NS5A activities regarding HCV
replication [41, 127, 131], second, the mode of action targets only assembly of HCV
virus [118, 126]. Soon, the confirmation of the impairment of HCV replication by NS5A
inhibitors led to one open question: what is the effect of NS5A inhibitors on HCV
assembly of viral particles. Our group and other [117] tried to target this question and
elucidate the mechanism of action of NS5A inhibitor, DCV.
Therefore, we wanted to study the impact of DCV on HCV assembly process, whether
the effect of NS5A inhibitors was affecting only the assembly process. For this purpose
we use SOF as positive control on our titrations studies to make the effect of DCV
evident, since as already known, SOF is a drug targeting NS5B, thus, only inhibiting
HCV replication. We confirmed that SOF had an effect in HCV replication and does not
interfere with HCV viral particles assembly process. Furthermore, we established EC50
values for SOF and DCV in our HCV electroporation protocol, which we used to prove
that DCV does not only inhibit replication but also affects assembly of viral particles
by blocking their envelopment, which was confirmed at the same time by Boson et al, in
124
125
2017. In addition, our titration experiments, showed that DCV and SOF achieved the
optimal concentrations that can be use in combination therapy [178, 179].
Additionally we showed that there is an evident peak of DCV inhibition at 24hrs post
transfection, where we can detect a decline on HCV replication and infection, coherent to
what described in literature [126, 131]. Finally, we showed that NS5A assembly functions
are blocked by DCV using several biochemical assays which confirmed that DCV had
an effect on HCV assembly, specifically on the envelopment of HCV viral particles.
Altogether, these experiments showed and support what others also proved [117], DCV
has a dual mode of action targeting NS5A protein activities. The mechanism of action
behind this dual mode of action was also described by Boson et al [117], where DCV
was shown to be inhibiting the envelopment of viral particles by blocking the transfer of
the viral genome to the assembly sites. The outcome of inhibiting both replication and
assembly of viral particles results in the clustering of HCV proteins because they cannot
exit. Therefore, this dual mode of action of DCV explains the efficacy of the drug.
The efficacy of DCV as an antiviral agent has been observed when using a single
ascending-dose in viral load 24h after drug administration in patients receiving a 100-
mg dose [36, 126]. This studies show that after in vivo administration of DCV, HCV
RNA declines with extreme rapidity, falling approximately 2 logs within the first 6h
post dosing, followed by a slower phase of decline [131]. These can be now explained
by our observations, since DCV can effectively block replication of viral HCV RNA and
virion assembly [127]. Likewise, we observed that time of drug addition affects DCV
inhibition of HCV infection. The envelopment of viral particles was disrupted already
at 24 hpi, were we see a slight decline of DCV effect. Hence, when virus assembly is
not blocked efficiently, there is a continued release of new viral particles, which is why
we see a delay after treatment. A more precise time of drug addition could target both
processes, replication and assembly, which can improve the dual action of the inhibitor.
Therapy using other DAA inhibitors can also be improved by the time of dosing DCV
in combination therapy.
A big remaining question regarding NS5A is its oligomerization state, as reported by
others [37, 38, 127], evidence of a higher oligomer formation of NS5A protein has been
hypothesized, however no prove of this oligomer has been made. Our results showed
evidence of the formation of high molecular weight oligomer of NS5A protein under PFA
treatment. We found that the optimal concentration of PFA is around 2% when treating
HCV wt genotype construct and 3% for the resistant mutant Y93H. The smear detected
in the experiments is an indication of oligomer formation, which are present in both
constructs at different PFA% concentrations. Moreover, when using 99 ◦C, the smear
disappeared into more defined bands, this suggested that there are several molecular
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weight NS5A protein detection [40, 48]. There were no evident features that the resistant
mutation on Y93H could affect the oligomer formation. However, the experiments were
not entirely conclusive and for future experiments PFA different concentrations and
temperatures can be used to define the molecular weight of the oligomer. Moreover,
addition of DCV treatment could answer whether or not NS5A forms an oligomer that
could be targeted by NS5A inhibitors. To achieve this, we propose biochemical BRET
assay, to determine the oligomerization state of NS5A and the effects of DCV on the
oligomer formation. In the present study we designed, improved and constructed the
necessary tools to perform such experiments in the future.
Another question that could be answer by using BRET assay as a tool, would be the
mode of action of synergistic compounds proposed by Sun et al, [62], where the formation
of a high oligomer has been supported by using additional drugs [62, 180], which can
enhance and restore the inhibition. This theory, is supported by the hypothesis that this
cooperative interaction between the compounds is due to NS5A protein communication
with each other, meaning, that one inhibitor binds to a resistant NS5A, which leads to
a conformational change that is transmitted to adjacent NS5As, resensitizing resistant
NS5A. This leads to restore the inhibition by the second inhibitor bound to the next
NS5A, which are together forming an oligomer [62]. Important to realize that the drug
sensitivity-determining residues are located away from dimerization which shows that
DCV does not interfere with dimerization, this does not rule out if the compound affects
other forms of oligomerization [181]. As future perspective, the baseline of our studies
can provide initial studies to elucidate the mechanism behind the synergistic effect.
The novel features discovered in our results together with recent research on NS5A
inhibitor, DCV [26, 117, 162, 182], can improve specific development of new inhibitors
by exploiting the dual mode of action. In addition to the understanding of the mechanism
of action of the synergistic compounds.
13.2 Proline mutations impact on HCV replication, infec-
tion and DCV binding
Furthermore, deciphering the MOA of NS5A inhibitors is important to understand how
antiviral therapy works, but improving the structural model of NS5A, can be used to
improve and develop new antivirals. Moreover, fortunately, amphipatic helix structure is
known by NMR studies [33] and domain I has been previously crystallized [37–39], their
functions are very well studied, as reviewed in the Introduction section I. Information
on the structure of NS5A components is key to fulfill gaps in the understanding how
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the virus-inhibitors work [1, 158]. Few studies focused on the analysis of the linker
connecting the AH to the domain I of NS5A protein. Hence, this information is crucial
since most of the resistant mutations are clustering in this area, located on the surface
of domain Ia and the unstructured linker region (amino acids 2635) that connects the
N-terminal AH with the core of DI [45, 62].
Additionally, exploring the structure of NS5A in detail, would explain recent experi-
mental data about DCV and synergistic compounds [62, 180], as already mentioned.
Some hypothesis include the involvement of conformational changes and/or the binding
of DCV to folding intermediate(s), for example, between AH and DI.
For this purpose we looked into AH-DI linker to find conserved residues that could be in-
volved in the stability of NS5A structure, thus important for DCV binding pocket. Our
collaborators (Cristoph Combet, Lyon) found very conserved Proline residues, which
are also present in the linker regions connecting DI subdomain a and b, and the linker
connecting DI-DII[183, 184], which were subjected to site-directed mutagenesis to study
the impact on HCV life cycle, experiments were performed in vitro and then studied
using Molecular Dynamics, to merge both branches of science and corroborate the re-
sults. The ultimate goal was to obtain a model in silico, which can be use to predict
new NS5A conformations in relation to new mutations when DCV is present.
In fact, in silico models have predicted conformations of full-length NS5A DI protein
receptor which were suitable for docking [1, 158]. Then, we integrated this model into
our studies were we mutated each Proline and docked DCV molecule. As observed in
the Molecular Dynamics, each mutation introduced a different arrangement which led
to a conformational change that could make the mutation as wildtype (such as: P35A,
P35G, P100V, P102G, P102V, P103A, P103G, P103V, P189A, P189G, P189V, P192A,
P192G, P192V and P194G) or inhibiting HCV replication and infection (such as: P29A,
P29V, P32A, P32G, P32V, P100A, P100G, P102A, P194A and P194V). Accordingly,
the MD showed why and how each Proline mutation impacted on NS5A conformation
and thus, on HCV life cycle. Additionally, we observed that the Prolines which behaved
as the wildtype HCV virus JCR2a, Prolines 29A, P29V, P32A, P32G and P32V on
AH-DI linker, P100A, 100G and 102A on DIa-DIb linker and P194A and 194V on linker
DI-DII, showed complete RNA replication inhibition, thus these residues showed also
a critical conformational changes on the binding site of DCV. The importance of the
amino acid substitution (Proline to Alanine, Glycine or Valine) could be due to clashes
or amino acid interactions, which made each mutation have a different effect on NS5A
structure, therefore changing the nature of DCV binding site. Key elements (AH, AH-DI
linker and the interdomain region) in the binding site showed different rearrangements
when conserved Proline residues were mutated.
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Notably, P29G, showed major changes in the AH conformation, which provokes lost
contact between DCV and the interdomain region of the binding pocket. Mutations on
Proline 32, to any other amino acid also showed drastic conformational changes that
led to the lost of contact between DCV and key elements in the binding pocket. In
addition to the slight change in AH conformation that showed an insertion into the
cellular membrane location, this changes led to a change in the binding site of DCV.
Coherent to our results, this year it was reported that deletion of Proline 32 results in
the virological failure in patients receiving NS5A inhibitors, glecaprevir and pobrentasvir
[185], which can be explained using our MD model, that shows this Proline mutations
having an impact in binding DCV. Finally, mutations on Proline 35, to any amino
acid did not alter the structure of NS5A, which gives the binding site the stability to
maintain DCV in its binding pocket. Importantly, we and others [182] recently showed
that P35A retained the ability to replicate but showed defects in virus assembly. P35A
exhibited a modest reduction in infectivity which explained why this mutation could be
crucial for HCV life cycle and DCV binding [182]. The binding pocket described for
DAAs has been suggested to contain residues located in the flexible linker region and
the amphipathic alpha-helix at the N-terminal to the structured cytosolic portion of
domain DI, in different computational models [1, 39, 158, 177]. In addition, several of
these conserved Proline residues have been found to be essential through the different
HCV genotypes [183, 184, 186].
Altogether, these results suggest that NS5A conserved Proline residues are important for
the conformation and/or self-interaction of NS5A protein. Importantly, the correlation
of the experimental results with our computational model, showed how each substitution
is changing the interaction partners and key elements on the activities of NS5A DI and
the binding pocket of DCV, plus as discussed in the next section, these Proline residues
also have an impact on membrane association and DCV binding.
Interestingly, it is known that Proline residues can undergo cis-trans isomerization,
which has been found to be very important for protein folding, cell signaling, auto-
inhibition and other cellular processes. In contrast to covalent modifications performed
by post-translational processes, Proline isomerization is an intrinsic conformational ex-
change process that has the potential to control protein activity without altering the
covalent structure of the protein [187]. It has been described that the isomerization pro-
cess has two distinct features, one is to introduce dramatic effects on protein structure
due to the difference between cis and trans conformations states of the dihedral angle
(ω) of the prolyl bond (X-P) that is large (180◦); the second one is, that the process
can be modulated by both intramolecular and intermolecular interactions [187]. At this
end, this could explain the MD observations on Proline mutations and the effects of
these mutations in the overall NS5A structure and therefore in DCV binding. Several
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other studies are looking to develop a new inhibitors using this approach; for exam-
ple, cyclophilins, a family of host peptidyl-prolyl cis-trans isomerases (PPIases), play
a pivotal role in the life cycles of many viruses and therefore represent an attractive
target for broad-spectrum antiviral development such as: small-molecule cyclophilin in-
hibitor (SMCypI), DEB025/Debio 025 (Alisporivir) [188, 189]. In our studies we observe
that when mutating Proline residues, cis-trans isomerization can be important for the
mechanism of action of NS5A inhibitors [159], as this modification introduces drastic
conformational changes that promote or not the binding to DCV. Our computational
model can be use in the future to predict the importance of Proline residues inside the
binding pocket.
Another interesting point is when we looked at residues 24, 30, and 35 all lie inside or
close to a potential double SH3 domain-binding motif P29-xx-P-xx-P35, (referred in the
present study as the AH-DI linker). Although interaction with host factors containing
SH3 domains has been reported for NS5A [190, 191], there has been no evidence reported
yet that this particular motif takes part in such interactions. On the other hand, a P-
xx-P-xx-P motif has been identified and structurally resolved in the sorting nexin 5
[1, 62, 192], where it plays a role in specific lipid binding. In NS5A, mutation P35A
has been shown to slightly reduce virus infectivity, induce defects of virus assembly
and not to have much effect on viral RNA replication, as already mentioned [182].
Taken together, the present experiments together with the recent reports, support the
existence of this conserved and potentially functional motif, as well as the presence of
compensating mutations in and around it, suggest that these regions of NS5A plays a
role in specific interactions with lipids or host factors. [186]
These results are merely limited by the absence of the cellular membrane which might
play a key role in NS5A and in DCV binding. This led us to study in detail then how
is the AH associated to the membrane and whether this is important for DCV binding.
13.3 AH and membrane dynamics
NS5A is tightly associated with the ER membrane and behaves as an integral membrane
protein. In fact, based on targeted mutagenesis and RNA replication analyses of polar
residues at the membrane surface, it has been define as a unique platform that is involved
in specific protein-protein interactions essential for the assembly of a functional HCV
replication complex [13, 45]. The amphipatic helix of NS5A exhibits a hydrophobic,
tryptophan-rich side embedded in the cytosolic leaflet of the membrane bilayer, whereas
the polar, charged side is exposed to the cytosol which is found to be highly conserved
among 280 HCV isolates of various genotypes [175]. Molecular dynamic studies have
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shown that when restraining the two α helices by the membrane lipid bilayer in the close
conformation, results in the stability of the homodimer interactions and reduction of its
flexibility [158]. Very clear differences were also observed by superimposing the two
models (claw-like and back-to-back), the differences rely on the hinge region connecting
the alpha-helix to the core of D1 for each monomer. This hinge region is important for
resistance mutations emergence to DCV treatment [158]. Importantly, the hydrophobic
and basic residues following the NS5A amphipathic alpha-helix could participate in
membrane association [33, 131]. Other residues or segments located downstream of
amino acids 131 were determined to interact with the membrane. Even though the N-
terminal amphipathic helix is the main anchor, the region can be extended to ensure the
membrane association, creating a platform with hydrophilic residues and asymmetric
distribution of charge resides on the cytosolic side of the N- terminal [33].
There is no consensus orientation of the α helix in the computational model attempts,
sometimes it can be modelled in parallel to each other in the two monomers with its
N-terminus pointing to the centre of the dimer [1], sometimes away from the dimer, and
in other analysis kinked and pointing sideways [158, 193]. Multiple models reported
the amphipathic helix, differing in their bending, based on the NMR data (PDB IDs
1R7C through 1R7G) [175, 176]. For this reason in our studies we wanted to determine
which is the optimal AH position and to build-up a model that could be use in the
future to study resistance mutations, NS5A inhibitors positioning and mode of action
of NS5A inhibitors. For this purpose first, we decided to perform MD on the position of
the AH on cellular membranes. Therefore, we included the Proline rich linker, and the
amphipatic helix structure (PDB: 1R7G) together with POPE cellular membrane. Our
results show that from the two potential conformations (horizontal or vertical) of the
AH in relation to the cellular membrane, it is very likely to be sitting horizontally on
top of the membrane and keeps associated with NS5A, which is consistent to previous
reports [175]. Moreover, our studies reveal that NS5A protein is linked to the membrane
using the AH in its horizontal position, and that this interaction changes through time
(MD: 500ns). This conformational changes are important for the protein dynamics in
relation to the cellular membrane and play key role in the binding site of DCV.
Second, we studied in detail the conformation of the AH-DI, Proline rich linker in as-
sociation with the cellular membrane, and we observed that the linker does not change
drastically its conformation staying in close proximity to the cellular membrane. This
could explain why NS5A remains attached to the cellular membrane via the AH, plus
the additional interactions from the AH-DI linker promote NS5A-membrane association.
Reports have described that HCV RNA replication is not impaired by membrane asso-
ciation of NS5A but of additional functions of the N-terminal [33], which is consistent to
our experimental and computational data. In addition to the fact that AH-DI linker has
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been suggested to affect the association of NS5A to membranes and/or host proteins,
which can also be disrupted by NS5A inhibitor (DCV) binding [118].
The MD performed in the present study reveal the mechanism behind it, where the AH-
DI linker contains important residues (for example: Prolines to Alanie, Valine or Glycine)
that can insert or delete amino acid interactions which are critical for the maintenance
of NS5A functions. Berger et al, also hypothesized that NS5A inhibitors (DCV and
other BMS compounds) docked into the cleft at the dimer interface, suggesting that the
segment connecting AH and D1 might compete for the same binding site as inhibitors. In
our data, we can observe that the conformational changes might induce drastic changes
in AH-DI which can result in a modification of its interaction with the cellular membrane,
this could be totally explained when using the re-docking DCV molecule on the system.
Consistent to our data, DCV and NS5A showed mainly hydrophobic interactions without
possibilities for water molecules to mediate those interactions [193]. Additional changes
in DI-DII linkers were also observed this could further explain differences in RNA binding
or in the interaction with different host proteins. However, molecular dynamics studies
have certain limitations in the number of atoms to study, which is why our aim was to
build a model that can be use in the future to study amino acid substitutions during
inhibitors presence in relation to the cellular membrane.
Furthermore, our results indicated that AH of HCV NS5A protein can spontaneously
bind and penetrate to an endoplasmic reticulum complex membrane containing (POPE).
We observed that the AH shows its anchoring role in keeping the protein on the mem-
brane surface. Proper orientation of the AH at membrane surface was identified through
MD analysis. Remarkably, AH-DI linker was observed to be important to maintain the
protein structure stable. Simulated results provide us with a detailed characterization
of insertion, orientation and AH-interaction of NS5A amphipatic helix at membrane
environment, thus enhancing our understanding of structural functions and mechanism
for the association of HCV NS5A protein with respect to ER membranes. In conclusion,
Proline mutations seem to affect the conformation of AH or the AH-DI linker which
can possibly have an effect not only in the binding to DCV (as previously described)
but also on the cellular membrane interaction. Thus, our in silico model predictions
can be used to: elucidate interactions within DCV binding site key components; predict
mutations on the Proline rich linker that can affect DCV binding, and ultimately as a
build-up model to study protein-membrane association via an amphipatic helix.
Lastly, it has also been reported that the presence of amphipatic helices are one of
the most important classes of membrane curvature sensors found in a wide range of
proteins, including trafficking proteins, where they regulate, for example, protein coat
assembly. This fact was of interest in our study since our molecular dynamics showed an
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indication of membrane curvature when the amphipatic helix was present together with
the cellular membrane. The mechanism by which AHs can achieve membrane curvature
involves the AHs fold upon contact to membranes and insert their hydrophobic face
in the lipid bilayer often with the help of positively charged residues situated on the
polar face of the helix. The insertion process is thought to be facilitated by curvature-
induced defects in lipid packing that result in a higher affinity of AHs for positively
curved membranes [194]. In fact other viruses such as Influenza virus has been shown
to use membrane curvature process to promote assembly of the virus [195]. In addition,
experimental results by Schley et al, confirmed that viral protein is associated with
increased membrane curvature, where they used a mathematical model to show that
localized increases in curvature alone are sufficient to generate viral buds. The magnitude
of the protein-induced curvature is calculated from the size of the amphipathic region
hypothetically removed from the inner membrane as a result of translation, with a
change in membrane stiffness estimated from observed differences in virion deformation
as a result of protein depletion [196]. However more detailed studies and research on this
aspect using our model could elucidate the mechanism by which HCV is using membrane
curvature during infection.
In summary, our results showed that DCV inhibits envelopment of HCV viral particles,
thus, showing a dual mechanism of action. Furthermore, studies on Proline mutations,
showed that some of these residues are critical not only in stabilizing NS5A conformation
and self-interaction, but also in DCV binding process, shown by computational tools.
Additionally, we showed the importance of the cellular membrane when studying NS5A,
NS5A inhibitors and resistant mutations. Altogether we build-up a model which can
be use the future to study NS5A protein- membrane association, in presence of NS5A
inhibitors. Although there are many groups contributing to the studying of HCV life
cycle, there are still open questions that can be targeted by computational tools, working
together with experimental data, which can extend and clarify our understanding of
NS5A inhibitors and apply this knowledge to the improvement of antiviral development.
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Figure A.1: Conserved Proline residues
Analysis of conserved Proline residues in HCV genotype JFH-1, using Amphipatic
helix PDB: 1R7G and using NS5A PDB: 1ZH1.
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A.2 HCV assembly impaired by DCV activity
Figure A.2: Diagram of experimental design
This diagram represents the experimental design of all the experiments using SOF and
DCV. Details are also described in the Methods section 10.
A.3 Drug titration
Figure A.3: DCV and SOF titration
DCV and SOF titration data, replication and reinfection n=3. Details are also
described in the Methods section 10.
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Figure A.4: DCV titration
DCV titration data, replication and reinfection n=3. Details are also described in the
Methods section 10.
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Figure A.5: SOF titration
DCV titration data, replication and reinfection n=3. Details are also described in the
Methods section 10.
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